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Summary 
Prostate cancer is the second most common cancer in the UK and incidence is 
gradually rising. Prostate cancer has a specific tendency to establish bone metastases, 
and this process significantly affects patient mortality and morbidity. This PhD 
evaluates the importance of EPLIN in the development and progression of prostate 
cancer, aims to explore any relevance of EPLIN in the establishment of bone 
metastases and to clarify the functional and mechanistic implications governing 
EPLIN biology in prostate cancer. 
EPLIN expression was established in clinical prostate cancer tissue and prostate 
cancer cell lines and revealed a downregulation or loss of EPLIN in more aggressive 
cancer phenotypes. Importantly, EPLIN was abolished in clinical cancer sections 
including hyperplasia and adenocarcinoma, in addition to being markedly lost in 
aggressive cell lines PC-3, LNCaP and VCaP. Subsequently, EPLINα, the main 
isoform linked to cancer progression, was overexpressed in PC-3 and LNCaP cells 
lines to explore the functional significance of EPLINα at a cellular level. In vitro 
functional analyses revealed EPLINα is able to influence several tumour cell 
characteristics. EPLINα overexpression reduced cell proliferation, migration and 
invasion, and was able to increase cellular adhesion, when compared to control cell 
lines. EPLINα expression was also explored in an in vitro bone environment via 
culturing cells with Bone Matrix Extract solution, and also using a co-culture method 
with human osteoblasts. 
To establish the mechanism of action of EPLINα in prostate cancer progression, the 
EPLIN interactome was evaluated, identifying several key molecular associations. 
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EPLINα expression influenced transcript, protein and phosphoprotein expression of 
signalling molecules paxillin and FAK in PC-3 and LNCaP cell lines. Lastly, a 
protein microarray was performed and identified several potential signalling 
pathways for EPLINα’s mechanism in prostate cancer. Namely, molecular 
associations between EPLINα and ITGB1, ERK1/2 and Src were identified for 
validation and verified by Western Blotting, proposing a role for EPLINα’s ability to 
regulate the aggressive characteristics of prostate cancer cells. 
Collectively, this thesis explores the functional role of EPLIN in prostate cancer 
progression and provides insights into the mechanism of action of EPLIN in prostate 
cancer pathophysiology. 
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ERK: Extracellular signal–regulated kinase 
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NHS: National Health Service 
NICE: National Institute for Health and Care Excellence 
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OPG: Osteoprotegerin  
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PCa: Prostate cancer 
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PSA: prostate specific antigen 
PTEN: Phosphate and tensin homology  
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PTPLAD1: Protein tyrosine phosphatase-like a domain containing 1 
PVDF: Polyvinylidene fluoride 
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Rac1: Ras-related C3 botulinum toxin substrate 1  
RANK: Receptor Activator of Nuclear factor kappa-B  
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RTPCR: Reverse Transcription Polymerase Chain Reaction 
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TURP: Transurethral resection of the prostate. 
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WHO: World Health Organisation 
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1.1 Cancer 
Cancer categorises over 200 types of disease and is a growing problem worldwide. 
Cancer originates following transformation of healthy cells to cancerous cells, a 
process involving abnormal cell proliferation and potential invasion of surrounding 
tissue.  Cancer cells have various characteristics and traits which make them difficult 
to treat and manage and these include extensive cell proliferation, cellular invasion, 
increased motility and proliferation, evasion of cell death and the ability to ignore 
physiological extracellular signals like hormones and proliferation signals. These 
characteristics allow an abundant proliferation of cells, which divide continuously, 
leading to possible tumour formation. If a tumour is formed, it can potentially move 
to various sites in the body and this process is called metastasis (Hanahan and 
Weinberg, 2011). Cancer metastasis is a complex and sophisticated process which 
creates various complications for patients diagnosed with cancer. According to the 
World Health Organisation (WHO), 8.2 million people died from cancer in 2012 
worldwide (WorldHealthOrganisation, 2016a). This clearly illustrates that better 
treatment, diagnosis and management of the disease is required. Although different 
cancers share characteristics in cancer progression, each cancer type can be unique in 
its mechanism of action, its pathophysiology and morphology, along with methods 
for diagnosis and treatment. This PhD will focus on prostate cancer metastasis and 
how the molecule Epithelial Protein Lost in Neoplasm (EPLIN) is associated with 
prostate cancer development and progression. 
1.1.1  The prostate gland: structure, function and development 
The prostate gland is an exocrine gland below the bladder whose main role is in the 
secretion of prostatic fluid which contributes to the production of semen in men 
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(CancerResearchUK, 2016h). The prostate is described as being the size of a walnut 
and can range in weight from 7-16 grams, consisting of various anatomical 
components including fibrous, elastic, vascular, lymphatic and muscular tissue 
(Leissner and Tisell, 1979, Wilson, 2014). The tissue morphology of the prostate 
gland consists predominantly of basal cells, luminal cells and neuroendocrine cells 
(ProstateCancerUK, 2016d) (Figure 1.1). These compact epithelial cells line the 
prostate and it is here where cancer can originate (ProstateCancerUK, 2016d).  
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Figure 1.1 Schematic representation of the cellular morphology in the prostate 
gland.  
Adapted from (ProstateCancerUK, 2016d).  
 Chapter I 
5 
 
For appropriate prostate gland function, regulation of the molecules and mechanisms 
involved in prostate organogenesis is crucial. The prostate generates from an area at 
the bottom of the bladder called the urogenital sinus and this happens at around the 
9
th
 week of embryonic development in males (Thomson, 2008). The prostate is an 
accessory sex gland with branched epithelia and is responsible for secreting various 
proteins and sugars into seminal plasma and thus contributing to a high proportion of 
the seminal fluid (Murashima et al., 2015). Key molecules in prostate gland 
development are groups of hormones called androgens. Androgen function relies on 
signalling mechanisms via the androgen receptor (AR), which is a member of the 
nuclear receptor superfamily (Escriva et al., 2000).  
1.1.2  Prostate cancer: statistics  
Cancer of the prostate occurs when healthy cells located in the prostate gland are 
transformed, begin to divide abnormally and ignore physiological body cell signals. 
What causes this is unknown, but there are various factors which can increase the 
likelihood of onset of prostate cancer. Approximately 1.11 million men were 
diagnosed with prostate cancer in 2012 worldwide (CancerResearchUK, 2017). In 
the UK, prostate cancer is the most common male cancer with 47,300 men diagnosed 
annually in 2013 (CancerResearchUK, 2017). In 2014, approximately 307,000 men 
died from prostate cancer across the world, including 11,287 men from the UK, 
making prostate cancer the second most common male cancer killer in the UK 
following lung cancer (CancerResearchUK, 2017). The incidence of prostate cancer 
has steadily increased over the last 40 years (Figure 1.2), with biggest increases in 
disease incidence occurring in the early 1990’s and early 2000’s 
(CancerResearchUK, 2017). This increase is not limited to men in the UK, with the 
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number of intermediate and high risk prostate cancers also on the rise in the United 
States; recent data suggests the number of men with higher-risk prostate cancer has 
increased sequentially by 3% each year from 2011-2013 (Hall et al., 2015). The 
reason for this steady increase in the rate of prostate cancer is generally unknown; 
however it is likely that better modern day detection and screening methods are 
contributors in addition to increased public awareness of cancer. 
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Figure 1.2 The incidence of prostate cancer in the UK between 1970 and 2013.  
Adapted from (CancerResearchUK, 2017).  
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1.1.3  Prostate cancer: Detection 
Early diagnosis and detection of prostate cancer is critical to successfully manage 
and treat the disease. Prostate cancer presents various signs and symptoms and 
doctors regularly check for these to ensure the right diagnostic test is used if 
required. In 2015, the National Institute for Health and Care Excellence (NICE) 
published guidelines for doctors to aid diagnosis 
(NationalInstituteforHealthandCareExcellence(NICE), 2016), and the symptoms 
include: 
 Increased need to urinate 
 Difficultly urinating  
 Weak or interrupted flow of urine 
 Blood in urine or semen 
 Painful or burning urination 
 Erectile dysfunction 
 Painful ejaculation 
If someone experiences some of these symptoms, it is recommended they visit their 
GP in order to be examined for presence of prostate cancer 
(ProstateCancerFoundation, 2016).  
1.1.3.1 Prostate Specific Antigen (PSA) testing 
PSA was discovered three decades ago and named as the prostate specific antigen in 
1970 by Richard J Ablin (Ablin et al., 1970, Ablin, 1985). It is a glycoproteinenzyme 
encoded in humans by the KLK3 gene, and also known as gamma-seminoprotein or 
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kallikrein-3 (KLK3)(Lundwall and Lilja, 1987) and initially purified from prostate 
tissues (Wang et al., 1979) and blood (Papsidero et al., 1980). PSA is secreted by the 
prostate epithelial cells, with a main function in liquidifying semen and allowing 
sperm to freely swim (Ablin et al., 1970, Ablin, 1993, Wang et al., 1981, Ablin, 
1985). 
The PSA test involves a blood test which determines the level of PSA in a patient’s 
blood. PSA is a protein produced by the prostate gland present in both normal and 
cancer cells, however the amount of PSA in normal cells increase with age and 
higher levels of PSA may be an indication of altered prostate function 
(ProstateCancerUK, 2017). Prostate cancer can cause the amount of PSA production 
to be upregulated, so a PSA test is used to evaluate levels in the blood to give 
indication of prostate cancer presence. The main drawback of PSA testing is its 
specificity; PSA testing will not give a definitive answer for prostate cancer, it is 
only a predictive test and some men with prostate cancer may not have raised PSA 
(NHS, 2016a, Ablin, 2000, Haythorn and Ablin, 2011). In addition, some men with 
high PSA level may not have cancer but can be attributed to conditions like 
prostatitis or benign prostatic hyperplasia (BPH) (Sarwar and Adil, 2017). The lack 
of specificity with PSA testing creates a fundamental problem for doctors and 
patients in diagnosis of the disease and illustrates the critical demand for a specific 
molecular test in determining cancer initiation and establishment. 
1.1.3.2 Digital Rectal Exam (DRE) 
Once PSA levels have been established, the next confirmatory measure would be a 
DRE, carried out by a GP. A DRE is a physical exam where a doctor puts a 
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lubricated, gloved finger into the rectum of the patient with another hand on the 
lower back. This is done to evaluate proliferation or enlargement of the prostate, 
including if the gland is hard or bumpy which could indicate presence of a tumour 
(WebMD, 2016a). 
1.1.3.3 Biopsy 
Following on from a PSA test and a DRE, a GP may refer the patient to a specialist 
or consultant at a hospital to discuss further diagnostic testing. The most common 
procedure after the initial tests is a transrectal ultrasound-guided biopsy (TRUS) 
(NHS, 2016a). This involves a probe which is inserted into the rectum and produces 
harmless high-frequency sound waves which can be used to generate an image of the 
prostate gland (WebMD, 2016b). These images are then used to estimate the size of 
the prostate and provide indication of any unusual proliferations (WebMD, 2016b). 
Once the images are taken, a doctor can then visualise where a biopsy needs to be 
taken and a needle is passed through the rectum wall and tissue is extracted from the 
prostate (NHS, 2016a). Once the sample is taken, the biopsy can be analysed in a 
laboratory and if any cancer cells are found they can be studied further to decide 
their metastatic capacity. The next step in prostate cancer detection is to evaluate the 
stage and grade of a cancer. 
1.1.4  Prostate cancer: Staging and grading 
Staging and grading of a cancer describes how far along a cancer may have 
progressed and is useful for deciding the type of treatment which is necessary. For 
prostate cancer detection, the TNM system is used (Table 1.1), standing for Tumour 
(T), Node (N) and Metastases (M) (ProstateCancerUK, 2016e). The early stages (T 
 Chapter I 
11 
 
stages) represent the initial developments which occur when a tumour is formed in 
the prostate gland (Figure 1.3). Node stages demonstrate tumour stages with nodal 
involvement, and Metastases stages illustrate advanced stages of tumour 
development where metastases are present. Table 1.1 illustrates the differences in 
staging and how each stage is identified. 
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Table 1.1 Prostate cancer TNM staging.  
Adapted from (CancerResearchUK, 2016f). 
Stage Description 
T1 Localised prostate cancer, small tumours, too small to be seen/felt 
during prostate examination, possible to be identified by needle biopsy 
or seen under microscope 
T2 Localised prostate cancer, cancer is big enough to be seen on scans but 
is contained inside the prostate gland. Stage T2 can be divided into 3 
sub-stages; T2a, T2b and T2c. 
T2a Localised prostate cancer, the tumour is in only half of one of the 
lobes of the prostate gland 
T2b Localised prostate cancer, the tumour is in more than half of one of the 
lobes of the prostate gland  
T2c Localised prostate cancer, the tumour is in both of the lobes of the 
prostate gland  
T3 Locally advanced prostate cancer, the cancer starts to break away 
through the capsule of the prostate; this can be felt/seen on a scan. The 
cancer is yet to spread to additional organs. Stage T3 can be divided 
into 2 sub-stages; T3a and T3b. 
T3a Locally advanced prostate cancer, the cancer has broken through the 
capsule of the prostate but is yet to spread to the seminal vesicles. 
T3b Locally advanced prostate cancer, the cancer has broken through the 
capsule of the prostate and has spread to the seminal vesicles. 
T4 Locally advanced prostate cancer, the cancer has penetrated the capsule 
of the prostate and began to infiltrate organs of the body in the 
immediate area, such as the bladder and the rectum. 
NX Locally advanced prostate cancer. Stage NX is when the lymph nodes 
cannot be measured. 
N0 Locally advanced prostate cancer. Stage N0 is when the lymph nodes 
can be measured and reveals there are no cancer cells in lymph nodes 
surrounding the prostate. 
N1 Locally advanced or metastatic advanced prostate cancer. Stage N1 is 
when the lymph nodes surrounding the prostate are measured and 
contain cancer cells. 
MX Locally advanced or advanced metastatic prostate cancer. Stage MX 
may indicate results were unclear as to whether metastases were present 
or not. 
M0 Locally advanced or advanced metastatic prostate cancer. Stage M0 
means the cancer hasn’t progressed outside of the pelvic region. 
M1 Locally advanced or advanced metastatic prostate cancer. Stage M1 
means the cancer has progressed outside of the pelvic region. 
M1a Advanced metastatic prostate cancer. Stage M1a indicates there are 
cancer cells in lymph nodes outside of the pelvic region. 
M1b Advanced metastatic prostate cancer. Stage M1b indicates there are 
cancer cells present in the bone. 
M1c Advanced metastatic prostate cancer. Stages M1c indicates there are 
cancer cells in other organs such as the liver, brain or lungs. 
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Figure 1.3 Schematic representation illustrating early stages of prostate cancer 
development. 
The prostate gland is situated below the bladder. The proximity to the bladder and 
urinary organs can lead to bladder related issues when cancer is present. T1 prostate 
cancer is the first stage of prostate cancer where the cancer is difficult to observe 
during a prostate examination. The next stage, T2, is when the cancer has grown 
slightly larger and can now be clearly identified on prostate scans. Stage T3 is where 
the cancer first starts to penetrate the lining of the prostate. This stage can be both 
felt during a prostate examination and seen on a prostate scan. During T3 the cancer 
has yet to reach other organs of the body but may have reached the seminal vesicles 
near the prostate.  
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Figure 1.4 Illustration of Gleason Grading System, a microscopic based grading 
method for prostate cancer (Gleason et al 1974).  
The total Gleason score is generated from the sum of two key scoring: The 
appearance of the most common cell morphology and the appearance of the second 
most common cell morphology are each assigned to grade 1-5. Using this system the 
most well-differentiated tumours have a Gleason score/grade of 2, and the least-
differentiated tumours a score of 10. Grade 2-4 being well-differentiated neoplasm, 
Grade 5-6 intermediate-grade neoplasm, Grade 7 moderately - poorly differentiated 
grade neoplasm, Grade 8-10 high-grade neoplasm. 
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The prostate cancer staging system is used to describe how far the cancer has spread, 
starting with primary localised prostate cancer and finalising with advanced 
metastatic cancer. Additionally, a method to determine how aggressive the cancer 
will be is calculated using the Gleason score and Gleason grade, named after David 
Gleason who initiated the scoring method (Gleason and Mellinger, 1974) and 
modified in the following decades (Brimo et al., 2013) (Figure 1.4). Once the tissue 
biopsy has been evaluated under a microscope in the laboratory, a Gleason score is 
determined using a total of Gleason grades, and this illustrates the level of 
differentiation to the cells. The morphology or pattern of the tumour is given a 
Gleason grade by numbering from 1-5, depending on the extent of abnormality to the 
cells, with 1 being the lowest and 5 the highest, then varying Gleason grades are 
added together to give an overall Gleason score (ProstateCancerUK, 2016c). The 
two most common morphologies of tissue are graded, then added together to give the 
Gleason score. The higher the Gleason score, the more aggressive the tumour is and 
more likely it is to spread to distinct areas of the body (TackleProstateCancer, 2016). 
The tests described above provide significant clues on whether the cancer will 
metastasise and become more aggressive, infiltrating other areas of the body, in 
addition to providing aspects on patient morbidity and mortality. However, the main 
disadvantage for the tests in use for prostate cancer diagnosis and prognosis is the 
specificity of the test; currently, there is no single diagnostic assay which can give a 
definitive result for presence of prostate cancer and whether a cancer will metastasise 
or not. For this to be achieved, a specific, molecular target which correlates with 
prostate cancer progression is therefore required. A crucial part of this PhD will be to 
evaluate EPLIN for its role in prostate cancer and to establish whether EPLIN can be 
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successfully utilised as a suitable prognostic marker or therapeutic strategy for 
prostate cancer development and progression. 
1.1.5  Prostate cancer: Risk factors 
The cause of prostate cancer is unknown but there are various risk factors which can 
increase the likelihood of developing prostate cancer. Age and ethnicity are 
prominent factors determining prostate cancer risk. Men in their 20’s have been 
reported to have a 1-2% chance of developing histological prostate cancer, whereas 
men aged 90+ have a 59-72% risk of developing the disease (Leal et al., 2014). 
Similar reports have been made highlighted age as a critical risk factor of prostate 
cancer development with men younger than 39 having a 0.005% risk of developing 
the disease, with the risk increasing to 13.7% for men aged 60-79 
(AmericanCancerSociety, 2007). Men most at risk are aged 65-75 and this age group 
contributed ~62% of all new prostate cancer cases in the UK between 2009 and 2011 
(Figure 1.5) (CancerResearchUK, 2017). Estimations on ethnic associations with 
prostate cancer have also highlighted areas of risk for males; white men, for 
example, have been reported to be at significantly higher risk than Chinese/Japanese 
men (Leal et al., 2014). Additionally, black men are the most susceptible in 
developing prostate cancer, and it has been estimated that 1 in 4 British black men 
will acquire prostate cancer during their lifetime (ProstateCancerUK, 2016b). Recent 
estimations in England reveal that black men are twice as likely as white men to 
develop, and die from, prostate cancer (Lloyd et al., 2015). 
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Figure 1.5 Average number of male new prostate cancer cases per year based on age of individual, UK, 2009-2011.  
Adapted from (CancerResearchUK, 2017). 
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1.1.5.1 Risk factors: Diet and lifestyle  
There is also growing evidence that prostate cancer may be circumvented by 
modifications to diet and lifestyle, with certain lifestyle choices having a reduced 
risk of disease onset. For example, diets that are high in naturally occurring 
phytochemicals like lycopene, curcumin and resveratrol may induce cancer 
protective effects (Bommareddy et al., 2013). The cancer protective effects of these 
dietary compounds have been analysed recently in prostate cancer cell lines PC-3, 
DU-145 and immortalised normal prostate cell line PNT-2 where addition of 
lycopene influenced cell adhesion and migration of cancer cells (Elgass et al., 2014). 
The use of curcumin, resveratrol and lycopene also has potential as anti-cancer foods 
via their ability to target tumour angiogenesis. These compounds have been shown to 
exert anti-angiogenic effects, with stronger anti-angiogenic efficacies than certain 
cancer drugs like Tamoxifen (Li, 2010) suggesting a combination of medical 
treatment and dietary treatment may be optimal for treating cancer proliferation and 
progression. Other dietary measures which could be implemented to protect from 
cancer include a plant based lifestyle void of animal products. There is growing 
evidence to suggesting eliminating animal products from a person’s diet can lead to a 
reduced risk of not only cancer, but other chronic ailments like heart disease and 
diabetes, in addition to increasing longevity (Dinu et al., 2016, Gilsing et al., 2016, 
van Nielen et al., 2014). A recent comprehensive meta-analysis illustrated a 
significant protective effect from total cancer (-8%) and ischemic heart disease (-
25%) of those who adopted a vegetarian diet vs. those who chose to eat meat (Dinu 
et al., 2016). In prostate cancer, a recent report demonstrated how a vegan lifestyle 
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can reduce the risk of developing prostate cancer by up to 35% (Tantamango-Bartley 
et al., 2016). This compliments previous work in prostate cancer and lifestyle 
intervention where LNCaP cells were incubated with serum of someone eating 
standard American diet vs. those eating a plant based diet (Ornish et al., 2005). The 
study revealed that treatment of LNCaP cells with blood of those eating a plant based 
diet had an eight fold inhibitory action on LNCaP proliferation compared to cells 
treated with serum of participants consuming a standard American diet, and further 
illustrates the potential of a plant based/vegan lifestyle in the prevention of prostate 
cancer in this model (Ornish et al., 2005). These data compliments recent 
announcements from the World Health Organisation that processed meat is 
carcinogenic and red meat is a likely carcinogen (WorldHealthOrganisation, 2016b). 
Various other animal products like calcium containing dairy products may also 
contribute to cancer progression (Raimondi et al., 2010). Calcium levels in milk 
greater than 2000mg/d have been associated with advanced stage and high grade 
prostate cancer (Wilson et al., 2015). Other dietary issues include a low dietary fibre 
intake which can increase the likelihood of prostate cancer and may act via 
influencing sex hormone levels (Sawada et al., 2015). Other elements influencing 
prostate cancer may be higher levels of cadmium and folate where high levels are 
associated with increased prostate cancer risk (CancerResearchUK). Lastly, in 
addition to dietary measures, there is growing evidence to suggest increased exercise 
and physical activity, opposed to a sedentary lifestyle may have a protective effect in 
prostate cancer (Peisch et al., 2016). Accompanying dietary measures and exercise, 
smoking may have a detrimental effect on prostate cancer development with smokers 
potentially being at an increased risk of prostate cancer incidence and mortality 
(Islami et al., 2014, Huncharek et al., 2010).  
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1.1.5.2  Risk factors: Family history and genetics 
Prostate cancer susceptibility can also be related to family history. Men who have a 
father or brother with prostate cancer are significantly more likely to develop the 
disease (CancerResearchUK, 2016c, ProstateCancerUK, 2016a) Research suggests 
known cancer genes BRCA1 and BRCA2 may be involved in prostate cancer 
development (CancerResearchUK, 2016c, ProstateCancerUK, 2016a). The BRCA1 
gene has been implicated in prostate cancer in a number of publications (Fiorentino 
et al., 2010, Mitra et al., 2011, Leongamornlert et al., 2012).  For example, a 
nonsynonymous A>G substitution at c.1067 of chromosome 17q21, resulting in a 
Glu-Arg amino acid change at position 356, has been associated with prostate cancer 
susceptibility (Douglas et al., 2007). Further genetic and molecular changes have 
also been implicated in the pathogenesis of prostate cancer. The tumour suppressor 
gene, Phosphate and tensin homology (PTEN), is down-regulated or deleted in a 
number of cancer types and frequently is so in prostate cancer (Li et al., 1997). 
Additional genetic changes in prostate cancer can include modifications to the AR. 
During physiological processes, Testosterone and Dihydrotestosterone (DHT) bind 
to the androgen receptor (AR) in the cytoplasm; this causes the AR to translocate to 
the nucleus and bind to Androgen Response Elements (AREs) in target genes to 
engender cellular processes like cell proliferation and apoptosis (Figure 1.6) 
(Heinlein and Chang, 2004). However, when this process goes awry due to genetic 
changes to the AR, for example, variability in the polymorphic CAG repeat sequence 
which regulates transcriptional activity, an increased risk of prostate cancer is 
frequently associated (Giovannucci et al., 1997). Due to the complexity of cancer 
cell biology, the molecular pathology of prostate cancer remains largely elusive. 
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Different genes exert various downstream cellular effects and may be subject to 
deleterious mutation, potentially initiating a cascade of complications ultimately 
leading to cancer. 
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Figure 1.6 Action of Androgen receptor in prostate gland.  
Binding of Testosterone and DHT to the androgen receptor causes association with 
androgen receptor coregulators (ARAs) and translocation of the AR to the nucleus. 
At the nucleus the AR binds to AREs in the promoter region of target genes and 
causes downstream cellular processes. Adapted from (Lattouf et al., 2006).   
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1.1.6  Prostate cancer: Treatment  
Currently, there are a number of different treatment options for people with prostate 
cancer.  These typically include surgery (removal of the prostate gland), radiotherapy 
(use of high energy rays) and hormone therapy (targeting testosterone in the body) 
(CancerResearchUK, 2016g). Current treatment options, however, have a number of 
associated problems such as the harshness of certain treatments, cost and 
unavoidable side effects. For example, hormone therapy can lead to erectile 
problems (impotence), fatigue, long term weight gain, long term memory problems, 
depression and osteoporosis (CancerResearchUK, 2016e). As a way of avoiding side 
effects associated with prostate cancer treatment, some patients may opt for the 
monitoring of slow growing prostate cancer by long term tracking of the cancer, 
known as Watchful Waiting or Active Surveillance (ProstateCancerUK, 2016f). In 
addition to surgery, radiotherapy and hormone therapy, there are other treatments 
which could be utilised for suppressing or treating prostate cancer development, 
listed in Table 1.2. 
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Table 1.2 Prostate Cancer Treatment  
Adapted from (ProstateCancerUK, 2016f) and (NHS, 2016b). 
Treatment Description 
Radical Prostectomy 
(surgery) 
Surgical removal of the prostate gland. This treatment can be used when a cancer has not metastasised and is localised to the 
prostate. Possible to remove cancer cells, however if not all cells are removed, the cancer may return. Side effects and risks 
include: erectile dysfunction, infertility and lack of ejaculate, urinary incontinence and in some very rare cases, death.  
Radiotherapy Radiation uses high energy beams and radiation to damage, prevent proliferation and kill cancer cells. Can be utilised to treat 
local cancer or slow down advanced cancer. The treatment is pain free but has side effects including: anal discomfort, tiredness 
and fatigue, loss of pubic hair, cystitis, erectile dysfunction, urinary incontinence and back passage issues. 
Hormone therapy Hormone therapy works by targeting testosterone and stopping it from reaching cancer cells and thus preventing cell 
proliferation. Hormone therapy is often used in conjunction with radiotherapy as a means of slowing down the cancer prior to 
radiation treatment. Side effects of hormone use include: erectile dysfunction, weight gain and loss of libido. 
Temporal 
brachytherapy 
Temporal brachytherapy is a treatment method utilising high dose radiation that is inserted into the prostate gland at varying 
intervals as a means of damaging or destroying the prostate cancer cells. Advantages of this treatment option include: quick and 
easy (1/2 day treatment) and that nearby healthy cells are less likely to be damaged due to receiving a smaller dose of radiation. 
Disadvantages of the treatment include: bowel, urinary and erectile issues, and lack of certainty as to whether the treatment has 
been successful. Side effects with the treatment include: tiredness and fatigue, urinary incontinence, erectile dysfunction and 
bowel issues. 
Permanent seed 
brachytherapy 
 
This treatment option is similar to temporal brachytherapy but uses low doses of radiation in the form of seed implants being 
inserted into the prostate gland. 
The treatment has similar advantages to temporal brachytherapy including lack of damage to surrounding tissue and length of 
treatment time. The disadvantages of the treatment include lack of certainty as to whether the treatment has worked, use of a 
general anaesthetic, and bowel, erectile and urinary issues. Side effects of the procedure include: semen discolouration and 
blood in urine, testicle bruising and pain, pelvic pain, urinary discomfort, frequent urination, erectile dysfunction, tiredness and 
fatigue, and urinary incontinence.  
Transurethral resection 
of the prostate 
(TURP). 
TURP is a procedure where a looped metal wire is inserted into the urethra to relieve pressure from the urethra. TURP doesn’t 
prevent cancer but can aid some of the symptoms involved with other prostate cancer treatments. 
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High intensity focused 
ultrasound (HIFU) for 
prostate cancer 
HIFU is a relatively low risk procedure used to kill cancer cells by heating them to high temperatures using high frequency 
sound waves that are inserted into the rectum using an ultrasound probe. Risks of HIFU can include urinary incontinence, 
erectile dysfunction and back passage issues. HIFU is usually a technique used for men who have localised prostate cancer 
rather than advanced cancer. 
Cryotherapy Cryotherapy is the use of extremely cold temperatures to destroy cancer cells. There are two types of this procedure known as 
Whole Prostate Cryotherapy where the whole prostate is frozen, or Focal Cryotherapy which targets the area where the cancer is 
in the prostate. Side effects of cryotherapy include urinary incontinence and erectile dysfunction. 
Chemotherapy Chemotherapy is the use of drugs to target and destroy cancer cells, usually utilised for advanced metastatic cancer. 
Chemotherapy isn’t curative but aims to slow down cancer cell progression and development. The main drawback of 
chemotherapy is the lack of specificity, meaning healthy cells will also be damaged in addition to cancer cells. Side effects of 
chemotherapy include tiredness and fatigue, hair loss, vomiting and nausea and infections due to immunocompromisation.  
Steroids Steroids, like hydrocortisone and dexamethasone, are used to treat cancer cells by preventing cell proliferation and shrinking the 
tumour. 
Bisphosphonates Bisphosphonates are drugs specifically used to treat cancer that has spread to the bones. If a cancer has spread to bone sites, 
they can cause bone breakdown and osteolysis. Bisphosphonates aim to reduce this effect by promoting bone generation. 
Prostate cancer can cause both osteolytic lesion and osteoblastic lesions (more common in prostate cancer). Importantly, 
Bisphosphonates act to inhibit bone destruction by osteoclasts. As prostate cancer generally forms osteoblastic lesions when it 
moves to bone, it makes Bisphosphonates less effective for use in metastatic prostate cancer, compared to cancer which form 
osteolytic lesions (for example breast cancer).    Bisphosphonates can also be used to alter calcium levels in the blood, as high 
blood calcium is common in patients with metastatic bone cancer. Side effects of Bisphosphonates include nausea and 
vomiting, flu-like symptoms, kidney issues and loss of appetite. 
Abiraterone and 
Enzalutamide  
Abiraterone and Enzalutamide are two new types of hormone therapy which can be utilised for men with advanced metastatic 
prostate cancer, specifically if other hormone therapies have previously failed. Abiraterone (also known as Zytiga® or 
abiraterone acetate) works via targeting the enzyme cytochrome P17 and, through this enzyme, prevents testosterone production 
thus causing shrinkage of the tumour. Enzalutamide (also known as Xtandi) is a drug which works via the androgen receptor 
which blocks male signalling hormones controlling cancer cells proliferation. As with abiraterone this will cause the tumour to 
shrink. Side effects of Enzalutamide include tiredness and fatigue, loss of fertility, muscle spasms and weakness and hot 
flushes. Side effects of Abiraterone include tiredness and fatigue, diarrhoea, high blood pressure, low potassium levels, bladder 
infections and heart problems. 
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As illustrated in the above table, there are various ways in which prostate cancer can 
be managed depending on how far the cancer has progressed and the type of cancer. 
A significant issue with almost all of the treatments however is the often debilitating 
risks and side effects of each individual treatment. The majority of prostate cancer 
patients undergo chemotherapy, hormone therapy and radiotherapy, all of which 
present unpleasant effects. This epitomises the global need for better treatment 
utilising a specific molecular target in prostate cancer.  
1.1.7  The metastatic cascade  
When cancer cells break away from the primary tumour and begin to move around 
the body, the process is known as metastasis. Metastasis and oncogenic progression 
is difficult to decipher and elucidating molecules involved in metastasis and their 
mechanism of action is extremely important in cancer biology. The transition of 
localised cancer to advanced, metastatic cancer involves various biochemical and 
morphological cellular changes. The process for how cells become cancerous was 
first evaluated in 1889 by a surgeon called Stephen Paget, where he postulated on 
how otherwise healthy cells became unhealthy and dysfunctional. This reasoning led 
to a milestone publication of his hypothesis which became known as the ‘seed and 
soil’ hypothesis of cancer (Paget, 1989b). Although little was known at the time of 
biochemical interactions and cell signalling mechanisms, the idea proposed that the 
process of cancer spread depends on interaction or cross-talk between various cancer 
cells (the ‘seeds’) and the surrounding microenvironment (the ‘soil’) (Fidler, 2003, 
Paget, 1989a). This discovery was ground-breaking and served as a basis for future 
discoveries and developments in the field of cancer biology and medicine.  
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Metastatic cancer arises when cancer cells escape the primary site where the tumour 
originated (for example, the prostate gland) and travel to a distinct, secondary site 
(for example, bone). This is a multi-step process involving cancer cell proliferation, 
migration, proliferation, invasion, survival, adhesion and colonisation. The cancer 
cells travel to other parts of the body via the circulatory system, where cancer cells 
enter the bloodstream, or the lymphatic system, where cancer cells enter the lymph 
vessels and lymph nodes (Figure 1.7). This complex metastatic cascade remains 
poorly understood, and is one of the most important factors for patient prognosis. An 
initial trigger, for example a genetic mutation or a chemical carcinogen, can cause 
generation of multiple abnormal cells which divide continuously, forming an initial 
tumour localised to one area of the body. Upon expansion, these cancer cells will 
start to infiltrate the cell barrier and pass into the extra cellular matrix (ECM) and 
this process is referred to as Local Invasion (CancerResearchUK, 2016a). Cancer 
cells can penetrate blood vessels and lymph vessels, in a process known as 
intravasation, and this allows them to move to secondary sites forming secondary 
tumours. For successful metastatic spread of cancer cells, a development and 
expansion of a vascular network is crucial in order to supply cancer cells with 
oxygen and vital nutrients and to remove waste products (Nishida et al., 2006). Once 
this is achieved, metastatic cancer cells can then effectively rely on this network for 
sustenance and don’t require pre-existing vessels. Tumour angiogenesis itself is a 
complex process and is regulated by a number of pro- and anti- angiogenic factors 
which influence metastasis proliferation (Russo et al., 2012). Various proteins have 
been implicated in activation of tumour angiogenesis; these include but are not 
limited to vascular endothelial proliferation factor (VEGF) (Moens et al., 2014), 
angiogenin (Adams and Subramanian, 1999), transforming proliferation factor 
 Chapter I 
28 
 
(TGF)-α (Schreiber et al., 1986), TGF-β (Ferrari et al., 2009), basic fibroblast 
proliferation factor (bFGF) (Rifkin and Moscatelli, 1989) and tumour necrosis factor 
(TNF) (Wajant, 2009). VEGF, a key player in tumour angiogenesis, is a potent 
angiogenic factor promoting angiogenesis during embryonic development, 
contributing to wound healing in healthy cells and also inducing angiogenesis in 
malignant tumours (Carmeliet, 2005). The VEGF family help orchestrate 
angiogenesis by triggering signalling cascades, binding to one or more specific 
receptors, VEGF receptor 1 (VEGFR1) for example, on the surface of target cells 
like endothelial cells (Ferrara et al., 2003). This ultimately can lead to downstream 
processes influencing angiogenic signalling pathways and hence tumour 
angiogenesis (Seguin et al., 2014). Once this is accomplished it provides tumours 
with sufficient resources to expand rapidly and also, due to abnormal structures, 
provides close links to the circulatory system for metastatic cancer cells to break 
away, further facilitating metastatic dissemination to secondary sites. Once cancer 
cells are able to migrate around the body, they may arrest at secondary locations, 
begin to leak out of blood vessels and into surrounding tissue, a process known as 
extravasation (Strell and Entschladen, 2008). Finally, this allows cancer cells to 
reach a secondary site and form secondary tumours (Figure 1.7). Cancer cells have 
various mechanisms enabling enhanced cell survival and thus allow them to evade 
the anoikis process or programmed cell death (Paoli et al., 2013). Collectively, this 
perpetuates cancer progression and ultimately contributes to a more aggressive form 
of cancer.    
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Figure 1.7 The metastatic cascade.  
Schematic diagram describing steps involved in the transition from normal cells to 
cancerous metastatic cells and how they are distributed to distinct regions in the 
body. 1) Local Invasion: Cells invade nearby tissue and surrounding area. 2) 
Intravasation: Cancer cells bypass basement membrane and move through nearby 
blood vessels and lymph vessels. 3) Circulation: Cells travel to other parts of the 
body utilising the lymph or blood system. 4) Arrest and extravasation: Cancer cells 
reach secondary site of the body and infiltrate surrounding tissue. 5) Proliferation: 
Cancer cells proliferate at secondary site forming secondary tumours. 6) 
Development of secondary tumour and angiogenesis: Cancer cells stimulate the 
proliferation of new blood vessels creating their own blood supply, promoting 
further tumour proliferation. Adapted from (NationalCancerInstitute).  
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1.1.8  Prostate cancer metastasis: bone metastasis  
As discussed above, at an early stage of cancer, cancer cells will be confined to the 
immediate areas of origin and in the case of prostate cancer, cancer cells are 
confined to the prostate gland. The main sites in which  prostate cancer may spread 
to are the adrenal gland, bone, liver, and lung (NationalCancerInstitute) and a key 
area of interest for this study will be to evaluate any implications EPLIN has in the 
spread of prostate cancer to the bone. 
Bone metastasis involves the infiltration, invasion and adhesion of migrating tumour 
cells to bone, which utilises various molecular mechanisms (Weidle et al., 2016). 
Bone cells are a frequent target for metastases from multiple cancers including 
prostate, breast and lung and can progress rapidly. Of all people with prostate cancer, 
bone is frequently the first target for metastasis and greater than 2 out of 3 prostate 
cancers that spread to secondary tumour sites will spread to bone 
(AmericanCancerSociety, 2016). The preference of prostate cancer spread to bone is 
likely due to the bone microenvironment and its favourable proliferation conditions 
and proliferation factor abundance, rich vasculature and cytokine enrichment for 
tumour cells (Bussard et al., 2008, Paget, 1989a). Bone metastasis is commonly 
associated with severe bone pain, osteolysis, increased bone fragility, increased 
fracture risk, bone deformity, hypercalcaemia and leukoerythroblastic anaemia 
(Mundy, 2002). Bone metastasis has a significant and detrimental effect on survival 
rates of people with prostate cancer. Mortality rates and outlook can depend on 
various factors including age and how far the cancer has spread, but metastatic bone 
cancer is significantly worse compared to primary prostate cancer with 
approximately 50% of patients surviving only 5 years following diagnosis 
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(CancerResearchUK, 2016d). A study established the five year survival rate of 
prostate cancer patients will drop from 56% to just 3% comparing those with or 
without bone metastasis (Norgaard et al., 2010). Treatment options for metastatic 
bone cancer can include hormone therapy, radiotherapy, chemotherapy and surgery, 
but can also include the use of drugs like bisphosphonates to alter and control blood 
calcium levels (Table 1.2). Bone metastasis therefore is an extremely important 
consideration for patients with prostate cancer, along with researchers investigating 
prostate cancer metastasis and cancer biology. 
1.1.8.1 Bone microenvironment - Osteoblasts, osteoclasts and osteocytes 
Bone is a specialised type of connective tissue which makes up the vertebral skeleton 
and has many vital functions including structural support, protection and in the 
regulation of calcium levels in the body (Marks, 2002). Bone is made up of various 
cellular constituents and these include osteoblasts and osteoclasts. Osteoblasts are 
derived from mesenchymal stem cells and make up a large proportion of bone cells 
which function in bone formation (Clarke, 2008). Osteoblasts are mononuclear cells 
which play a pivotal role in regulating and maintaining skeletal architecture and 
regulating osteoclast activation (Caetano-Lopes et al., 2007). Osteoclasts on the 
other hand are multinucleated cells responsible for breaking down bone cells and 
bone resorption. Osteoclasts function to repair, maintain and remodel bones of the 
skeleton but are also utilised by cancer cells for osteolytic bone destruction 
(Roodman, 2001). For appropriate bone turnover in the body, bone remodelling must 
continuously occur and osteoblasts and osteoclasts are pivotal for this process. 
Figure 1.8 illustrates a simplified overview of the process of osteogenesis in which 
osteoblasts are formed. 
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Figure 1.8 Schematic representation of osteogenesis and the bone formation 
process.   
MSC, Mesenchymal stem cell. Adapted from (Bose et al., 2013).   
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1.1.8.2 Bone metastasis: pathophysiology and molecular genetics 
1.1.8.2.1 Receptor Activator of Nuclear factor kappa-B ligand (RANKL) 
There are various molecular factors established in the development and progression 
of metastatic bone cancer. These can include molecules involved in osteoblast and 
osteoclast signalling, cytokines and angiogenic molecules. For example, one of the 
factors involved in the formation of bone lesions is receptor activator of nuclear 
factor kappa-B ligand (RANKL) which is a protein involved in bone regeneration 
and remodelling and signals via the receptor activator of nuclear factor kapp B 
(RANK) / RANKL / osteoprotegerin (OPG) pathway. RANKL is positively 
associated with prostate cancer progression, with high levels in prostate cancer cell 
lines PC-3, LNCaP and DU-145 compared to normal prostate cell line RWPE2 (Li et 
al., 2014). In addition, increased RANKL is also seen in aggressive cancer samples 
and samples which have metastasised to bone, compared to non-aggressive samples 
(Li et al., 2014). It has been reported that RANKL can influence cancer cell 
invasiveness, with treatment of RANKL significantly increasing cellular invasion in 
prostate cancer, and knockdown of RANK suppressing this pro-metastatic effect (Li 
et al., 2014). Manipulation of RANKL expression has also revealed in vivo 
implications on cell proliferation. Mice which have been injected with MDA-MB-
231 breast cancer cells with RANKL knock-down demonstrated an 80% reduction in 
osteolytic lesions compared to control mice (Zheng et al., 2014).  
1.1.8.2.2 Receptor Activator of Nuclear factor kappa-B (RANK) 
RANK is the signalling receptor for RANKL and both molecules are synergistic in 
their related function, and have key regulatory roles in bone remodelling and bone 
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physiology (Boyce and Xing, 2007). Similar to RANKL, RANK expression is 
frequently elevated in various cancers (Santini et al., 2011), can act as a predictive 
marker in cancer progression (Zhang et al., 2012), and can influence chemotherapy 
response and survival rates in osteosarcoma (Bago-Horvath et al., 2014). 
RANK/RANKL is also able to influence several cellular functions in cancer 
progression including cellular migration and invasion (Li et al., 2014, Song et al., 
2014), in addition to having roles in the establishment of bone metastasis (Mori et 
al., 2007), suggesting a complex network of regulatory molecules co-ordinating this 
signalling cascade.  
1.1.8.2.3 Osteoprotegerin (OPG) 
An additional molecule in RANKL signalling and cancer progression is the cytokine 
receptor OPG. OPG acts as a decoy receptor to RANKL and like RANKL has 
implications in bone metastasis. It has been recently demonstrated that patients with 
clear-cell renal cell carcinoma (ccRCC) have an increased ratio of RANK/OPG and 
elevated RANK/OPG levels were associated with bone metastasis and reduced 
patient survival (Beuselinck et al., 2015). This increased ratio also has implications 
in non-small cell lung cancer patients where elevated RANK/OPG ratios were 
associated bone metastases and correlated with lymph node involvement, tumour 
stage and overall cancer aggressiveness and metastatic potential (Peng et al., 2013). 
These findings indicate the RANK/RANKL/OPG pathway is a paramount signalling 
pathway involved in cancer progression and bone metastasis. Both RANKL and 
OPG display differential expression in cancer, demonstrate potential for 
manipulating cancer cell characteristics and have potential to control bone 
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metastases formation by targeting cellular invasion, osteolytic lesion proliferation 
and influencing overall cancer development. 
1.1.8.2.4 Interleukin 6 (IL-6) 
A further prominent molecule implicated in bone metastasis is interleukin 6 (IL-6). 
Interleukins are a group of cytokines involved in a myriad of biological functions 
and there is an abundance of evidence linking IL-6 to cancer development and 
progression. IL-6 has been shown to promote cell proliferation and proliferation in 
many tumour cells including prostate cancer via activation of various signalling 
pathways (Ogata et al., 1997, Smith et al., 2001). IL-6 also has roles in promoting 
osteolysis via RANKL/OPG signalling (Itoh et al., 2006), angiogenesis (Huang et 
al., 2004) and immunomodulation (Yu et al., 2007). The diversity of IL-6 on 
physiological functions and the abundance of evidence associating IL-6 as a pro-
cancer molecule and in bone metastasis has led to IL-6 being utilised in various 
clinical trials via inhibitor models testing therapeutic potential (Ara and Declerck, 
2010). 
1.1.8.2.5 Parathyroid hormone related peptide (PTHrP) 
Another relevant player in the establishment of bone metastases is the parathyroid 
hormone related peptide PTHrP. Physiologically, PTHrP functions in autocrine and 
paracrine signalling specifically in embryonic development and in the regulation of 
cell proliferation and proliferation in various cell types (Devys et al., 2001). PTHrP 
has been evaluated for its potential role in the regulation of bone cancer in several 
cancer systems and in bone metastasis. In lung cancer, it has been demonstrated that 
PTHrP facilitates bone metastasis in SBC-5 cells (Miki et al., 2004) and in breast 
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cancer, PTHrP is associated with the formation of bone metastases and poor patient 
outcome alongside TGF-β (Xu et al., 2015). In prostate cancer, increased expression 
of PTHrP has been found in bone metastases from prostate cancer (Iddon et al., 
2000) and PTHrP has been shown to promote Epithelial to Mesenchymal Transition 
(EMT) (Ongkeko et al., 2014). PTHrP is therefore an important molecule in cancer 
progression and bone metastasis not only through its physiological cell function but 
also with its persuasive implications in bone metastasis pathophysiology.  
1.1.8.2.6 Macrophage inflammatory protein 1 alpha (MIP-1α) 
A further molecule associated specifically in the formation of osteolytic bone 
metastasis is the chemokine macrophage inflammatory protein 1 alpha (MIP-1α). 
MIP-1α functions as a pro inflammatory protein able to induce osteoclast formation 
and has been associated in cancer development (Kukita et al., 1997). MIP-1α has 
been evaluated as a stimulatory factor in multiple myeloma where it induces cell 
migration and causes activation of the Mitogen Activated Protein Kinase (MAPK) 
pathway accelerating proliferation and survival (Lentzsch et al., 2003). Additionally, 
elevated MIP-1α has also been associated with poor patient prognosis and formation 
of osteolytic bone lesions in multiple myeloma (Hashimoto et al., 2004). These data 
suggest an integral role for MIP-1α in multiple myeloma and thus may be a crucial 
regulator in the establishment of bone metastases. 
1.1.8.2.7 Bone metastasis: The Vicious Cycle 
The Vicious Cycle is a term used in cancer biology to describe how cancer cells 
hijack the characteristics of bone forming osteoblasts and bone absorbing osteoclasts 
to promote cancer cell proliferation, survival and proliferation (Figure 1.9). The 
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vicious cycle is a complex process involving many molecular factors including TGF-
β, PTHrP, OPG, RANK and RANKL. These molecules play key roles in 
osteoblast/osteoclast activity in normal cells and in cancer and thus have a crucial 
impact on bone remodelling. Firstly, PTHrP is secreted by cancer cells which can 
cause osteoclastic bone resorption and bone destruction in metastatic breast cancer 
cells (Guise et al., 2002). TGFβ has also been implicated with the vicious cycle in 
association with PTHrP; TGFβ acts upstream increasing PTHrP to mediate 
osteolysis via the Smad and MAPK signalling pathway (Kakonen et al., 2002). The 
osteoclast activating increase in PTHrP seen in tumour cells also produces RANKL 
and downregulates OPG, further causing osteolysis (Mundy, 2002). Once RANKL is 
activated, RANK signalling can then further activate downstream transcription 
factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB) and Activator protein 1 (AP-1) promoting osteoclast differentiation, encouraging 
bone resorption (Mundy, 2002). Osteolysis, mediated by osteoclasts formed in 
response to RANKL, PTHrP and TGFβ then causes the release of proliferation 
factors including insulin-like proliferation factor 1 (IGF1) and TGFβ, in addition to 
activating the Smad and MAPK signalling pathway, which stimulate tumour cell 
proliferation, thus continuing the cycle (Mundy, 2002). This process is not limited to 
these molecules but they play important roles to tightly regulate and promote the 
cycle. The vicious cycle is multifactorial involving various cell types and intricate 
regulation and is therefore a target for cancer therapy, utilising molecules like 
RANKL, PTHrP and TGFβ, for preventing bone metastases formation. 
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Figure 1.9 The Vicious Cycle.  
The vicious cycle is a term used to describe the signalling mechanisms and 
molecules involved in bone remodelling in metastatic bone cancer. PTHrP, RANK, 
RANKL, OPG and TGFβ are all key components of the cycle. PTHrP is secreted by 
metastatic cancer cells and initiates osteoclastogenesis by binding osteoblasts. 
PTHrP causes an increase in the expression of RANKL, in addition to other 
molecular factors like IL-6 and TNF, and decreases expression of OPG. RANKL 
binds osteoclasts, induces osteoclast formation and drives bone resorption and 
osteolysis. This process generates proliferation factors like TGFβ and IGF1, which 
promote production of PTHrP by cancer cells, in addition to causing tumour 
expansion. With the generation of PTHrP, the cycle continues and bone is further 
destroyed accompanying further tumour proliferation. Adapted from (Gartrell and 
Saad, 2014).  
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The vicious cycle illustrates that the establishment of bone metastases is a crucial 
determinant for mortality rates and in the progression of cancer due to the 
sophisticated nature of signalling mechanisms in bone remodelling. Subsequent to 
this, biomarkers for detecting pre-bone metastases are vital. Currently, there is no 
validated biomarker to establish whether prostate cancer will metastasise to bone and 
bone metastasis itself is difficult to specifically identify. Prognostic indicators like 
the PSA test, Gleason score and clinical tumour stage exist but are limited and it is 
difficult to get definitive answers on metastatic potential (Briganti et al., 2014). 
Various suggested biomarkers including bone-morphogenetic protein-6 (BMP6) 
(Deligezer et al., 2010), bone-specific alkaline phosphatase (BAP) (Zhao et al., 
2011) and procollagen type 1 amino-terminal propeptide (P1NP) (Klepzig et al., 
2009) have provided recent prognostic clues in bone metastasis however there is yet 
an identified biomarker with sufficient prognostic clinical value for prostate cancer 
and bone metastasis. EPLIN has been established by our lab as a putative tumour 
suppressor and as an indicator of prognosis in multiple cancer phenotypes (Jiang et 
al., 2008, Liu et al., 2012a, Liu et al., 2012b, Sanders et al., 2011). Based on this 
previous research, and the current lack of a suitable molecular biomarker for bone 
metastasis, a key consideration of this PhD will be to elucidate if EPLIN can provide 
prognostic value in the metastatic cascade of prostate cancer to bone locations.  
1.2  Epithelial Protein Lost in Neoplasm (EPLIN) 
The primary focus of this PhD is on EPLIN; a cytoskeletal, actin-binding protein 
encoded by the LIMA1 gene. EPLIN is expressed preferentially in epithelial cells, 
with high levels in the placenta, prostate, kidneys, ovary and heart but low levels can 
be detected ubiquitously around the body. EPLIN was initially identified in oral 
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cancers for its differential expression between normal oral epithelial cells and 
Human Papilloma Virus (HPV)-immortalised oral epithelial cells (Chang et al., 
1998). EPLIN exists as 2 distinct isoforms, a 600 amino acid, 90kDa EPLINα 
isoform and a larger 759 amino acid, 110kDa EPLINβ isoform, and these isoforms 
are generated from an alternative pre-mRNA splicing event (Figure 1.10) (Maul and 
Chang, 1999). The EPLINα isoform has been implicated in the progression of 
various cancers and this was initially recognised in oral cancer, breast, prostate and 
xenograft tumours where EPLIN expression was either down regulated or 
completely abolished (Maul and Chang, 1999). The EPLIN genomic structure 
consists of 11 exons and 10 introns, with exons 1-3 only present in EPLINβ and 
EPLINα utilising exons 4-11 of LIMA1 for transcription (Chen et al., 2000). EPLIN 
is present on chromosome 12 and the EPLIN gene has 2 separate promoter regions; 
the EPLINβ promoter is near the start of the gene in exon 1, whilst EPLINα initiates 
~50Kb downstream near the end of intron 3, prior to exon 4 and at amino acid 
position 161 in the EPLINβ protein (Figure 1.10) (Chen et al., 2000). 
 Chapter I 
41 
 
 
Figure 1.10 Schematic diagram of the LIMA1 genomic structure and EPLIN structural isoforms.  
The LIMA1gene consists of 11 exons and 10 introns. EPLINα differs from EPLINβ at the amino terminus where an additional 159 
amino acids is present in EPLINβ. Shown below EPLINβ is the 52 amino acid centrally located LIM domain common to both EPLIN 
isoforms. Adapted from (Maul and Chang, 1999). 
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The amino acid sequence of EPLIN is characterised by a single centrally located 
LIM domain which supposedly aid structural self-dimerisation and contains 
subdomains for Zinc binding (Figure 1.11) (Maul and Chang, 1999, Chen et al., 
2000). LIM-domain containing proteins are frequently present in molecules 
responsible for cytoskeletal organisation, such as the focal adhesion phosphoprotein, 
paxillin, and the LIM domain is generally responsible for sites of protein-protein 
interaction (Brown et al., 1996). LIM domain proteins are also associated with 
important cellular roles including cell cycle progression, are involved in 
developmental processes and are implicated in several cancers including leukaemia, 
breast cancer and neuroblastoma (Matthews et al., 2013). EPLIN is important in the 
regulation of actin dynamics and aids actin filament bundle assembly, and the amino 
terminal of the EPLIN protein structure is essential for this localisation to the actin 
cytoskeleton (Song et al., 2002).  
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Figure 1.11 Protein structure of EPLIN LIM domain (PDB ID=2D8Y).   
Protein structure of the EPLIN centrally located LIM domain. Zinc binding domains depicted. This domain may aid self-dimerisation. 
Image generated using UCSF Chimera software. 
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Sequence analysis has revealed EPLIN is conserved across species with EPLINα and 
EPLINβ isoforms present in mouse, displaying 77% and 75% identity similarity for 
human EPLINα and EPLINβ, respectively (Figure 1.12) (Maul et al., 2001). A role 
for EPLIN has also been suggested in muscle development in pigs, where EPLIN 
displayed a temporal expression pattern with only the EPLINα isoform present in 
developing skeletal muscle (Wang et al., 2007). Since the discovery of EPLIN, our 
lab has shown that aberrant EPLIN expression is associated with the progression of 
various cancer types including breast, oesophageal, pulmonary and prostate cancer. 
EPLIN levels decrease as the cancer progresses and become more advanced, giving 
EPLIN potential to provide prognostic value, and overexpression analysis suggests 
EPLINα  is a putative tumour suppressor (Jiang et al., 2008, Liu et al., 2012a, 
Sanders et al., 2011, Sanders et al., 2010, Liu et al., 2012b). The described loss of 
EPLIN in cancer has functional implications on the actin cytoskeleton and may 
contribute to enhanced metastatic potential of cancer cells.
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Figure 1.12 ClustalW protein alignment of Human, Mouse and Pig EPLINβ.  
Areas of amino acids that are conserved across species are highlighted. The region shown is amino side of the EPLINβ protein, where 
EPLINα originates at amino acid (AA) p.161. ClustalW generated using BioEdit Biological Sequence Alignment software. 
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1.2.1 The EPLIN interactome: regulation in actin dynamics  
EPLIN has a number of functional partners (Figure 1.13/Table 1.3) and the globular 
protein actin is central to the function of EPLIN. EPLIN has 2 functional actin 
binding sites which flank the central LIM domain and it is this binding capacity that 
engenders actin cross linking and actin filament bundle assembly (Maul et al., 2003). 
A fibrillar pattern is displayed by both isoforms and expression of EPLINα enhances 
the size and number of actin filament stress fibres and can also inhibit membrane 
ruffling via the signalling GTPase, Ras-related C3 botulinum toxin substrate 1 
(Rac1) (Maul et al., 2003). EPLIN therefore directly interacts with actin which 
suggests a possible role for EPLIN in cell migration, adhesion and cell morphology. 
Actin is an abundant, multifunctional protein responsible for cell migration in 
eukaryotic cells. Actin is part of the cytoskeletal network which consists of 
microtubules, microfilaments and intermediate filaments which are vital for cellular 
functions. Actin exists as monomers (G-actin) and filamentous polymers (F-actin) 
and is important for physiological functions including cell locomotion, cytokinesis, 
maintenance of cell shape and muscle contraction (Stricker et al., 2010). 
Transcription of the LIMA1 gene is suggested to be primarily controlled by 
monomeric G actin, with the actin-MAL-SRF signalling pathway regulating EPLIN 
production (Leitner et al., 2010).  Maul et al., (Maul et al., 2003) illustrated that 
EPLINα has 3 significant features: EPLINα has binding sites for actin and can cross-
link and bundle actin filaments, EPLINα stabilises actin filaments in vitro and 
EPLINα inhibits branching nucleation of actin filaments by the Actin related protein 
(Arp) 2/3 complex (Maul et al., 2003). Therefore, this suggests EPLIN may 
orchestrate actin filament dynamics by stabilising actin cytoskeletal networks (Maul 
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et al., 2003). Additionally, EPLIN has been shown to form part of an actin-
remodelling complex comprising of EPLIN, β-actin, γ-actin and gelsolin which co-
localises at the plasma membrane to the tumour suppressor, PTEN (Kim et al., 
2011). PTEN is a well-established tumour suppressor molecule so this postulates 
whether the interaction of PTEN and the actin-remodelling complex is itself an 
element supressing the development of neoplastic tissue and whether any 
interruption of these complexes may promote cancer progression. Based on these 
findings, EPLIN accommodates actin to accomplish various actin-related cellular 
processes including cell motility and migration and cell junctional adhesion (Abe 
and Takeichi, 2008).  
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Figure 1.13 EPLIN predicted functional partners.  
EPLIN (LIMA1) has various associations including Cadherin and Catenin molecules 
which contribute to cytoskeleton regulation. LIMA1: LIM domain and actin binding 
1; CDH1: Cadherin 1; CTNNA1: Catenin-α1; CTNND1: Catenin-δ1; CTNNB1: 
Catenin-β1; EGF: Epidermal Growth Factor C; PTPLAD1: Protein tyrosine 
phosphatase-like A domain containing 1; ATP6V1B1: ATPase, H+ transporting, 
lysosomal 56-58kDa, V1 subunit B1; PXN: Paxillin; RHOA: Ras homolog gene 
family, member A. Image generated and extracted from online STRING database.
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Table 1.3 EPLIN associated molecules.  
EPLIN 
association 
Biological significance  
References 
Actin 
Actin is an abundant protein important for cell migration. EPLIN has 2 actin binding 
domains that flank the EPLIN LIM domain. Pull down assays revealed EPLIN binds actin 
monomers and these results in actin cross linking and actin filament bundle assembly. 
(Maul et al., 2003) 
Paxillin 
May form a complex with EPLIN to co-ordinate actin dynamics. Immunohistochemical 
analysis of prostate cancer tissue/cells vs. normal revealed EPLIN overexpression 
influences paxillin expression and localisation. Co-localisation, co-precipitation and an in 
situ proximal ligation assay revealed direct association between the two molecules in 
cultured human mesangial cells. 
(Sanders et al., 2010, 
Sanders et al., 2011, 
Tsurumi et al., 2014) 
α-Catenin 
Immunoprecipitation and GST pull down assays reveal EPLIN interacts with α-catenin, 
forming a cadherin-β-catenin-α-catenin-EPLIN complex. 
(Abe and Takeichi, 
2008) 
Supervillin 
In vivo co-localisation studies and in vitro GST pull down revealed EPLIN interacts with 
the peripheral membrane protein, supervillin.  
(Smith et al., 2010) 
PINCH-1  
(Particularly 
interesting 
new cysteine-
histidine-rich 
protein-1) 
Pull down assays revealed endogenous EPLIN co-immunoprecipitates with endogenous 
PINCH-1 in keratinocytes. 
(Karakose et al., 
2015) 
ERK 
Extracellular 
signal–
regulated 
kinase 
ERK phosphorylates EPLIN and decreases EPLINs affinity to F-actin promoting cell 
migration. Inhibition of ERK abolishes EPLIN expression and reduces tumour suppressive 
ability of EPLIN. 
(Han et al., 2007, 
Jiang et al., 2008, 
Sanders et al., 2010) 
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DNp73 (TP73) 
In melanoma cells, both EPLIN isoforms are inhibited by DNp73 and this drives a more 
invasive phenotype.  
(Steder et al., 2013) 
SATB2 
(Special AT-
rich sequence-
binding 
protein 2) 
EPLIN is differentially regulated by the DNA binding protein, SATB2. SATB2 regulates 
the actin cytoskeleton via EPLIN association. When SATB2 is knocked out, osteosarcoma 
cells show reduced migration and are less invasive and this is mediated by EPLIN. 
(Seong et al., 2014) 
Arv1 (ACAT-
related protein 
required for 
viability 1) 
EPLIN interacts with and recruits Arv1 to the cleavage furrow during cell division. Co-
immunoprecipiation experiments reveal EPLIN interacts with Arv1 and show a stronger 
association with the EPLINβ isoform.  
(Sundvold et al., 
2016) 
Cav-
1(Caveolin-1) 
EPLIN regulates the lipid raft tumour suppressive protein, Cav-1. Co-immunoprecipitation 
and mass spectroscopy analysis revealed that EPLIN and Cav-1 bind to each other in 
normal and RasV12 cells.  
(Ohoka et al., 2015) 
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1.2.2  Paxillin and Focal Adhesion Kinase (FAK): potential links with EPLIN 
There is increasing evidence to suggest EPLIN regulates actin structures in 
cooperation with the focal adhesion protein paxillin. Paxillin is a 68kDa 
phosphotyrosine containing protein involved in signal transduction and focal 
adhesion and associated in various signalling pathways. Similarly to EPLIN, paxillin 
contains LIM domains which mediate protein-protein interactions but also 
accommodates further structural domains including SH2 and SH3 domain binding 
sites and LD motifs which co-ordinate cytoskeletal dynamics via interaction with 
cytoskeletal proteins, GTP activating proteins and various kinases that form a 
complex with paxillin (Figure 1.14) (Schaller, 2001). Paxillin therefore functions as 
a regulatory docking molecule with diverse roles in cellular adhesion, movement and 
motility acting via various signalling mechanisms and thus has implications in 
cancer development. Due to the complex molecular architecture and diverse 
signalling mechanisms of paxillin, paxillin is strongly associated in cancer 
development and progression, with paxillin being linked with various invasive, 
aggressive tumours including lung, colorectal, breast and prostate (Bhattacharjee et 
al., 2001, Farmer et al., 2005, Mackinnon et al., 2011, Mestayer et al., 2003, Yang et 
al., 2010). Paxillin is widely expressed in normal tissue but displays differential 
expression in cancer and expression can be targeted to manipulate cancer cell 
characteristics; for example, overexpression of paxillin influences cell motility, 
migration, and inhibits filopodia formation  in lung cancer (Salgia et al., 1999). In 
prostate cancer, paxillin knockdown can inhibit in vivo cancer cell proliferation in 
prostate cancer xenografts (Sen et al., 2012), and in breast cancer paxillin can 
influence cellular invasion, morphology and metastasis (Deakin and Turner, 2011). 
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In addition to potential use as a molecular therapeutic, paxillin is a promising agent 
for use as a prognostic marker in various cancers including breast (Madan et al., 
2006), lung (Kanteti et al., 2009) and ovarian cancer (Kim et al., 2012). 
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Figure 1.14 Paxillin domain structure and paxillin interactions in integrin 
signalling.  
(A) Paxillin structure. Paxillin gene is located on chromosome 12 and has 4 
isoforms. Paxillin contains 4 LIM domains which co-ordinate protein-protein 
interactions. Paxillin has multiple phosphorylation sites including phosphotyrosine 
and phosphoserine residues (indicated by red and blue circles respectively) and these 
aid cellular functions including cellular adhesion. Tyrosine phosphorylation creates 
docking sites for SH2 domain containing proteins encouraging downstream 
signalling. Serine phosphorylation contributes to paxillin conformation and thus 
influences interaction with paxillin binding partners. (B) Paxillin interactions in 
integrin signalling. Paxillin serves as a scaffolding protein to facilitate the functional 
organisation of various focal adhesion signalling molecules. These include but are 
not limited to FAK, Src, Vinculin, Talin and Actopaxin. The paxillin complex 
associates with integrin heterodimers and initiates integrin signalling which co-
ordinates various cellular processes. The putative EPLIN associated to paxillin site is 
depicted. Adapted from (Brown and Turner, 2004) and (Deakin and Turner, 2008).  
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Paxillin has strong implications in cancer due to its diverse roles as a signalling 
molecule and in focal adhesion. Paxillin may be functionally linked to EPLIN as 
recent reports highlight a link between the two molecules. When EPLINα is 
overexpressed, paxillin exhibits an increased staining pattern for both HECV 
endothelial cells and PC-3 prostate cancer cells (Sanders et al., 2011, Sanders et al., 
2010). This co-localisation pattern is also observed in cultured human mesangial 
cells at focal adhesion sites and co-immunoprecipitation results confirm an 
association between the two molecules (Tsurumi et al., 2014). EPLIN and paxillin 
may form a complex and potentially stabilise focal adhesions to co-ordinate actin 
dynamics in a complimentary manner. Given EPLINs role in actin dynamics it is 
strongly implicated in cellular processes including cell migration and invasion and 
thus down-regulation or loss of EPLIN in cancer may affect the metastatic potential 
of cancer cells, which could have downstream effects on paxillin signalling.  
Although there is an apparent association between these two molecules, exactly how 
they interact mechanistically remains elusive.  
Focal Adhesion Kinase (FAK) is also a crucial cytoplasmic regulatory protein 
involved in tyrosine kinase signalling and actin dynamics. FAK is located on 
chromosome 8 and has structural domains consisting of an N-terminal FERM (ezrin-
radixin-moesin) domain, a central catalytic domain, proline rich domains and a 
carboxy C-terminal domain for focal adhesion targeting (Figure 1.15) (Schaller, 
2010). These domains are responsible for focal adhesion targeting (FAT domain) and 
for interactions of FAK with other signalling molecules (FERM domain) including 
epidermal proliferation factor (EGF) receptor (EGFR), platelet derived proliferation 
factor (PDGF) receptor (PDGFR), the epithelial and endothelial tyrosine kinase 
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(ETK) and ezrin (Mitra et al., 2005). A key role of FAK is to recruit additional 
signalling molecules (including paxillin) at focal contacts during cellular adhesion 
(Mitra et al., 2005). In additional to the role of FAK as a docking protein in cellular 
adhesion, FAK is a critical component of actin cellular dynamics. FAK is known to 
interact with various signalling molecules to co-ordinate actin-related cellular 
processes like cell movement and these include but are not limited to Neural 
Wiskott-Aldrich Syndrome Protein (N-WASP), Arp2/3, GTPase Regulator 
Associated with Focal adhesion Kinase (GRAF) and paxillin (Schaller, 2010), 
suggesting a complex network of molecules orchestrating cellular function. FAK has 
two crucial phosphorylation events; Tyr397 and Tyr925. These two phospho-
tyrosine residues are critical to FAK function and for interaction with molecules 
including the tyrosine kinase Src and paxillin. Phosphorylation of FAK Tyr397 
creates a SH2 binding site for Src and promotes the binding of Src to FAK leading to 
Src-FAK signalling and downstream FAK phosphorylation (Schlaepfer et al., 2004) 
whereas phosphorylation of FAK Tyr925 in the FAT region is responsible for 
Proliferation Factor Receptor Bound Protein (Grb)2 adaptor protein binding and 
induces integrin associated focal adhesion autophosphorylation (Cheng et al., 2014).  
FAK and paxillin both play key roles in integrin signalling. Paxillin can act as a 
scaffolding protein for many integrin related signalling molecules, including FAK, 
and these proteins act cooperatively to engage integrin’s at the extracellular matrix 
(Turner, 2000b). Upon docking of paxillin and FAK at integrin sites, FAK can 
phosphorylate paxillin to create additional binding sites for further downstream 
signalling molecules (Shen and Schaller, 1999). This interaction of FAK and paxillin 
leads to signal activation of the MAPK pathway and thus stimulates gene expression 
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of genes involved in critical cell functions, including cancer cell migration (Crowe 
and Ohannessian, 2004). Overexpression of either of FAK and/or paxillin can 
promote cancer cell migration and invasion, illustrating the importance of cellular 
regulation of these two molecules in MAPK signalling and cancer development 
(Crowe and Ohannessian, 2004). The notion linking FAK and paxillin to integrin 
signalling and MAPK signalling is well documented (Giancotti and Ruoslahti, 
1999), however significantly less is available on the importance of EPLIN in integrin 
signalling. A recent article illustrated that EPLIN associates to integrin sites via 
interaction with the LIM-only domain protein, PINCH-1, and when depleted can 
exert an effect on keratinocyte spreading and migration (Karakose et al., 2015) 
suggesting EPLIN may have a crucial role on cell function via integrin signalling. It 
will be interesting to explore this potential role further via the interaction of EPLIN 
with paxillin and FAK. 
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Figure 1.15 Schematic representation of FAK domain structure.  
FAK has 3 major domains consisting of a FERM domain (ezrin, radixin and moesin 
homology) domain, a kinase domain and a focal adhesion targeting (FAT) domain. 
The FERM domain is responsible for interactions with molecules including ezrin and 
the epidermal proliferation factor (EGF) receptor. The FAT domain of FAK 
orchestrates focal adhesion activity of FAK via integrin signalling with molecules 
like talin and paxillin. FAK is subjected to various phosphorylation events primarily 
by tyrosine kinases and these include Tyr397, 576, 577, 861 and 925. FAK interacts 
with paxillin via Tyr925 phophorylation and also at Tyr397 with molecules 
including Src (via the SH2 binding domain), phospholipase Cγ (PLCγ), suppressor 
of cytokine signalling (SOCS) and p120 RASGAP. Phosphorylation of central 
tyrosine residues 576 and 577 is critical for catalytic response. The proposed sites for 
EPLIN interaction with FAK is illustrated in the figure. Adapted from (Mitra et al., 
2005).  
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Due to FAK’s primary role in cellular adhesion and movement, dysregulation of 
FAK has diverse implications in cancer which can act via various signalling 
pathways. FAK has been proposed to be activated and phosphorylated by integrin 
signalling to co-ordinate cell adhesion (Guan, 1997), in addition to having roles in 
cytokine receptor, proliferation factor and G-protein coupled receptor signalling 
(Yoon et al., 2015). These complex signalling mechanisms make FAK a key player 
in cancer development and progression. FAK has been shown to be upregulated in 
several cancers including pancreatic, colon and breast (Golubovskaya, 2014, Jiang 
and Hegde, 2016, Heffler et al., 2013a), with increased FAK levels correlating with 
poorer patient prognosis (Yom et al., 2011). This increased FAK expression has led 
to the development of inhibitor models for cancer therapy specifically targeting 
FAK, one of which is the small molecule inhibitor 1,2,4,5-Benzenetetraamine 
tetrahydrochloride  (Y15). This inhibitor acts by blocking autophosphorylation of 
FAK at Y397 and has promising implications in colon cancer where it could 
influence cellular traits including cell attachment and apoptosis and effectively 
inhibited tumour proliferation in mouse models (Daily, 2010). This inhibitor for 
FAK has also been used successfully as a supplement to chemotherapy with 
enhanced efficacy of therapeutic potential observed in colon cancer (Heffler et al., 
2013b). With the established use of FAK inhibitors in various cancer models, it will 
be interesting to see if FAK inhibition can be targeted in prostate cancer 
accompanying EPLIN expression manipulation. With FAK being overexpressed in 
cancer, and EPLIN being lost in cancer, and with the potential link between the two 
molecules it would be useful to see if they could be utilised to influence cancer cell 
characteristics and thus used to create a novel therapy for prostate cancer.  
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Although a putative link between EPLIN and paxillin has been previously 
demonstrated, less is known about interaction between EPLIN and FAK. It may be 
that interactions occur via tyrosine phosphorylation of FAK, possibly at Tyr397 or 
Tyr925, as there is already an established link between FAK and paxillin at the FAT 
domain of FAK (Hayashi et al., 2002) and between EPLIN and paxillin (Tsurumi et 
al., 2014, Sanders et al., 2011).  
1.2.3  Role of EPLIN in the Adherens Junction (AJ) 
The Adherens Junction (AJ) is a type of anchoring junction found predominantly in 
epithelial cells which functionally attach the actin cytoskeleton together in cells via 
linker molecules. EPLIN is an actin binding protein which functions to bundle actin 
filaments, suggesting the presence of EPLIN at AJ along with filamentous actin. The 
AJ contain various protein complexes along with EPLIN and these include 
cadherins, catenins and p120 catenins (Figure 1.16) (Meng and Takeichi, 2009). 
Within the AJ, cadherins and catenins associate together to form the cadherin-catenin 
complex and EPLIN provides a direct physical link for this complex to the actin 
cytoskeleton (Abe and Takeichi, 2008). The cadherin-catenin complex is comprised 
of E-cadherin, β-catenin and α-catenin, with E-cadherin positioned between adjacent 
cells and the catenins positioned in the cytoplasmic space of each cell (Mege et al., 
2006). E-cadherin binds directly to β–catenin which sequentially binds α-catenin, 
generating the cadherin–catenin complex (Yonemura, 2011). α-Catenin is a crucial 
component at the AJ and was initially recognised as being responsible for providing 
the bridge between the cadherin-catenin complex and actin (Nelson, 2008, Meng and 
Takeichi, 2009). This principle however has come under scrutiny as direct in vitro 
binding between α-catenin and actin had never been detected (Drees et al., 2005, 
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Yamada et al., 2005). Cavey et al., (Cavey et al., 2008) realised that α-catenin is not 
essential for E-cadherin stability, as complexes of β-catenin and E-cadherin were 
detected in RNAi α-catenin embryos (Cavey et al., 2008). Therefore, it’s apparent 
that cadherin-actin interaction is regulated not only by α-catenin but by a number of 
actin-binding proteins that are associated with α-catenin, including EPLIN 
(Yonemura, 2011, Taguchi et al., 2011). Abe and Takeichi (Abe and Takeichi, 2008) 
demonstrated, using immunoprecipitation and GST pull down assays, that both 
EPLIN isoforms directly interact with the α-catenin VH3 plus C-terminal region to 
generate a cadherin-catenin-EPLIN-actin complex at cell junctions (Abe and 
Takeichi, 2008). When EPLIN is depleted, the bridge to F actin was unable to form 
due to loss of organisation of the apical actin belt, with punctate accumulation of E-
cadherin at cell junctional points (Abe and Takeichi, 2008). This illustrates the 
importance of EPLIN in producing functional epithelial junctions.  
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Figure 1.16 Schematic representation of Adherens Junctions.  
The AJ between epithelial cells consists of various protein complexes to orchestrate 
actin cytoskeletal dynamics. The cadherin-catenin complex is associated with 
filamentous actin via EPLIN and/or vinculin which bind α-catenin in the cytoplasm.  
During functional AJ formation, E-Cadherin is expressed in the nucleus. During 
cancer progression and processes like EMT, proteins including E-Cadherin and 
EPLIN are downregulated or lost, enhancing cancer development. Adapted from 
(Ratheesh and Yap, 2012).  
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Additional molecules involved in regulating the AJ include the membrane-
cytoskeletal protein, vinculin, and the actin filament-binding protein, afadin (Geiger 
et al., 1980, Sawyer et al., 2009). Recent work from Taguchi et al., (Taguchi et al., 
2011) illustrated that EPLIN and vinculin may collaborate together in AJ formation 
via binding α-catenin either together or individually and cooperatively aid junctional 
adhesion (Taguchi et al., 2011). The cooperation of EPLIN and vinculin in cellular 
adhesion is also evident in endothelial cells. At the endothelial AJ, the endothelial E-
cadherin homolog, VE-cadherin, interacts with β- and γ- catenins which sequentially 
bind α-catenin and EPLIN in an analogous fashion to epithelial cells (Chervin-
Petinot et al., 2012). This allows the recruitment of vinculin and ultimately promotes 
strengthening of inter-endothelial junctions (Chervin-Petinot et al., 2012). The 
authors propose a role for EPLIN in tension dissemination at the endothelial AJ in a 
mechanosensory mechanism (Chervin-Petinot et al., 2012). The machinery from 
actomyosin exerts tension through EPLIN, which causes α-catenin to adopt a more 
accessible conformation, revealing a vinculin-binding site and allowing vinculin 
recruitment and actin association at endothelial cell-cell AJ (Gulino-Debrac, 2013). 
This mechanotransduction mechanism consisting of EPLIN and α-catenin suggests 
the endothelial AJ is regulated in a spatial and temporal pattern (Gulino-Debrac, 
2013). Finally, EPLIN also appears to be important for attachment to F-actin in 
endothelial cells; when EPLIN expression is down-regulated the organisation of F-
actin is considerably disrupted, leading to multiple holes in the actin cytoskeleton 
(Chervin-Petinot et al., 2012). Altogether this suggests that the AJ of epithelial and 
endothelial cells are orchestrated by various actin-binding, α-catenin-associated 
molecules and are dynamically regulated, with EPLIN having a critical role in cell 
adhesion, creating further implications of EPLIN loss in cancer 
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1.2.4  EPLIN– a key player in cell division? 
Cell division is the splitting of one cell into two, where biological information is 
passed onto daughter cells. For this process to successfully occur, various proteins 
need to functionally regulate the division and these include molecules like Rho 
GTPases, cyclin dependant kinases, integrins, cell division control protein homolog 
42 (cdc42), focal adhesion kinases, myosin and the globular protein actin (Heng and 
Koh, 2010). With this in mind, an actin-binding protein, such as EPLIN, may 
potentially have a regulatory role in cell division. This has been recently shown 
using HeLa cells where EPLIN depletion resulted in large numbers of multinucleated 
cells, signifying cytokinesis failure during cell division (Chircop et al., 2009). In 
successful mitotic division, actin and myosin II accumulate at the cleavage furrow 
during cytokinesis and EPLIN loss compromised each proteins ability to efficiently 
do this (Chircop et al., 2009). EPLIN appears to be important for the accumulation of 
other mitotic regulatory proteins including the GTPases RhoA and cdc42, where 
EPLIN depletion resulted in either a significantly reduced concentration of RhoA or 
a miss-placed location of cdc42 at the cleavage furrow (Chircop et al., 2009). EPLIN 
aids this successful cell division in conjunction with a number of regulatory proteins 
including supervilin and the oncogenic kinesin, Kinesin Family Member 14 (KIF14), 
suggesting a complex network of regulatory proteins at the cleavage furrow (Smith 
et al., 2010).  More recently it has been suggested that EPLIN plays a role as a 
recruitment protein in cell division where EPLIN recruits the membrane lipid 
transporter protein, Arv1 (Sundvold et al., 2016). Liquid chromatography-tandem 
mass spectrometry and co-immunoprecipitation experiments demonstrated an 
interaction between the two molecules and suggested both co-localised to the 
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cleavage furrow during early telophase (Sundvold et al., 2016). Altogether, this 
suggests EPLIN may have an integral role in cytokinesis and loss may lead to 
aneuploidy and genomic instability of daughter cells (Chircop et al., 2009). 
Therefore, EPLIN likely acts at various stages of the cell cycle with crucial roles co-
ordinating actin and myosin dynamics and functions as a recruitment protein for 
molecules involved in cytokinesis. This multifunctional role may have implications 
in cancer cells resulting in downstream effects on successful cytokinesis, increasing 
their tendency to form a cancer (Chircop et al., 2009). 
1.2.5  Post translational modification of EPLIN 
Post translational modification refers to changes made to proteins following 
transcription and translation and these can include changes like phosphorylation, 
glycosylation and ubiquitination. EPLIN has functional links to Extracellular Signal-
Regulated Kinase (ERK) which is a member of the MAPK family and is important 
in the regulation of actin organisation by phosphorylating various proteins including 
paxillin, FAK and other protein kinases and nuclear transcription factors to co-
ordinate cellular processes (Pribic and Brazill, 2012, Pearson et al., 2001). ERK is 
implicated in cellular events including cell migration and may facilitate this by 
phosphorylation of actin bundling proteins like EPLIN (Han et al., 2007). The 
protein structure of EPLIN has multiple putative phosphorylation sites (Figure 1.17) 
and it has been shown that ERK phosphorylates EPLIN at Ser360, Ser602, and 
Ser692 in vitro and in vivo (Han et al., 2007). Phosphorylation at the carboxy 
terminal of EPLIN decreases affinity to F-actin and thus provokes a reorganisation of 
the actin cytoskeleton, enhancing cell migration (Han et al., 2007). This implicates 
ERK in actin organisation and cell motility with EPLIN being a critical substrate for 
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phosphorylation (Han et al., 2007). ERK also plays a role in targeting EPLIN to 
focal adhesions and effects the interaction with paxillin; activation of the MEK-ERK 
pathway both reduced localisation of EPLIN to sites of focal adhesions and 
abolished paxillin interaction (Tsurumi et al., 2014). A recent study by Zhang et al., 
(Zhang et al., 2013) illustrated that this ERK-mediated phosphorylation of EPLIN is 
itself regulated by EGF and revealed how targeting this signalling cascade can be 
manipulated to reduce epithelial-mesenchymal transition (EMT) and thus prostate 
cancer invasiveness (Zhang et al., 2013). EGF is also capable of promoting EPLIN 
protein turnover in vitro and in vivo, targeting it for polyubiquitination and 
proteomsome degradation, enhancing EPLIN downregulation and also inducing 
downregulation of E-Cadherin (Zhang et al., 2013). This suggests EGF is a primary 
driver around EPLIN protein regulation, and could be a reason why EPLIN is lost in 
aggressive cancer, as EGFR and EGF and generally overexpressed in cancer cells 
(Normanno et al., 2006).  Recently, the human phosphatase CDC14A has been 
shown to counteract EGF-induced EPLIN phosphorylation by ERK; CDC14A 
dephosphorylates EPLIN at Ser362 and Ser604, invoking changes to the actin 
cytoskeleton and regulating cellular migration and adhesion (Chen et al., 2017). 
These data suggest several molecules are functionally related to EPLIN and provide 
a critical regulatory role for appropriate actin dynamics and may have implications in 
cancer progression. Furthermore, ERK is an established kinase for the association of 
paxillin and FAK via paxillin phosphorylation (Liu et al., 2002). How EPLIN 
associates with these molecules is currently unknown, but it could be via a specific 
phosphorylation event, which in itself could be ERK-dependant or ERK-
independent. Phosphorylation events have proved to be crucial for cell signalling and 
actin association in FAK (Westhoff et al., 2004) and for cell matrix adhesion 
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dynamics in paxillin (Zaidel-Bar et al., 2007), so it seems reasonable that they may 
be important for EPLIN function and dynamics. 
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Figure 1.17 Predicted phosphorylation sites in EPLINα.  
The protein structure of human EPLINα has multiple putative phosphorylation sites at all regions of the protein, including various sites 
where Serine kinases would likely act. Predicted Threonine and Tyrosine phosphorylation sites not shown. Highlighted in red is the 
phosphorylated residue suggested in (Han et al., 2007). Phosphorylation status predicted using NetPhos 2.0 software.  
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1.2.6  The role of EPLIN in cancer  
Cancer progression involves various cellular, morphological and molecular 
alterations which result in a transformed cellular phenotype, ultimately having the 
potential to invade surrounding tissue and disseminate throughout the body. Cancer 
treatment options remain largely unspecific and create various undesired side effects, 
though more targeted approaches are emerging. Therefore, elucidating a molecular 
target for treating cancer, in addition to understanding the mechanism of cancer 
development is crucial. EPLINα first received attention for its involvement in cancer 
in 1999 where EPLINα down-regulation was described in various cancer cell lines 
(Maul and Chang, 1999). Altogether, low levels of EPLINα transcript were found in 
8/8 oral cancer cell lines, 5/6 breast cancer cell lines and 4/4 prostate cancer cell 
lines (Maul and Chang, 1999). Using PC-3 and DU-145 prostate cancer cell lines, 
EPLINα expression was significantly reduced compared to primary prostate 
epithelial cells (PrEC), whereas aggressive cell lines LNCaP and LAPC4 failed to 
express EPLINα at all (Maul and Chang, 1999). This notion of EPLINα loss was also 
seen in breast cancer where EPLINα expression in cell lines BT-20, SKBr-3, MCF-7, 
T-47D and MDA-MB-231 was either reduced or completely lost (Maul and Chang, 
1999). Lastly, the authors demonstrated that EPLINα was a putative tumour 
suppressor molecule, where overexpression of EPLINα in osteosarcoma cells altered 
cell morphology and caused a reduction in cancer cell proliferation (Maul and 
Chang, 1999). Interestingly, when EPLINα was depleted in breast cancer cell lines, 
EPLINβ either remained consistent or actually increased (Maul and Chang, 1999). 
This illustrates the potential cancer protective effects the EPLINα isoform may exert 
in various cancer cell systems. EPLIN overexpression has also proved effective in 
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altering the proliferation phenotype and morphology in additional cell systems 
including anchorage-independent NIH3T3 transformed cells (Song et al., 2002). 
Using a soft agar assay and utilising the activated Cdc42 or the chimeric nuclear 
oncogene EWS/Fli-1 to transform NIH3T3 cells, EPLIN overexpression resulted in a 
~80% decrease in colony formation for Cdc42 transformed cells, with a similar 
proliferation decrease in EWS/Fli-1 transformed cells (Song et al., 2002). 
Interestingly, EPLIN displayed heterogeneous staining throughout Ras cells rather 
than localisation to the actin cytoskeleton (Song et al., 2002). This implies oncogenic 
transformation affects the EPLIN/actin architecture and thus, the localisation of 
EPLIN to the actin cytoskeleton may be important to exert its suppressive ability 
(Song et al., 2002).  
1.2.7  EPLIN in cancer: development, progression and identification as a 
tumour suppressor 
1.2.7.1  Prostate cancer  
There is increasing evidence to suggest EPLIN is implicated in the development of 
prostate cancer and also the process of EMT. Metastatic cancer cells rely on 
assembly and disassembly of the actin cytoskeleton in order to move, therefore 
expression of certain cytoskeletal proteins at cell junctions is crucial. EMT is a 
process where polarised epithelial cells are down regulated and subjected to 
biochemical and morphological changes which ultimately can contribute to prostate 
cancer (Serrano-Gomez et al., 2016). Epithelial cells become transformed to a 
mesenchymal cell phenotype, losing their cell polarity and cell adhesion at cellular 
junctions (Kalluri and Weinberg, 2009). The converted mesenchymal cell phenotype 
has a reorganised cytoskeleton and experience alterations in cell signalling  which 
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engenders enhanced migratory and invasiveness capabilities and increased resistance 
to apoptosis (Lamouille et al., 2014, Kalluri and Weinberg, 2009). During these 
cellular changes, the actin molecular architecture is disrupted and protein complexes 
like the cadherin-catenin complex and epithelial markers are lost (Figure 1.18) 
(Zhang et al., 2011). E-cadherin is a key epithelial marker and has implications in 
EMT where down regulation or loss of E-cadherin is frequently observed in tumour 
cell progression (Acs et al., 2001). As discussed, EPLIN is associated with the 
cadherin-catenin complex and contributes to functional cytoskeletal dynamics (Abe 
and Takeichi, 2008). Zhang and co-workers (Zhang et al., 2011) used biochemical 
and functional approaches to demonstrate EPLIN is a negative regulator of EMT and 
invasiveness in prostate cancer cells. EPLIN was significantly decreased in cells of 
more mesenchymal morphology (known as the Androgen Refractory Cancer of the 
Prostate (ARCaPM) cell lineage model), suggesting EPLIN down regulation is 
implicated in EMT, along with the cadherin-catenin complex (Zhang et al., 2011). 
Depletion of EPLIN also provokes various other morphological changes including 
disassembly of AJ, increased migratory and invasive potential of cells in vitro, 
activation of β-catenin signalling, increased expression of vimentin, increased chemo 
resistance and decreased expression and nuclear translocation of E-cadherin (Zhang 
et al., 2011). The authors also demonstrated that altered EPLIN expression affects a 
host of downstream genes involved in not only EMT, but various other biochemical 
processes including Wnt signalling, actin cytoskeleton regulation, proliferation factor 
signalling and functions important for cancer cell survival and progression (Zhang et 
al., 2011). Lastly, the authors used immunohistochemistry (IHC) to show that EPLIN 
downregulation is correlated with cancer progression in multiple cancer models 
including lymph node metastasis in prostate cancer, where EPLIN expression was 
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significantly reduced (Zhang et al., 2011). Altogether this illustrates that EPLIN may 
be involved in the regulation of EMT and prostate cancer progression and loss of 
EPLIN can lead to diverse downstream cellular and molecular effects. EPLIN in 
prostate cancer has also been evaluated by our laboratory using the prostate cancer 
cell line, PC-3. Using  IHC analysis, EPLIN displayed a significant decrease in 
staining intensity in tumour cells in comparison to normal (Figure 1.19) (Sanders et 
al., 2011). This was accompanied by quantification of staining intensity within the 
cohort, where lower levels of EPLIN staining were associated with cancerous and 
higher tumour grade samples (Sanders et al., 2011). Overexpression analysis of 
EPLINα resulted in decreased proliferation rate in tumour cells in vitro, along with 
reduced invasiveness and cell adhesion to the ECM (Sanders et al., 2011). Mice 
injected with PC-3 cells overexpressing EPLINα developed tumours at a markedly 
decreased rate in comparison to control (Sanders et al., 2011). Furthermore, cells 
overexpressing EPLINα displayed a greater staining pattern for the focal adhesion 
targeting protein, paxillin, implying EPLIN may also be present at these plaques or 
play a role in regulating paxillin (Sanders et al., 2011, Maul and Chang, 1999). 
Altogether these results demonstrate the potential of EPLIN in regulating prostate 
cancer progression and how it can be manipulated to suppress prostate cancer and 
EMT via impeding cancerous traits. 
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Figure 1.18 Schematic representation of early stages involved in Epithelial 
Mesenchymal Transition (EMT).  
EMT is a process where epithelial cells lose polarity and have a less organised and 
compact morphology. This change is both morphological and biochemical where 
molecules like E-Cadherin, Claudins, Occludins and EPLIN are lost and pro-
mesenchymal molecules are increased, including N-Cadherin, Fibronectin and 
Vimentin. This results in the degradation of the basement membrane of epithelial 
cells, and potential migration and invasion of cells. Adapted from (Micalizzi et al., 
2010).   
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1.2.7.2  Breast cancer  
EPLIN was first investigated in breast cancer by Maul and Chang (Maul and Chang, 
1999) where EPLINα expression was either reduced or completely lost in breast 
cancer cell lines BT-20, MCF-7, T-47D and MDA-MB-231(Maul and Chang, 1999). 
Our lab has also evaluated EPLINs involvement in breast cancer progression by 
comparing EPLIN staining in normal vs. tumour sections using IHC analysis. EPLIN 
was found to be substantially weaker in tumour cells than in normal epithelial cells 
(Figure 1.19) (Jiang et al., 2008). This correlated with lower EPLIN transcript in 
tumour samples compared to normal samples (Figure 1.19E) with lower EPLIN 
levels being associated with higher tumour grade, a poorer patient prognosis and 
reduced overall survival rates (Figure 1.19.F G, H) (Jiang et al., 2008). IHC analyses 
in breast cancer from additional research groups also show EPLIN loss as the tumour 
becomes more aggressive, specifically comparing EPLIN immunointensity of 
primary tumours vs. tumours with lymph node metastases (Zhang et al., 2011). 
Lastly, in vitro and in vivo overexpression analysis of EPLINα highlighted 
significant reductions in cell proliferation and cell invasion using transfected breast 
cancer cell lines, and also highly significant reductions in tumour size were observed 
in nude mice inoculated with EPLINα transfected vs. control MDA-MB-231 breast 
cancer cells (Jiang et al., 2008). This further strengthens the use EPLIN has as a 
tumour suppressive molecule and how it may be employed as a therapeutic agent in 
cancer. 
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Figure 1.19 EPLIN profile in prostate and breast cancer.  
Immunohistochemical staining (X20 objective magnification) of normal and cancerous (A) prostate and (B) breast clinical samples 
demonstrating EPLIN localisation and expressional differences. (C & D) Semi-quantitative analysis of EPLIN staining within prostate 
clinical cohort demonstrates lower levels of EPLIN staining are associated with cancerous and higher grade samples. (E) Within a 
clinical breast cancer cohort, lower transcript expression of EPLIN is seen in tumour samples compared to normal breast tissue and was 
associated with a higher grade (F), a poorer patient prognosis (G) and reduced overall survival rates (H). Figure modified from (Jiang et 
al., 2008, Sanders et al., 2011). 
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1.2.7.3  Oesophageal cancer 
In oesophageal cancer, Q-PCR analysis displayed reduced expression of EPLIN for 
both cancerous tissue and cancer cell models (Liu et al., 2012a). With regard to 
tumour histological grade, TNM status, nodal status and survival status, EPLIN 
transcript generally decreased with levels significantly lower in patients who 
ultimately died from the cancer, suggesting EPLIN is implicated in oesophageal 
cancer progression and may give an indication for oesophageal cancer prognosis 
(Liu et al., 2012a). Overexpression analysis of EPLINα in the KYSE150 cell line 
resulted in decreased proliferation and invasiveness compared to control KYSE150 
cells, suggesting EPLINα has tumour suppressive ability by regulating cellular 
aggressiveness in oesophageal cancer (Liu et al., 2012a).  
1.2.7.4  Lung cancer 
In a pulmonary cancer cohort also conducted within our lab, Q-PCR analysis showed 
a reduction of EPLIN expression in tumour vs. normal samples, where EPLIN was 
also reduced in later TNM stages and cancers with lymph node involvement (Liu et 
al., 2012b). Using the SKMES-1 cell line, overexpression of EPLINα via 
transfection in the pEF6 expression vector inhibited cell proliferation and cell 
motility (Liu et al., 2012b) in comparison to control SKMES-1 cells and again 
highlighting a role for EPLIN in regulating lung cancer progression. 
1.2.7.5 Ovarian Cancer  
Further work by our research group has also demonstrated EPLIN may be involved 
in the progression of ovarian cancer and has clinical potential as a prognostic marker 
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(Liu et al., 2016). Using knockdown models of EPLINα in epithelial ovarian cancer 
(EOC) cells SKOV3 and COV504, the loss of EPLINα was shown to have a 
significant pro-metastatic effect on cell proliferation (Liu et al., 2016). This trend 
was also seen on cell adhesion, invasion and motility using respective cell function 
assays with significant effects on cancer cell characteristics, with EPLINα 
knockdown and loss of expression causing the more metastatic phenotype (Liu et al., 
2016). This data is in agreement with previous reports of EPLIN loss in cancer, with 
more aggressive traits associated with loss of EPLIN. This study further supports 
EPLIN’s role as a potential prognostic marker for cancer development, and 
highlights how the molecule may contribute in the monitoring of cancer.   
1.2.7.6 Additional cancer implications and renal disease  
In addition to the apparent molecular loss of EPLIN in various cancers, EPLIN also 
appears to be reduced at the protein level for colorectal cancer and Squamous Cell 
Carcinoma of the Head and Neck (SCCHN), where IHC analysis revealed EPLIN is 
decreased in cancers with lymph node metastases vs. primary tumours (Zhang et al., 
2011). Lastly, in addition to the implication of EPLIN in the spread and progression 
of cancer, a recent publication provides a link between EPLIN and renal diseases 
where patients with either membranoproliferative glomerulonephritis (MPGN) or 
IgA nephropathy had a decreased expression profile for EPLIN via IHC analysis 
(Tsurumi et al., 2014). This advocates the idea that EPLIN may be involved in the 
pathology of various disease states. 
Collectively, these studies suggest two potential clinical roles for EPLIN: 1) as a 
clinical, prognostic indicator for cancer progression and development and 2) as a 
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tumour suppressive molecule in the regulation of cancer progression. Both these 
clinical options will be evaluated further throughout this study. 
1.2.7.7  Tumour angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing vessels and is 
essential for wound healing and normal proliferation and development. The 
angiogenic process is frequently utilised by cancer cells, by a means of metastasis 
and tumour angiogenesis, to support advanced tumour proliferation and as a means 
to reach secondary sites around the body and develop secondary tumours. 
Angiogenesis is therefore a critical factor when targeting cancer therapies and an 
active area of research. Molecular components are crucial for tumour angiogenesis 
and various drugs have been established targeting angiogenic molecules. VEGF is an 
established angiogenic molecule and therapies including Bevacizumab (Avastin), 
Aflibercept (Sanofi Aventis) and Sunitinib (Sutent) are all approved cancer therapies 
targeting VEGF and angiogenesis (Mukherji et al., 2013). EPLINα has been shown 
to have a suppressive role in angiogenesis, where overexpression in the HECV 
endothelial cell line resulted in a reduced capacity to generate tubular structures in a 
Matrigel tubule formation assay when compared to vector controls (Sanders et al., 
2010). This regulatory effect was also apparent in vivo where mice injected with 
HECV cells overexpressing EPLINα in conjunction with cancer cells developed 
tumours significantly slower than controls (Sanders et al., 2010). Forced expression 
also appears to exert an effect on cell matrix adhesion and migration capabilities in 
this cell line where cells overexpressing EPLINα both migrated at a significantly 
slower rate and were significantly less able to adhere to the Matrigel basement 
membrane (Sanders et al., 2010). This suppressive role in angiogenesis illustrates 
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EPLIN has potentially various regulatory mechanisms for reducing cancer metastasis 
and could be an effective strategy for cancer therapy.  
1.3 Conclusions and outlook   
The interaction of EPLIN and actin has provided an excellent model for investigating 
multiple aspects of cancer progression over the last decade. The discovery of EPLIN 
led to a subtle paradigm shift in structural view and organisation of cytoskeletal 
dynamics, with the acknowledgment that various actin-related molecules contribute 
to multiple dynamic processes underlying cellular migration and invasion. There is 
an established link between EPLIN and cancer progression with frequent down 
regulation of EPLIN in more aggressive cell lines, reduced staining in cancerous 
tissue samples and reduced proliferation potentials when there is forced expression 
of the EPLINα isoform in vitro and in vivo. EPLIN is functionally linked to 
molecules like actin and potentially paxillin and has been implicated in a number of 
potential pathways to enhance metastatic potential (outlined in Figure 1.20). 
However, the precise mechanistic action of EPLIN and subsequently how EPLIN 
loss contributes to the development of cancer remains elusive. Mechanistic 
investigations in this PhD study will therefore be crucial to elucidate the full 
importance of EPLIN in cancer pathophysiology. 
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Figure 1.20 Proposed EPLIN signalling pathways and implications for loss in 
cancer. 
In non-cancerous epithelial cells, EPLIN associates with the actin cytoskeleton 
linking the cadherin-catenin complex to F-actin via interaction with α-catenin. The 
signal transduction protein, paxillin, interacts with EPLIN in the cytoplasm and this 
complex likely stabilises actin dynamics. ERK phosphorylates EPLIN regulating cell 
motility and migration. In cancerous cells EPLIN is lost, the actin cytoskeleton 
becomes less organised and this induces membrane ruffling. Paxillin targeting is 
likely lost reducing focal adhesion between the cadherin-catenin complex and actin. 
These molecular, cellular and morphological consequences may result in increased 
metastatic potential including enhanced cell migration and motility. Signalling 
pathways summarised from: (Han et al., 2007, Zhang et al., 2011, Tsurumi et al., 
2014, Sanders et al., 2011). Image generated using Pathway Builder 2.0 software.  
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1.4  PhD Thesis Aims and Objectives  
EPLIN is a cytoskeletal molecule involved in actin dynamics and has associations 
with cancer development. As previously stated, EPLIN localises to epithelial cell 
junctions and interacts with various proteins to co-ordinate cell function. The role of 
EPLIN in cancer development is an active research area and thus altered expression 
of EPLIN is periodically being established in various cancer types. To date, altered 
expression of EPLIN has been illustrated by our research group in breast, 
oesophageal, lung, ovarian and prostate cancer, in addition to providing evidence of 
EPLIN as a potential tumour suppressive molecule and in cancer prognosis. This 
PhD will aim to build on previous work in this area and elucidate the functional role 
of EPLIN in prostate cancer metastasis. It is hypothesised that loss of EPLIN will 
correlate clinically with later stage, metastatic tumours, more aggressive in vitro 
cancer cell traits which will occur through a variety of mechanisms including 
paxillin and FAK.  Specific aims of this PhD study are: 
1. Determining the expression level and distribution of EPLIN in human 
prostate cancer using prostate cancer cell lines by RT-PCR, Q-PCR and 
Western Blotting. In order to demonstrate a potential link of EPLIN to 
clinical outcome, EPLIN expression in a larger cohort of prostate cancer and 
comparison of expression to clinical pathological information will be 
undertaken. 
2. Evaluating the in vitro functional effects of forced expression of EPLINα in 
prostate cancer cell lines PC-3 and LNCaP. Manipulated EPLINα expression 
will be investigated in various in vitro functional assays including cell 
proliferation, cell adhesion, cell invasion and cell motility.  
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3. The effect of EPLINα manipulation on the establishment of bone metastases 
will be evaluated. This will be done by A) using an in vitro bone like 
environment, utilising Bone Matrix Extract (BME), and B) using a co-culture 
method utilising a human osteoblast cell line hFOB1.19, to assess any 
implications for EPLINα in prostate cancer metastasis to bone tissue.  
4. Establishing and clarifying potential links of EPLINα to associated molecules 
paxillin and FAK. Determine how EPLINα expression effects FAK and 
paxillin transcript and protein expression in prostate cancer cell lines, in 
addition to the effect of EPLINα expression on FAK/paxillin phosphorylation 
status.  
5. Explore the mechanistic relationship between EPLINα and FAK/paxillin and 
determine if the suppressive effect of EPLINα in cancer progression is linked 
to FAK and paxillin biology. 
6. Explore other molecular avenues relating to EPLINα’s mechanism of action 
and related signalling pathways. Determine any functional and mechanistic 
significance of these potential associations, and further clarify the mechanism 
behind EPLINα’s functional role in prostate cancer progression and 
development. 
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2 Chapter II: Materials 
and Methods 
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2.1 Materials and solutions  
2.1.1  Solutions for cell culture 
All standard chemicals and reagents used in this study, unless otherwise specified, 
were obtained from Sigma (Dorset, UK). 
0.05M Ethylene Diaminetetraacetic Acid (EDTA) trypsin 
A stock solution of 10x trypsin-EDTA solution was purchased from Sigma-Aldrich, 
Inc. (Dorset, UK) and was diluted to a working concentration of 1x with sterile 
water. This solution was aliquoted into 25ml universal containers and stored at -20°C 
until required. 
Antibiotics 
A stock solution of 100x antibiotic solution (A5955) was purchased from Sigma-
Aldrich, Inc. (Dorset, UK). This was aliquoted into 5ml aliquots and stored in 
universal containers at -20°C until required. One 5ml aliquot of antibiotics was 
added to each 500ml media bottle required prior to use. 
Foetal Calf Serum (FCS)  
FCS was purchased from Sigma-Aldrich, Inc. (Dorset, UK) and aliquoted into 25ml 
aliquots in universal containers and stored at -20°C until required. Two 25ml 
aliquots of FCS was added to each 500ml media bottle required giving a final 
volume of 10% FCS. 
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Phosphate buffered saline (PBS)  
A stock solution of 10x phosphate buffered saline (P5943) was purchased from 
Sigma-Aldrich, Inc. (Dorset, UK) and autoclaved for cell culture use. This was then 
diluted with sterile water to reach a working concentration of 1x PBS. This solution 
was aliquoted into 25ml sterile universal containers and stored at room temperature 
until required.  
2.1.2  Primers 
Primers were designed using either Beacon software (PREMIER Biosoft 
international, California, USA) or Primer BLAST (National Center for 
Biotechnology Information, Bethesda, USA) and synthesised by Sigma (Sigma-
Aldrich, Inc., Dorset, UK). Primer sequences are outlined in Table 2.1 
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Table 2.1 Primers used in this study. 
 The Z sequence for Q-PCR reactions are highlighted in bold and italicised. 
 
Target Application Primer Sequence (5’ – 3’) 
LIMA1 
(EPLIN) 
PCR/Q-
PCR 
Forward (F8) TCAAACTAAGATTCTCCGGG 
LIMA1 
(EPLIN) 
PCR Reverse (R8) CAATAGGGGCATCTTCTACC 
LIMA1 
(EPLIN) 
PCR/Q-
PCR 
Forward (F9) AATGAAGAAGTTTCAGGCAC 
LIMA1 
(EPLIN) 
PCR Reverse (R9) TTGTTTTGCCAGGTTGTTTT 
LIMA1 
(EPLIN) 
Q-PCR Reverse 
(ZR8) 
ACTGAACCTGACCGTACACTCCGAGTC
AAATGTAGAAGA 
LIMA1 
(EPLIN) 
Q-PCR Reverse 
(ZR9) 
ACTGAACCTGACCGTACAGACTGAGT
TTGTTGTTGCAA 
LIMA1 
(EPLINβ) 
PCR/Q-
PCR 
Forward (F1) TCTCCATTTAATAGACGGCAA 
LIMA1 
(EPLINβ) 
PCR Reverse (R1) TTCGGTGTTACTTCTCTTCTT 
LIMA1 
(EPLIN) 
PCR/Q-
PCR 
Forward (F2) TTAATAGACGGCAATGGACC 
LIMA1 
(EPLIN) 
PCR Reverse (R2) TGCAGAAATCTTTTCCCCTT 
LIMA1 
(EPLIN) 
Q-PCR Reverse 
(ZR1) 
ACTGAACCTGACCGTACATTCGGTGTT
ACTTCTCTTCTT 
LIMA1 
(EPLIN) 
Q-PCR Reverse 
(ZR2) 
ACTGAACCTGACCGTACAGTTTGTTTC
TTCAGCTGCTT 
LIMA1 
(EPLIN) 
PCR Forward (F3) CATTTAATAGACGGCAATGGA 
LIMA1 
(EPLIN) 
PCR Reverse (R3) CCGGAGAATCTTAGTTTGAGT 
LIMA1 
(EPLIN) 
PCR – for 
full coding 
sequence 
Forward 
(ExF1) 
ATGGAAAATTGTCTAGGAGAA 
LIMA1 
(EPLIN) 
PCR – for 
full coding 
sequence 
Reverse 
(ExR1) 
TCACTCTTCATCCTCATCCTC 
FAK PCR Forward 
(F22) 
CTATCCAGGTCAGGCATCT 
FAK PCR Reverse 
(R22) 
CGATTTTACTGGACATCTCG 
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Paxillin PCR Forward CTGACGAAAGAGAAGCCTAA 
Paxillin PCR Reverse CTTTTCACAGTAGGGCTGTC 
GAPDH PCR Forward (F8) GGCTGCTTTTAACTCTGGTA 
GAPDH PCR Reverse (R8) GACTGTGGTCATGAGTCCTT 
GAPDH Q-PCR Forward (F2) CTGAGTACGTCGTGGAGTC 
GAPDH Q-PCR Reverse 
(ZR2) 
ACTGAACCTGACCGTACACAGAGATG
ATGACCCTTTTG 
PDPL Q-PCR Forward (F8) GAATCATCGTTGTGGTTATG 
PDPL Q-PCR Reverse 
(ZR8) 
ACTGAACCTGACCGTACACTTTCATTT
GCCTATCACAT 
T7F PCR - 
Coding 
sequence 
orientation 
checking 
Forward TAATACGACTCACTATAGGG 
BGHR PCR - 
Coding 
sequence 
orientation 
checking 
Reverse TAGAAGGCACAGTCGAGG 
 
2.1.3 Antibodies 
Antibodies used in this study are outlined in Table 2.2 below. 
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Table 2.2 Antibodies used in this study for Western Blotting. 
Antibody name  Host species Molecular 
weight 
Final 
Concentration 
Supplier and catalogue 
number 
EPLIN (20) sc-
136399 
Mouse 90kDa / 
110kDA 
1:200 Santa Cruz 
Biotechnology (Sc-
136399) 
EPLIN Rabbit 90kDa / 
110kDA 
1:200 Bethyl Laboratories 
(A300-103A)  
GAPDH (0411) Mouse 37kDa 1:300 Santa Cruz 
Biotechnology  (Sc-
47724) 
Paxillin Mouse 68kDa 1:200 BD Biosciences 
(610051) 
pPaxillin Tyr31 Rabbit 68kDa 1:150 Santa Cruz 
Biotechnology (Sc-
14035R) 
pPaxillin 
Tyr118 
Rabbit 68kDa 1:200 Santa Cruz 
Biotechnology (Sc-
14036R) 
FAK Mouse 125kDa 1:200 BD Biosciences  
(610087) 
pFAK  Tyr397 
(2D11) 
Mouse 125kDa 1:200 Santa Cruz 
Biotechnology (Sc-
81493) 
pFAK Tyr 397 Rabbit 125kDa 1:150 Santa Cruz 
Biotechnology (Sc-
11765R) 
pFAK Tyr925 Goat 125kDa 1:200 Santa Cruz 
Biotechnology (Sc-
11766) 
c-Src Rabbit 60kDa 1:500 Abcam (Ab109381) 
p-c-Src Tyr 419 Rabbit 60kDa 1:500 Abcam (Ab185617) 
p-c-Src Tyr 530 Mouse 60kDa 1:200 Santa Cruz 
Biotechnology (Sc-
166860) 
ITGB1 Rabbit 135kDa 1:500 Abcam (Ab52971) 
ERK1/2 Mouse 42kDa / 
44kDa 
1:150 Santa Cruz 
Biotechnology (Sc-
514302) 
pERK1/2 
T202/Y204 
Rabbit 42kDa / 
44kDa 
1:200 Cell signalling (#9101) 
Anti-Mouse IgG Mouse N/A 1:500 Sigma Aldrich (A9044) 
Anti-Rabbit IgG Rabbit N/A 1:500 Sigma Aldrich (A0545) 
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2.1.4 Solutions for microbiological methods 
Luria Bertani (LB) agar 
LB agar was made by dissolving 10g of LB Broth low salt granulated powder 
(Melford Laboratories Ltd., Suffolk, UK) and 7.5g of agar (A1296) (Sigma-Aldrich, 
Inc., Dorset, UK) in 500ml of distilled water. This was adjusted to pH value 7.0 prior 
to autoclaving. The final solution was allowed to cool and stored at room 
temperature. LB agar solidifies at room temperature, so was microwaved to melt the 
agar prior to each use. 
LB broth 
A solution of LB broth was made consisting of 8g LB Broth low salt granulated 
powder (Melford Laboratories Ltd., Suffolk, UK) and dissolving in 400ml sterile 
water. This solution was pH adjusted to 7.0 prior to autoclaving. The solution was 
allowed to cool and stored at room temperature until required. 
Ampicillin  
A 100mg/ml Ampicillin solution was prepared by dissolving 1g of ampicillin 
(Melford Laboratories Ltd., Suffolk, UK) in 10ml of sterile PBS. This was kept at 
4°C for short term or -20°C for longer term storage. 
2.1.5 Solutions for use in RNA and DNA molecular biology 
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Diethyl pyrocarbonate (DEPC) treated water 
A solution of DEPC water was made by mixing 250μl diethyl pyroncarbonate 
(DEPC) and 4750μl of distilled water. The final solution was autoclaved prior to use 
and subsequently stored at room temperature. 
Tris-Boric-Acid-EDTA (TBE)  
10x concentrated TBE buffer was purchased from Sigma-Aldrich, Inc. (Dorset, UK) 
and diluted in sterile water to make a final 1x concentration of TBE. The solution 
was kept at room temperature on the PCR bench until required. 
2.1.6  Solutions for protein analysis and Western Blotting 
Lysis Buffer 
A 1L volume of protein lysis buffer was made consisting of 8.76g of NaCl 
(150mM), 6.05g of Tris (50mM), 200mg Sodium azide (0.02%, w/v), 5g Sodium 
deoxycholate (0.5%, w/v) and 15ml Triton X-100 (1.5%, v/v) in sterile water and 
stored at 4°C in the fridge until required. A 50ml aliquot was taken and used to 
dissolve one tablet of cOmplete Tablets EASYpack protease inhibitor cocktail tablets 
(Roche Diagnostics, Mannheim, Germany) to ensure the blocking of protease 
activity in the lysis buffer for protein extraction. The 50ml was allowed to mix in a 
falcon tube on a rotating wheel for 15 minutes before further aliquoting into 1ml 
Eppendorf tubes (Greiner Bio-One Ltd, UK). 1ml aliquots were stored at -20°C until 
required. For screening of phospho-proteins, 100mM of Na3VO4 was added into the 
pre-made lysis buffer at the working concentration of 1mM prior to extraction. 
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10% Ammonium Persulfate (APS) 
A solution of 10% APS was made by dissolving 2g of ammonium persulfate in 20ml 
of distilled water and stored at 4˚C until it was required. 
Tris-Glycine-SDS running buffer 
A 10x stock solution of Tris-Glycine-SDS buffer (T7777) (Sigma, Dorset, UK) was 
diluted 1/10 mixing 1L 10x solution with 9L distilled water. This was stored at room 
temperature until required. 
Tris-Glycine transfer buffer 
Transfer buffer was made up using 1L 10x solution of Tris-Glyine-Buffer (T4904) 
(Sigma, Dorset, UK), 2L of methanol (Fisher Scientific UK, Loughborough, UK) 
and 9L distilled water. This was stored at room temperature until required. 
10X Tris Buffered Saline (TBS) 
A 10x TBS stock solution (Sigma, Dorset, UK) was diluted 1/10 by mixing 1L 10x 
solution with 9L distilled water and stored at room temperature until required. 
Resolving gel buffer 
1L resolving gel buffer (161-0798) at pH 8.8 was purchased from Bio-Rad (Bio-Rad, 
Hertfordshire, UK) and used neat for use in gel preparation. Solutions were stored at 
4°C.  
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Stacking gel buffer 
1L stacking gel buffer (161-0799) at pH 6.8 was purchased from Bio-Rad (Bio-Rad, 
Hertfordshire, UK) and used neat for use in gel preparation. Solutions were stored at 
4°C.  
2.1.7 Solutions for protein microarray analysis 
100mM Tris buffer was made by dissolving 6.0g of Tris powder in 1.5L sterile 
water. A 50ml Tris buffer was made using one cOmpleteTM, EDTA-free protease 
inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany), 5ml of 2-
mercaptoethonal (10%, v/v), nonident P-40 (1%, v/v) and 5ml of 500mM NaFl 
(50mM). This solution was allowed to mix and subdivided into further 1ml aliquots 
and stored at -20°C prior to use. 
2.2 Cell lines and cell culture 
All cell culture work was carried out in class II microflow cabinets under sterile 
conditions using aseptic techniques.. All cells were cultured in an incubator at 37˚C, 
5% carbon dioxide and 95% humidity with the exception of the hFOB1.19 human 
osteoblast cell line which was cultured at 34˚C. 
2.2.1  Cell lines  
The human prostate cancer cell lines PC-3, LNCaP, VCaP, DU-145 and CA-HPV-
10, immortalised ‘normal’ prostate cell line PZ-HPV-7, and a human osteoblast cell 
line hFOB1.19 were used for this study and obtained from ATCC. The majority of 
the study focused on prostate cell lines, whereas the hFOB1.19 cell line was used as 
part of a co-culture assay as part of functional testing.  PC-3 and LNCaP cell lines 
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chosen as the focus of the majority of the experimental work.  Full details of cell 
lines used are provided in Table 2.3. For functional analysis using cell lines 
transfected with the pEF6 control or EPLINα overexpression plasmid (see section 
2.5), PC-3 and LNCaP cells were designated PC-3
pEF6 
and LNCaP
pEF6 
once 
transfected with the empty vector plasmid control, and PC-3
EPLIN EXP 
and 
LNCaP
EPLIN EXP 
once transfected with the EPLINα expression sequence. The plasmid 
used for this PhD study was the pEF6/V5-His-TOPO TA (see section 2.5). 
2.2.2  Preparation of proliferation media 
Cell lines PC-3, DU-145, VCaP and CA-HPV-10 were routinely cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM / Ham’s F-12 with L-Glutamine 
(PAA Laboratories, Somerset, UK), supplemented with streptomycin (Streptomycin 
Sulphate salt, Sigma-Aldrich Co), penicillin (Benzylpenicillim, Britannia, 
Pharmaceutical, Ltd.) and 10% heat inactivated foetal calf serum (Invitrogen, 
Paisley, UK). Cells transfected with the pEF6/V5-His TOPO TA plasmid vector 
(with or without the EPLINα expression sequence) were first cultured for 6-14 days 
in selection media containing 5µg/ml Blasticidin S (Melford Laboratories Ltd., 
Suffolk, UK). Following the selection period the cells were transferred to 
maintenance media containing 0.5µg/ml Blasticidin S where they remained until 
they reached suitable confluence for RNA and protein extraction. LNCaP cells were 
routinely cultured in RPMI-1640 medium (Sigma-Aldrich Co) supplemented with 
streptomycin (Streptomycin Sulphate salt, Sigma-Aldrich Co), penicillin 
(Benzylpenicillim, Britannia, Pharmaceutical, Ltd.) and 10% heat inactivated foetal 
calf serum (Invitrogen, Paisley, UK). PZ-HPV-7 cells were routinely cultured in 
keratinocyte serum free medium supplemented with 0.05mg/ml BPE and 5ng/ml 
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EGF (Life Technologies, Paisley, UK). hFOB1.19 cells were routinely cultured in 
Ham's F12 Medium Dulbecco's Modified Eagle's Medium, with 2.5 mM L-
glutamine (without phenol red) (Life Technologies, Paisley, UK) with 0.3 mg/ml 
G418 (Melford Laboratories Ltd., Suffolk, UK); foetal bovine serum to a final 
concentration of 10%.  
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Table 2.3 Cell lines in use.  
Cells were grown in culture flasks and incubated at 37°C or 34°C and 5% carbon 
dioxide in a humidified incubator. Mycoplasma contamination in cell cultures was 
estimated using EZ-PCR Mycoplasma Test Kit (Biological Industries, Israel). Cell 
lines validated through short tandem repeat profiling. 
 
Cell Line Tissue Morphology  Features Medium used 
PC-3 
prostate; 
derived from 
metastatic 
site: bone 
Epithelial  
Grade IV, 
adenocarcinom, 
osteolytic  
Dulbecco's Modified 
Eagle Medium 
(DMEM) (+10% FCS) 
DU-145 
prostate; 
derived from 
metastatic 
site: brain 
Epithelial  Carcinoma  
Dulbecco's Modified 
Eagle Medium 
(DMEM) (+10% FCS) 
LNCaP 
prostate; 
derived from 
metastatic 
site: left 
supraclavicul
ar lymph 
node 
Epithelial  
Carcinoma, 
Osteolytic and 
osteoblastic  
RPMI-1640 (+10% 
FCS) 
VCaP 
prostate; 
derived from 
metastatic 
site: vertebral 
metastasis 
Epithelial  
Carcinoma, 
osteoblastic  
Dulbecco's Modified 
Eagle Medium 
(DMEM) (+10% FCS) 
PZ-HPV-7 
prostate; 
epithelium 
Epithelial  
Prostate 
epithelium 
transformed with 
human 
papillomavirus 
18 
Keratinocyte serum 
free medium (+ 
0.05mg/ml BPE, 
5ng/ml EGF) 
CA-HPV-
10 
prostate Epithelial  Adenocarcinoma  
Dulbecco's Modified 
Eagle Medium 
(DMEM) (+10% FCS) 
hFOB1.19 bone Osteoblast Bone 
Ham's F12 Medium 
Dulbecco's Modified 
Eagle's Medium, with 
2.5 mM L-glutamine 
(without phenol red) 
with 0.3 mg/ml G418; 
10% FCS 
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2.2.3 Maintenance of cells 
Cell lines were maintained in a cell culture incubator and maintained in 
supplemented media as described above. Cells were grown to confluence in either 
25cm
2 
(T25) or 75cm
2 
(T75) tissue cultured flasks loosely capped (Greiner Bio-One 
Ltd., Gloucestershire, UK) at 37°C in 5% carbon dioxide and 95% humidification. 
All cell culture work was carried out following aseptic techniques inside a class II 
laminar flow cabinet and autoclaved instruments to keep conditions sterile. 
2.2.4 Trypsinization of cells 
All cell lines were grown in incubators until they reached approximately 80-90% 
confluence. Cells were checked for confluence under a light microscope. The culture 
medium was removed using a sterile glass pipette under vacuum and briefly rinsed in 
sterile PBS to remove excess serum. Trypsin–EDTA (1-2ml) was added to the cells 
by pipetting and incubated for 5-15 minutes depending on cells used. LNCaP cells, 
for example, required less time to detach, so only required a 5 minute incubation. 
PC-3 cells take longer so were incubated for approximately 15 minutes to allow full 
detachment of cells. The detached cell suspension was transferred to a 20ml 
universal container (Greiner Bio-One Ltd., Gloucestershire, UK) and an equal 
volume of cell media was added to neutralise the trypsin before centrifuging at 1400 
rpm for 8 minutes to pellet the cells. The supernatant was discarded and the cells 
were resuspended in appropriate cell culture medium in a volume dependant on the 
size of the pellet. The cells were then re-seeded into new tissue culture flasks, 
counted for immediate experimental work or stored by freezing in liquid nitrogen. 
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2.2.5 Cell counting 
Cell number was determined by counting using a Neubauer haemocytometer 
counting chamber (Mod-Fuchs Rosenthal, Hawksley, UK) using an Olympus 
CKX31 microscope at an objective magnification of X10 (Olympus, Tokyo, Japan). 
2.2.6 Cell storage in liquid nitrogen 
For long term storage, the cell lines were stored in liquid nitrogen. Cells were 
resuspended and stored in culture medium containing 10% Dimethylsulphoxide 
(DMSO) (Sigma-Aldrich, Gillingham, Dorset, UK). The volume of resuspension 
medium was dependant on how many samples were frozen. 1ml of cells was 
transferred into pre-labelled 1ml CRYO.STM tubes (Greiner Bio-One Ltd,. 
Gloucestershire, UK). Tubes were wrapped in 3 layers of tissue paper and stored 
overnight at -80°C in a deep freezer before storage in liquid nitrogen tanks for long 
term storage. 
2.2.7 Cell revival  
Frozen cells were removed from storage and allowed to thaw at room temperature. 
After completely thawing the cell suspension was transferred to a universal container 
containing 10 ml of pre-warmed medium before being centrifuged at 1400 rpm for 8 
minutes to pellet the cells. The supernatant was aspirated, the pellet resuspended in 
1ml of pre-warmed medium and placed into a fresh T25 tissue culture flask and 
incubated at 37°C (34°C for hFOB1.19), 95% humidification and 5% CO2. The 
following day, the flask was examined under a light microscope to ensure a 
sufficient number of healthy adherent cells had survived the cell revival and 
subjected to a media change to remove any dead cells 
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2.3  Methods for detecting mRNA 
2.3.1  Total RNA isolation 
Cells were grown until they reached appropriate confluence (80-90%). Following 
this, cell media was aspirated, cells were washed with PBS and 1ml of Sigma Total 
RNA Isolation (TRI) Reagent was added (Sigma-Aldrich, Dorset, UK). Total RNA 
was allowed to detach cells from cell flask and subsequently transferred into a 1.5ml 
Eppendorf (Greiner Bio-One Ltd, UK). To allow dissociation of nucleoprotein 
complexes, the RNA was left to stand for 5 minutes at room temperature. Following 
this, 0.2ml chloroform was added and vigorously mixed by inversion for 15 seconds 
before Hettich centrifugation (DJB Labcare Ltd, United Kingdom) at 12000g for 15 
minutes at 4°C. The resultant homogenate forms 3 phases: a red organic phase 
(containing protein), an interphase (containing DNA), and a colourless upper 
aqueous phase (containing RNA). The upper aqueous phase was carefully removed 
and transferred in a clean Eppendorf before adding 500µl of 2-propanol and mixing 
via inversion for 15 seconds. The samples were then centrifuged for 10 minutes at 
12000g and 4°C. The supernatant was removed and the RNA pellet was washed with 
1ml of 75% ethanol (Fisher Scientific UK, Loughborough, UK) in DEPC water 
before vortexing and centrifugation at 7500g for 5 minutes at 4 °C. The supernatant 
was removed and the pellet was briefly dried for 10 minutes by air-drying. The final 
pellet was completely resuspended in 30µl DEPC water before quantification.  
2.3.2  RNA quantification 
The concentration of RNA was measured using an IMPLEN nanophotometer 
(Geneflow Ltd., United Kingdom) set to detect RNA in ng/µl. The RNA samples 
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were either stored at -80°C for further use or used immediately for reverse 
transcription (RT). 
2.3.3  Reverse transcription-polymerase chain reaction (RT-PCR) 
Once total RNA had been isolated and quantified, RT-PCR was carried out to 
generate complementary (cDNA) from the RNA template using GoScript™ Reverse 
Transcription System (Promega, UK). A 20µl RT-PCR reaction, containing 250ng of 
RNA was undertaken to generate cDNA according to the manufacturer’s 
instructions. The RT reaction is a 2 step reaction. For the first step, the following 
components were added to a PCR tube: 
 250ng experimental RNA (volume depends on RNA concentration) 
 1µl Oligo(dT) primer (0.5μg/reaction) 
 Nuclease free water to final volume of 5µl 
The RNA, primer and water was then transferred to a thermocycler and heated to 
70°C for 5 minutes. Following initial heating, the tubes were then transferred to ice 
for at least 5 minutes and centrifuged in a microcentrifuge before storing on ice until 
the reverse transcription mix was added. For the second step in the reaction, a 
following 15µl reaction was then made consisting of: 
 4µl GoScript™ 5X Reaction Buffer 
 1µl PCR Nucleotide Mix (final concentration 0.5mM each dNTP) 
 1.2µl  MgCl (final concentration 1.5–5.0mM) 
 1 µl GoScript™ Reverse Transcriptase 
 Nuclease-Free Water (to a final volume of 15μl) 
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The 15μl mix above was added to the 5μl RNA and primer reaction used in the first 
step. The reaction was then transferred to a thermocycler and the following 
conditions were input: 
 25˚C for 5 minutes 
 42˚C for 60 minutes 
 70˚C for 15 minutes 
Following RT reaction, the mix was diluted 1:4 in Nuclease free water and stored at -
20˚C until required. 
2.3.4  Polymerase chain reaction (PCR) 
PCR was carried out using GoTaq Green Master mix DNA polymerase protocol 
(Promega, Southampton, United Kingdom). A final reaction of 16µl was prepared 
for each sample, with each individual PCR sample containing: 
 8μl - GoTaq mastermix  
 1μl – specific forward primer 
 1μl – specific reverse primer 
 5μl – PCR water 
 •1μl –cDNA 
Primers were designed targeting different regions of the EPLINα and EPLINβ gene 
sequence and were synthesised by Sigma (Sigma-Aldrich, Dorset, UK). Both 
forward and reverse primers were diluted to 10pM prior to use in sterile water. The 
PCR reaction was initially set up by preparing a mastermix of all components 
common to the particular reaction/molecule of interest (for example GoTaq 
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mastermix, primers, water) in a 0.6ml tube with sufficient volume for the required 
number of PCR reactions. Once each ingredient was added, 15µl of mastermix 
solution was added to a PCR tube and 1µl of cDNA was added. These were then 
mixed, centrifuged and placed in an ABI thermocycler (Thermo Fisher Scientific, 
USA). PCR reactions were amplified under the following conditions: 
 Step 1: Initial denaturing period: 94 °C for 5 minutes. 
 Step 2: Denaturing step: 94 °C for 30 seconds. 
 Step 3: Annealing step: 55°C for 30 seconds. 
 Step 4: Extension step: 72°C for 40 seconds. 
 Step 5: Final extension period: 72°C for 10 minutes. 
Steps 2, 3 and 4 were repeated over 30 cycles. 
Products were separated on 1% agarose gel stained with SYBR Safe Gel Stain 
(Invitrogen, Paisley, UK) according to size and visualised using a U:Genius3 gel doc 
system (Syngene, Cambridge, UK). A negative control was included where cDNA 
was replaced with sterile water.  
2.3.5  Agarose gel electrophoresis 
Amplified PCR products were separated according to size on 1% agarose gels. 
Agarose gels were made by adding the required amount of agarose powder (Sigma-
Aldrich, Dorset, UK) to TBE solution. The mixture was heated in a microwave to 
dissolve the agarose and 5-10µl of SYBR® Safe DNA Gel Stain (Invitrogen, 
Paisley, United Kingdom) was added to allow staining of DNA bands. The gel 
mixture was poured into gel tanks with an electrophoresis cassette and plastic comb 
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already loaded.  Gels were allowed to set for 30 minutes. Once set, TBE buffer was 
poured into the electrophoresis tank, the comb removed and 8µl of the PCR products 
loaded each resultant well. To a separate well, 5µl of a 1Kb ladder (Geneflow, 
United Kingdom) was added to allow identification of resultant band sizes. Samples 
were electrophoretically separated using a electrophoresis power pack at 100V for 40 
minutes to allow sufficient DNA band separation. 
2.3.6  Real-time quantitative polymerase chain reaction (RT-QPCR) 
RT-QPCR was performed to detect and quantify transcript copy number of target 
genes using Precision 2X Q-PCR Mastermix (Primer Design, UK) and Amplifluor
TM
 
Uniprimer
TM
 (Uniprobe) Universal system (Intergen company®, New York, USA). 
The amplifluor probe consists of a 3’ region specific to the Z-sequence, 
ACTGAACCTGACCGTACA, which presents on the target specific primers and a 
5’ hairpin structure labelled with a fluoresent tag (FAM). Ten microliter reactions 
were set up and added to MicroAmp® Fast Optical 96-Well Reaction Plates with 
Barcode (Life Technologies, Paisley, UK). GAPDH copy number was also included 
within these samples to allow standardisation and normalisation of the samples. Each 
reaction was set up as follows:  
 Forward  primer - 0.3µl (10pmol/μl) 
 Reverse primer (containing Z sequence) - 0.3µl (1pmol/μl) 
 Q-PCR Master Mix -5μl 
 Uniprobe – 0.3µl (10pmol/μl) 
 PCR water – 3μl 
 cDNA - 1μl 
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The reverse primers in each reaction contain a sequence called the Z-sequence 
(ACTGAACCTGACCGTACA). This is a unique sequence that is present in both the 
reverse primers and also the uniprobe primer. During the reaction, the Z sequence 
contained on the reverse primer becomes incorporated into the PCR product 
sequence over the initial rounds of amplification.  Subsequently, as the reverse 
primer, containing the Z sequence, is a limiting factor, in later stages the uniprobe 
primer anneals to the incorporated Z sequence. Ultimately, this causes extension of 
the uniprobe primer, causing a conformational change leading to florescence which 
can be directly measured. The intensity of fluorescence within each sample 
compared to a range of standards of known transcript copy number allows the 
calculation of transcript copy number within each sample. PCR amplification was 
performed using Applied Biosystems® Real-Time PCR Thermocycler (Life 
Technologies, Paisley, United Kingdom) under the following conditions: 
 Step 1: Initial denaturing period: 94˚C for 10 minutes. 
 Step 2: Denaturing step: 94˚C for 10 seconds. 
 Step 3: Annealing step: 55˚C for 30 seconds. 
 Step 4: Extension step: 72˚C for 10 seconds. 
Steps 2, 3 and 4 were repeated over 100 cycles. 
Expression of the target sequence was detected alongside a known standard 
transcript (PDPL) that is used to generate a standard curve to allow the calculation of 
transcript copy number in each target sample. Lastly, the transcript copy number of 
target genes were normalised by the detected copy number of GAPDH. 
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2.4  Methods for detecting protein 
2.4.1 Cell lysis and protein extraction 
Cells were grown in T75 cell culture flasks until appropriate confluency (~90%) and 
the cell monolayer washed 2X with PBS before being removed from the base of the 
cell culture flask using a disposable plastic cell scraper. The detached cells were then 
transferred to a sterile 30ml universal container and centrifuged for 5 minutes at 
1800rpm. The supernatant was discarded and the protein pellet resuspended in 300µl 
lysis buffer. This solution was then transferred to a1.5ml Eppendorf tube and placed 
on a Labinco rotating wheel (Wolf Laboratories, York , UK) at 25rpm, 4°C for 45 
minutes.. The solution was then centrifuged for 15 minutes at 13000rpm to pellet 
insoluble protein and the supernatant placed into a fresh Eppendorf tube before 
freezing at -20°C. For smaller cell flasks (T25) or 6 well plates, the same procedure 
was performed but were resuspended in lower volumes of lysis buffer (150µl for 
T25, 100µl 6 well plates). 
2.4.2 Protein quantification 
Protein concentration of samples was determined using a Bio-Rad DC protocol (Bio-
Rad laboratories, Hammelhempstead, UK). Protein samples were compared to a 
known concentration of Bovine Serum Albumin (BSA) of 100mg/ml serially diluted 
to 0.029mg/ml (Sigma, Dorset, UK). Samples and standards were pipetted into a 96-
well plate at a volume of 5µl before adding 25µl of ‘working reagent A’ and 200μl 
of reagent B. Solutions were allowed to stand for 15 minutes to allow the 
colorimetric reactions to develop. Absorbance of both standards and samples were 
read at 620nm using an ELx800 plate reading spectrophotometer (Bio-Tek, Wolf 
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laboratories, York, UK). Using the BSA known concentrations, a standard protein 
curve was created to establish each sample concentration. All samples were 
normalised to working concentrations of 2mg/ml by diluting in cell lysis buffer 
before further dilution in 2x Lamelli buffer (Sigma-Aldrich, Dorset, UK) in a 
1:1(v/v) ratio of diluted sample and 2x Lamelli buffer. Samples were boiled at 100°C 
for 5 minutes before being stored at -20°C until required. 
2.4.3 Protein extraction, fluorometric protein quantification for KinexusTM 
antibody microarrays  
In order to acquire high concentration protein lysate, each cell type was cultured in 
two T75 flask until reaching ~80% confluency.  Upon protein extraction, cells were 
washed with sterile PBS twice and scraped from the flask using a sterile cell scraper 
in 5ml sterile PBS. Cell suspensions from both flasks were combined in a 30ml 
universal container using a glass pipette and centrifuged at 2000rpm for 10 minutes.  
The pellet was then resuspended in 600µl lysis buffer and transferred to a 1.5ml 
Eppendorf tube. This was subsequently placed on a Labinoco rotating wheel at 
25rpm for 1 hour at 4°C. The solution was then centrifuged at 13000rpm and the 
supernatant (containing protein lysate) was transferred into a fresh, pre-labelled 
eppendorf tube and stored at -20°C until required. For the Kinexus microarray, the 
standard Bio-Rad protein assay kit is unsuitable and not compatible with 2-
mercaptoethanol, which is part of the lysis buffer. Fluorescamine acetone was made 
by dissolving 15mg of fluorescamine (F9015) (Sigma-Aldrich, Inc., Dorset, UK) in 
5ml absolute acetone (10162180) (Fisher Scientific UK, Loughborough, UK) in a 
glass vial and stored at 4°C until required. A serial dilution of BSA standard samples 
was made, ranging from 10mg/ml to 0.078mg/ml, by mixing the appropriate amount 
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of BSA original stock and PBS. The extracted protein samples were diluted 1 in 10 
by adding 50μl of protein sample in 450μl of PBS. Following this, 150μl of each 
serially diluted BSA standard samples and the 10x diluted protein extracted samples 
were aliquoted into a 96-well plate in triplicates prior to adding 50μl of 
fluorescamine acetone and being shaken for 1 minute. The fluorescence signal was 
then determined using a GloMax®-Multi Microplate Multimode Reader (Promega 
Biosystems Inc., Sunnyvale, CA, USA) with a 365nm excitation and 410-460nm 
emission filter. Protein concentration was based on the standard curve before being 
normalised to the desired concentration of 4mg/ml through the addition of an 
appropriate amount of lysis buffer to make 300μl stock followed by being stored at -
20°C. The quantified protein samples were then sent to KinexusTM antibody 
microarray analysis (Kinexus Bioinformatics, Vancouver, British Columbia, 
Canada). 
2.4.4 SDS gel assembly and gel electrophoresis 
Acrylamide gels were assembled at 8-10% concentration depending on the molecule 
screened (proteins in the range of 20KDa to 120KDa are detected at these 
concentrations). Two solutions were made up; a 15ml resolving gel and a 5ml 
stacking gel and these solutions were prepared in a universal container. The 
components of the 8% resolving and 5% stacking gel are listed below: 
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Table 2.4 Western Blot gel preparation  
Component 8% Resolving gel (ml) Stacking gel (ml) 
Water 5.9 3.4 
30% acrylamide mix 5 0.83 
1.0M Tris  3.8 (pH 8.8) 0.63 (pH 6.8) 
10% SDS 0.15 0.05 
10% Ammonia Persulphate  0.15 0.05 
TEMED 0.006 0.005 
 
SDS-PAGE was undertaken using an OmniPAGE VS10 vertical electrophoresis 
system (OminPAGE, Wolf Laboratories, York, UK). Once resolving and stacking 
gels were prepared, the resolving gel was added to the glass plates using a disposable 
plastic pipette until the solution reached a level just below where the plastic comb 
would make contact with the solution. The solution was then covered with ethanol 
ensuring the gel sets evenly leaving a smooth surface for addition of the stacking gel 
and left to set for 15 minutes. Following this time, the ethanol was removed and the 
stacking gel was added in place of the ethanol and plastic combs were gently inserted 
inside, creating wells for protein insertion. This solution was allowed to set for an 
additional 15 minutes. Once the stacking gel had set, the loading cassettes were 
inserted into an electrophoresis tank and the tank was filled with 1x running buffer 
(see section 2.1.6). The plastic combs were removed carefully and samples were 
loaded to the tank using a flat tipped needle at equal volumes of 12-18µl. A 
molecular weight marker (Geneflow Limited, Fradley, Staffordshire, UK) was 
included with the samples and loaded at a volume of 8µl 
 
. 
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2.4.5 Poly acrylamide gel electrophoresis 
Total protein was allowed to separate at power settings 120V, 150mA and 50W for 
approximately 2 hours. The gels were run using a EV243 power consort (Topac Inc., 
Cohasset, MA, USA). 
2.4.6 Preparation of membrane and gel transfer 
Once the gel had successfully run and proteins size separated, the gel products were 
next transferred onto PVDF nitrocellulose membrane (Millipore UK, United 
Kingdom) using electroblotting. Gels were removed from electrophoresis tanks, the 
glass plates separated and the stacking gel removed. PVDF membrane was cut into 
7cm x 8cm rectangles and the top right of the membrane was cut off for orientation 
purposes. The membranes were immersed initially in 100% methanol (Fisher 
Scientific UK, Loughborough, UK) (30 seconds), followed by washing with water 
and then left in transfer buffer (see section 2.1.6) for 10 minutes. Following this, a 
‘sandwich’ was created of filter paper (Sigma-Aldrich, Inc., Dorset, UK), membrane, 
gel and a second filter paper. The sandwich was inserted into a SD10 SemiDry Maxi 
System blotting unit (Wolf Laboratories, York, UK) and air bubbles removed by 
rolling. Electroblotting was performed at 15V, 500mA and 50W for 50 minutes.  
Membranes were then placed in 0.2% milk blocking solution (0.2% milk, 0.1%  
polyoxyethylene (20) sorbitan monolaurate (Tween 20) in TBS) prior to antibody 
staining. 
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2.4.7 Blocking/wash buffer preparation 
A 200ml solution of blocking buffer and a 400ml solution of wash buffer was made 
in sterile 1L bottles. For the blocking buffer, 400mg milk powder and 200µl Tween 
20 was mixed with 200ml TBS. For the wash buffer, 400µl Tween 20 was mixed 
with 400ml TBS. Both buffers were mixed by inversion and kept at room 
temperature until required. 
2.4.8 Preparation for antibody solutions for western blotting 
Antibodies were prepared at 1/5 dilution of the original concentration (in 
0.1%BSA/PBS), aliquoted and stored at -20˚C until required. Diluted antibody 
solutions were prepared at varying working concentrations (see Table 2.2) for each 
Western Blot reaction by making to a final volume of 3ml in blocking buffer made 
as described above.  
2.4.9 Snap id® 2.0 protein detection system 
Once antibody solutions were made, any protein that was electroblotted onto the 
membrane was probed using a SNAP id® 2.0 Protein Detection System (Merck 
Millipore Ltd., Feltham, UK). First, the membrane holder was rinsed with distilled 
water and the membrane was placed protein side down inside, rolling out any air 
bubbles using a roller. The system holding frame was opened and the membrane 
placed inside protein side up before closing and locking the frame. Once the 
membrane was in place, 30ml of blocking solution (PBS 0.1% Tween 0.2% milk 
powder) was added, the frame pressed down and the system turned on to apply the 
vacuum. When the membrane appeared dry, the vacuum was turned off. Primary 
antibody solutions were then added at a volume of 3ml per membrane and incubated 
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at room temperature for 15 minutes. After the incubation period, the frame was 
pressed down and the vacuum turned on to pull through residual antibody solution. 
The membrane was then washed using wash solution (PBS 0.1% Tween) by adding 
30ml to the membrane with the vacuum continuously running and repeating 3 times 
before turning the vacuum off. When the membrane was completely dry, 3ml of 
secondary antibody were added to the membrane and incubated for 10 minutes. 
Following the incubation, the vacuum was turned on to pull through residual 
secondary antibody. When the membrane was completely dry, the membrane was 
washed a second time with a total of 4 wash steps as above. Finally, the vacuum was 
turned off, the membrane removed from the holder and incubated with EZ-ECL 
protein detection reagent (GeneFlow Ltd., Staffordshire, UK) before visualising on a 
G:BOX Chemi XRQ protein detection system (Syngene, Cambridge, UK). 
2.4.10 Semi-quantitative analysis on western blot results by densitometry  
Image J v1.50c software was utilised for the semi-quantitative analysis of Western 
blot results. The rectangular selection tool was used to select a set area for each band 
on the Western blot image and the value of the integrated density for the selected 
area was then measured. The density of the protein of interest was then normalised 
by dividing the density value of the protein band of interest by the density value of 
the GAPDH control band. 
2.4.11 Tissue Microarray (TMA) analysis of prostate cancer tissue 
Tissue Microarrays (TMA) were purchased to explore EPLIN expression in normal 
prostate tissue and prostate cancer tissue. TMA’s were purchased from US Biomax 
(US Biomax, Inc., Rockville, USA) and tissues were collected under HIPPA 
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approved protocols by the manufacturer. TMA’s were stored and logged according 
to local HTA regulations with double locking under restricted access. TMA1 was 
labelled HPro-Ade96Sur-01 and TMA2 was labelled PR8011a, according to the US 
Biomax reference numbers for each TMA. The details of each TMA are shown in 
Table 2.5 and Table 2.6 and such details were used in relation to the staining 
analysis, though no pathology support was available within our department to 
confirm specified clinical information. Following staining of TMAs (as described 
below in 2.4.12), images were captured over a range of magnifications. Staining 
intensities of EPLIN in each section were classified, by three independent 
researchers, as negative staining (0), weak staining (1), moderate staining (2) or 
strong staining (3) within epithelial components of the tissues. Staining intensities 
were subsequently aligned to patient/sample clinical information to identify 
differential staining patterns between groups.   
2.4.12 Immunohistochemical staining (IHC) of prostate sample tissues 
Prior to staining, slides were placed in an oven set at 45°C for 48 hours to aid the 
sections adherence to the slides. Following this, slides were de-waxed and re-
hydrated by immersing in the following solutions for 5 minutes each: 100% xylene 
(x2), 50% xylene/50% ethanol, 100% ethanol (x2), 90% ethanol, 70% ethanol, 50% 
ethanol, distilled water and PBS buffer. An antigen retrieval buffer was made during 
the last immersion step using 1mM EDTA buffer (0.37g EDTA in 1000ml dH2O, pH 
8). Antigen retrieval was performed by placing slides in a plastic container and 
covering with the EDTA buffer. These were then placed in a microwave oven on full 
power for 20 minutes. After 10 minutes, the microwave was stopped and the slide 
rack was shaken to disperse air bubbles. The slides were then gradually cooled and 
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washed for 10 minutes using tap water. Following washing, excess fluid was 
removed from the sections and a ring of wax was applied. The sections were then 
incubated with blocking solution (10% horse serum/0.1% BSA/PBS) for at least 90 
minutes. Slides were placed in a humidified box during incubations to prevent the 
sections from drying out.  
Whilst the sections were blocking, the primary and secondary antibodies, as well as 
the tertiary ABC reagent were prepared in the same blocking solution. Primary 
antibody used was EPLIN (20) (Santa Cruz Biotechnology, Inc., Heidelberg, 
Germany) and was prepared to give a final concentration of 2µg/ml. A Vectastain 
Universal Elite ABC Kit (PK-6200) (Vector Laboratories Ltd., Peterborough, UK) 
was used for the secondary antibody and the tertiary ABC reagent. For the secondary 
antibody, two drops of secondary reagent (biotinylated horse anti-mouse/rabbit IgG) 
was added to 5ml blocking solution, and for the ABC reagent, two drops of Reagent 
A and two drops of Reagent B were added to 5ml blocking solution. Following the 
blocking incubation, the solution was removed and sections were covered with the 
primary antibody and incubated overnight at 4
o
C. The following day, sections were 
washed three times for five minutes each in PBS buffer, and were then incubated 
with the biotinylated secondary antibody for 30 minutes. Sections were subsequently 
washed three times with PBS and finally incubated with ABC reagent for 30 
minutes. Three more wash steps were made prior to development with DAB 
(diaminobenzidine) substrate (D5637) (Sigma-Aldrich, Dorset, UK) for 10 minutes. 
DAB was made in 5ml PBS (final concentration 1mg/ml) and 6µl Hydrogen 
peroxide was added immediately before use. Slides were washed briefly with water 
before counterstaining with Gill’s Haematoxylin (Vector Laboratories Ltd, 
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Peterborough, UK) for 2 minutes, and then blued in running tap water for 5 minutes.  
Sections were then dehydrated for five minutes in each 50% ethanol, 70% ethanol, 
90% ethanol, 100% ethanol (x2), 50% ethanol/50% xylene and cleared in xylene 
(x2). Finally, sections were mounted with DPX/Histomount and left to dry prior to 
analysis. Prior to running TMA staining, the EPLIN antibody was optimised using a 
number of non-essential tissue sections and such sections were also run alongside the 
TMA slides to serve as a negative control.
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Table 2.5 Patient/Sample details for tissues present in TMA1 (HPro-Ade96Sur-01) 
Position Age Organ Pathology Stage 
Gleason 
score 
TNM Months Type 
PSA 
(ng/ml) 
Residual 
tumour 
Follow 
up 
(months) 
Follow-
up 
result 
Cause 
of 
death 
A1, A2 68 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant * * * *   
A3, A4 64 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant 30 R0 60 alive   
A5, A6 71 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 60.4 R1 55 alive   
A7, A8 64 Prostate Adenocarcinoma III 10 T3aN0M0 . Malignant 7.4 R1 47 alive   
A9, A10 59 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 9.8 R1 44 alive   
A11, 
A12 65 Prostate Adenocarcinoma IV 8 T4N0M0 . Malignant 34.9 R1 43 alive   
B1, B2 73 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant 48.1 R1 42 alive   
B3, B4 69 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant 10.6 R0 42 alive   
B5, B6 62 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant 37.3 R1 39 alive   
B7, B8 66 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 1.2 R1 39 alive   
B9, B10 60 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 40 R1 39 alive   
B11, 
B12 70 Prostate Adenocarcinoma IV 7 T4N0M0 . Malignant 7 R1 37 alive   
C1, C2 65 Prostate Adenocarcinoma III 9 T3bN0M1 . Malignant 17.5 R1 23 dead cancer 
C3, C4 67 Prostate Adenocarcinoma IV 9 T3bN1M0 . Malignant 13.1 R1 34 alive   
C5, C6 69 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant 1.1 R1 33 alive   
C7, C8 69 Prostate Adenocarcinoma III 7 T3aN0M1 . Malignant 17.6 R1 27 alive   
C9, C10 70 Prostate Adenocarcinoma III 7 T3aN0M1 . Malignant 9 R1 26 alive   
C11, 
C12 58 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 5.8 R0 26 alive   
D1, D2 71 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant 31.4 R1 24 alive   
D3, D4 70 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant 14.4 R1 19 alive   
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D5, D6 59 Prostate Adenocarcinoma II 6 T2bN0M0 . Malignant 18.3 R0 18 alive    
D7, D8 63 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 16.6 R1 17 alive   
D9, D10 72 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant * R1 16 alive   
D11, 
D12 66 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant 10.8 R1 17 dead cancer 
E1, E2 70 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant * R0 15 alive   
E3, E4 68 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant 26.9 R1 15 alive   
E5, E6 63 Prostate Adenocarcinoma III 10 T3bN0M1 . Malignant * R1 15 alive   
E7, E8 57 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant 25 R1 15 alive   
E9, E10 72 Prostate Adenocarcinoma III 8 T2cN0M0 . Malignant 16.8 R1 15 alive   
E11, 
E12 70 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant 0.5 R1 15 alive   
F1, F2 75 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 98 R1 15 alive   
F3, F4 62 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant * R1 15 alive   
F5, F6 63 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 91 R1 14 alive   
F7, F8 53 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant 161 R1 17 dead cancer 
F9, F10 63 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant 13 R1 13 alive   
F11, 
F12 44 Prostate Adenocarcinoma III 7 T3bN0M1 . Malignant * R1 11 alive   
G1, G2 65 
Abdominal 
wall 
Metastatic 
adenocarcinoma 
from prostate IV . M1 36 Malignant 
    
  
G3, G4 61 Bone 
Metastatic 
adenocarcinoma 
from prostate IV . M1 32 Malignant 
    
  
G5, G6 69 Bone 
Metastatic 
adenocarcinoma 
from prostate IV . M1 34 Malignant 
    
  
G7, G8 59 Bone 
Metastatic 
adenocarcinoma IV . M1 0 Malignant 
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from prostate 
G9, G10 69 Prostate 
Normal (match 
of #8) . . . . Nat 
    
  
G11, 
G12 62 Prostate 
Normal (match 
of #9) . . . . Nat 
    
  
H1, H2 65 Prostate 
Normal (match 
of #13) . . . . Nat 
    
  
H3, H4 69 Prostate 
Normal (match 
of #16) . . . . Nat 
    
  
H5, H6 70 Prostate 
Normal (match 
of #17) . . . . Nat 
    
  
H7, H8 70 Prostate 
Normal (match 
of #25) . . . . Nat 
    
  
H9, H10 63 Prostate 
Normal (match 
of #27) . . . . Nat 
    
  
H11, 
H12 44 Prostate 
Normal (match 
of #36) . . . . Nat           
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Table 2.6 Patient/Sample details for details for tissues present in TMA2 (PR8011a) 
Position Age Organ Pathology Grade Stage 
Gleason 
Grade 
Gleason score TNM Type 
A1 60 Prostate Adenocarcinoma 1 II 1 1+2 T3aN0M0 Malignant 
A2 71 Prostate Adenocarcinoma 1 II 1 1+1 T2N0M0 Malignant 
A3 72 Prostate Adenocarcinoma 2 II 3 3+3 T2N0M0 Malignant 
A4 74 Prostate Adenocarcinoma 2 IV 2 2+3 T4N1M1c Malignant 
A5 60 Prostate Adenocarcinoma 1 IV 1 1+2 T4N1M1c Malignant 
A6 70 Prostate Adenocarcinoma 2 II 2 2+3 T2aN0M0 Malignant 
A7 70 Prostate Adenocarcinoma 2 IV 2 2+3 T2N1M1c Malignant 
A8 61 Prostate Adenocarcinoma 2 IV 3 3+3 T3N1M0 Malignant 
A9 65 Prostate Adenocarcinoma 2 II 3 3+3 T2N0M0 Malignant 
A10 76 Prostate Adenocarcinoma 2 II 4 4+2 T2aN0M0 Malignant 
B1 62 Prostate Adenocarcinoma 2 IV 3 3+4 T3N1M1b Malignant 
B2 26 Prostate Adenocarcinoma 3 II 4 4+4 T2N0M0 Malignant 
B3 76 Prostate Adenocarcinoma 3 IV 4 4+4 T3N1M0 Malignant 
B4 81 Prostate Adenocarcinoma 3 III 4 4+5 T3aN0M0 Malignant 
B5 80 Prostate Adenocarcinoma 2--3 IV 3--4 3+4 T2N1M1c Malignant 
B6 64 Prostate Adenocarcinoma 2 II 3 3+3 T2N0M0 Malignant 
B7 64 Prostate Adenocarcinoma 3 IV 4 4+3 T3N0M1 Malignant 
B8 75 Prostate Adenocarcinoma 2 IV 3 3+3 T2N1M1c Malignant 
B9 73 Prostate Adenocarcinoma 3 IV 4 3+4 T3N1M1 Malignant 
B10 65 Prostate Adenocarcinoma 3 IV 4 4+3 T2N1M1 Malignant 
C1 75 Prostate Adenocarcinoma 2 IV 2 2+3 T4N1M1 Malignant 
C2 69 Prostate Adenocarcinoma 1 III 1 1+2 T3bN0M0 Malignant 
C3 82 Prostate Adenocarcinoma 3 II 4 4+5 T2N0M0 Malignant 
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C4 72 Prostate Adenocarcinoma 3 IV 4 4+5 T2N0M1 Malignant 
C5 67 Prostate Adenocarcinoma 3 IV 4 4+4 T2N2M0 Malignant 
C6 60 Prostate Adenocarcinoma 4 II 5 5+5 T2N0M0 Malignant 
C7 40 Prostate Adenocarcinoma 1 IV 1 1+2 T2N1M1 Malignant 
C8 78 Prostate Adenocarcinoma 4 IV 5 5+4 T4N1M1 Malignant 
C9 69 Prostate Adenocarcinoma 4 IV 5 5+5 T4N0M1 Malignant 
C10 87 Prostate Adenocarcinoma 4 II 5 5+5 T2N0M0 Malignant 
D1 69 Prostate Small acinous carcinoma 2 II 2 2+3 T2N0M0 Malignant 
D2 70 Prostate Small acinous carcinoma 3 II 4 4+4 T2N0M0 Malignant 
D3 63 
Costal 
bone Metastatic adenocarcinoma 2--3 - - - - Metastasis 
D4 62 
Lymph 
node Metastatic adenocarcinoma 3 - - - - Metastasis 
D5 78 Prostate Hyperplasia - - - - - Malignant 
D6 67 Prostate Hyperplasia - - - - - Malignant 
D7 66 Prostate Hyperplasia - - - - - Malignant 
D8 72 Prostate Hyperplasia - - - - - Malignant 
D9 78 Prostate Hyperplasia - - - - - Malignant 
D10 56 Prostate Hyperplasia - - - - - Malignant 
E1 72 Prostate Hyperplasia - - - - - Malignant 
E2 65 Prostate Hyperplasia - - - - - Malignant 
E3 69 Prostate 
Hyperplasia 
(adenocarcinoma) 1 - - - - Malignant 
E4 73 Prostate Hyperplasia - - - - - Malignant 
E5 77 Prostate Hyperplasia - - - - - Malignant 
E6 56 Prostate Hyperplasia - - - - - Malignant 
E7 69 Prostate Hyperplasia - - - - - Malignant 
E8 60 Prostate Hyperplasia - - - - - Malignant 
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E9 70 Prostate Hyperplasia - - - - - Malignant 
E10 64 Prostate Hyperplasia - - - - - Malignant 
F1 72 Prostate Hyperplasia - - - - - Malignant 
F2 70 Prostate Hyperplasia - - - - - Malignant 
F3 62 Prostate Hyperplasia - - - - - Malignant 
F4 74 Prostate Hyperplasia - - - - - Malignant 
F5 67 Prostate Hyperplasia - - - - - Malignant 
F6 69 Prostate Hyperplasia - - - - - Malignant 
F7 71 Prostate Hyperplasia - - - - - Malignant 
F8 68 Prostate Hyperplasia - - - - - Malignant 
F9 72 Prostate Hyperplasia - - - - - Malignant 
F10 71 Prostate Hyperplasia - - - - - Malignant 
G1 73 Prostate Chronic inflammation - - - - - Inflammation 
G2 84 Prostate Chronic inflammation - - - - - Inflammation 
G3 64 Prostate Chronic inflammation - - - - - Inflammation 
G4 69 Prostate Chronic inflammation - - - - - Inflammation 
G5 68 Prostate Chronic inflammation - - - - - Inflammation 
G6 82 Prostate Chronic inflammation - - - - - Inflammation 
G7 25 Prostate 
Cancer adjacent prostate 
tissue - - - - - AT 
G8 21 Prostate 
Cancer adjacent prostate 
tissue - - - - - AT 
G9 27 Prostate 
Cancer adjacent prostate 
tissue - - - - - AT 
G10 64 Prostate 
Cancer adjacent prostate 
tissue - - - - - AT 
H1 77 Prostate 
Cancer adjacent prostate 
tissue - - - - - AT 
H2 80 Prostate Cancer adjacent prostate - - - - - AT 
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tissue 
H3 40 Prostate Prostate tissue - - - - - Normal 
H4 37 Prostate Prostate tissue - - - - - Normal 
H5 33 Prostate Prostate tissue - - - - - Normal 
H6 35 Prostate Prostate tissue - - - - - Normal 
H7 28 Prostate Prostate tissue - - - - - Normal 
H8 40 Prostate Prostate tissue - - - - - Normal 
H9 35 Prostate 
Prostate tissue (smooth 
muscle) - - - - - Normal 
H10 45 Prostate Prostate tissue - - - - - Normal 
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2.5 Generation of EPLINα overexpression plasmid 
2.5.1 Generation of full length EPLINα expression sequence 
Full length EPLINα was targeted and amplified using primers previously designed in 
(Jiang et al., 2008) and a Platinum® Taq DNA Polymerase High Fidelity PCR 
reaction mix (Life Technologies, Paisley, UK). EPLINα was found to be highly 
expressed in the PZ-HPV-7 cell line and thus used to generate the full length 
sequence of EPLINα. It was initially attempted to amplify EPLINα from tissue 
cDNA, however this was not possible due to lack of sufficient tissue quality at time 
of cloning and PZ-HPV-7 cells were therefore used as a template. The reaction was 
set up as follows: 
 45µl Platinum Supermix master mix 
 1.5µl EPLIN forward primer (ExF1) 
 1.5µl EPLIN reverse primer (ExR1) 
 2µl PZ-HPV-7 cDNA 
These primers, together with PZ-HPV-7 cDNA, were used in a PCR reaction with 
the following parameters: 
 Step 1: Initial denaturing period: 94˚C for 2 minutes. 
 Step 2: Denaturing step: 94˚C for 40 seconds. 
 Step 3: Annealing step: 60˚C for 50 seconds 
 Step 4: Extension step: 72˚C for 120 seconds. 
 Step 5: Final extension period: 72˚C for 10 minutes. 
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The reaction was repeated for 36 cycles. The resultant product was 
electrophoretically run on a 1% agarose gel to confirm full length EPLIN band size. 
When EPLINα was confirmed this was then used for TOPO TA plasmid cloning. 
2.5.2 Cloning of EPLINα expression sequence into plasmid vector 
The pEF6/V5-His TOPO TA Expression system (Figure 2.1) is a one-step cloning 
strategy that provides an efficient, 5 minute, one-step cloning protocol for the 
insertion of Taq polymerase-amplified PCR products into a plasmid vector for high-
level expression in mammalian cells. This cloning strategy requires no ligase, post-
PCR procedures or PCR primers containing specific sequences. Once cloned, 
analyzed, and transfected into a mammalian host cell line, the PCR product can be 
constitutively expressed. The pEF6/ V5-His TOPO TA plasmid vector (Invitrogen, 
Inc., Paisley, UK) was used in the current study in accordance with the protocol 
provided (Figure 2.2). The TOPO cloning reaction was set up in a pre-labelled PCR 
tubes for each expression sequence used: 
 PCR product (EPLINα expression sequence): 3μl 
 Salt solution: 1μl 
 TOPO vector: 1μl 
The reaction was mixed gently and then left for 5 minutes at room temperature. 
Chemically competent Escherichia coli cells were removed from the deep freezer 
and allowed to thaw on ice. Five microlitres of the cloning reaction was transferred 
into chemically competent Escherichia coli (One Shot TOP10 E.coli, Life 
Technologies., Paisley, UK) and mixed gently by stirring with the pipette tip. The 
suspension was then placed on ice for 30 minutes before a 30 second heat shock at 
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42°C in a pre-heated water bath. The suspension was then immediately transferred 
back to ice for 2-5minutes. Following this, 250µl of pre-warmed SOC medium was 
added. The cells were incubated for 1 hour at 37°C with shaking at 200rpm on an 
orbital shaker. After one hour incubation, cells were spread onto agar plates 
(containing 100μg/ml ampicillin) at one high volume and one low volume to allow 
suitable colony proliferation and allowed to grow overnight at 37°C in an incubator.  
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Figure 2.1 Map of pEF6/ V5-His TOPO TA plasmid vector  
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Figure 2.2 Experiment flow chart of pEF6/ V5-His TOPO TA plasmid vector 
cloning procedure  
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2.5.3 Selection and orientation analysis of positive colonies and colony PCR 
Colonies grown on agar plates should contain the pEF6/ V5-His TOPO TA plasmid 
vector due to antibiotic resistance sites within the vector. Colonies were selected and 
analysed to check correct orientation of the insert. Fifteen colonies for EPLINα 
expression sequences were randomly selected for PCR amplification and amplified 
using vector-specific forward and reverse primers, T7F and BGHR, or EPLIN-
specific primers, F8 and R8. Colonies were selected by touching the selected colony 
using a sterile pipette tip and placed into a PCR reaction mixture ready for 
amplification of the desired sequence. This resultant PCR gave products indicating 
either wrong orientation, right orientation, or mixed orientation. The colony PCR for 
expression sequences are as follows: 
PCR product insertion primer pair mix  
 8μl  - GoTaq Green master mix  
 1μl  - T7F plasmid specific forward primer  
 BGHR plasmid specific reverse primer  
 5μl - PCR water  
 1μl – Expression plasmid DNA 
 EPLINα overexpression ‘negative’ orientation reaction: 
 8μl – GoTaq® DNA Polymerase Reaction mix 
 5μl – PCR water 
 1μl – T7F plasmid specific forward primer 
 1μl – EPLIN sequence specific forward primer (F8) 
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 1μl – Expression plasmid DNA 
EPLINα overexpression ‘positive’ orientation reaction: 
 8μl – GoTaq® DNA Polymerase Reaction mix 
 5μl – PCR water 
 1μl – T7F plasmid specific forward primer 
 1μl – EPLIN sequence specific forward primer (R8) 
 1μl – Expression plasmid DNA 
Each reaction was subjected to the following conditions: 
 Step 1: Initial denaturing period: 94˚C for 10 minutes. 
 Step 2: Denaturing step: 94˚C for 60 seconds. 
 Step 3: Annealing step: 55˚C for 60 seconds. 
 Step 4: Extension step: 72˚C for 60 seconds. 
 Step 5: Final extension period: 72 ˚C for 10 minutes. 
Steps 2, 3 and 4 were repeated over 32 cycles. The PCR products were run on a 1% 
gel. If the ‘negative’ reactions produced a positive result, it means the plasmid from 
that colony was in the wrong orientation and wasn’t suitable. If the ‘positive’ 
reactions produced a positive result, it means the plasmid from that colony was in the 
right orientation and was suitable. Colonies in the right orientation at the expected 
product size were selected, taken from the agar plate and was used to inoculate 10 ml 
of ampicillin selective LB broth in universal containers and were horizontally shaken 
at 225 rpm overnight. 
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2.5.4 Plasmid extraction, purification and quantification (Miniprep) 
Plasmid extraction was carried out using Sigma GenElute Plasmid MiniPrep Kit 
(Sigma-Aldrich, Dorset, UK), according to the provided protocol. Colony cultures 
were removed from incubator and centrifuged at 3000 rpm for 10 minutes to obtain a 
pellet of bacteria. The supernatant was discarded and the pellet fully resuspended in 
200µl of Resuspension Solution (containing RNAase A) and mixed through 
pipetting and vortexing. To lyse samples, 200µl of Lysis Solution was added and 
mixed 6-8 times by inversion and followed immediately by adding 350µl 
Neutralisation/Binding Solution and then centrifuged at 12,000g for 10 minutes in a 
micro centrifuge. Mini Spin Columns were then prepared by adding 500µl Column 
Preparation Solution and centrifuged for 12000g for 30 seconds. The cell lysate was 
then transferred into prepared Mini Spin Columns centrifuged at 12000 x g for 1 
minute. The flow-through was discarded and 750µl Wash Solution was added to the 
column before centrifuging at 12,000g for 1 minute. The flow-through was discarded 
and an additional spin was carried out to remove excess Wash Solution. The Mini 
Spin Column was transferred to a clean collection tube and the plasmid DNA eluted 
in 100µl Elution Solution by centrifugation at 12,000g for 1 minute. The plasmid 
DNA was then run on a 1% gel to check both plasmid purity and product size. 
2.5.5 Transfection of mammalian cells using electroporation 
Following purification, quantification and verification of plasmids, 10μg of 
overexpression plasmid, and 5µg control pEF6 plasmid, was used to transfect 
prostate cancer cell lines, PC-3 and LNCaP. Once cells reached confluence, wild 
type cells were detached from cell flasks using trypsin EDTA, pelleted and 
resuspended as previously described. Electroporation cuvettes were removed from 
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packaging and 1ml of cells (at a density of 1x10
6
 cells/ml) added with the purified 
plasmid. The cuvette was loaded into a Cell Pulser Xcell™ Total System (BioRad, 
Hertfordshire, UK) and was pulsed with electricity (see table below for 
electroporation conditions). The electrical pulse causes cell membrane perforation 
and integration of plasmid DNA. Transfection conditions consisted of 310V and 
1500μA for PC-3 cells, and 290V and 1500 μA for LNCaP cells.  The mixture was 
immediately transferred into 5ml of prewarmed media in a T25 flask and placed in 
an incubator under standard incubation conditions overnight. Cells were selected the 
following morning for 6-14 days (6 for LNCaP cells, 14 for PC-3 cells) in 
appropriate cell line media containing 5μg/ml Blasticidin S (Melford, Suffolk, UK). 
Cells were subsequently maintained in 0.5μg/ml Blasticidin. Once cells reached 
sufficient confluence, RNA and protein was extracted as above. 
2.5.6 Plasmid sequencing  
To confirm and verify presence of full length EPLINα sequence in pEF6/ V5-His 
TOPO TA plasmid vector, plasmid samples were analysed using Sanger sequencing. 
This was done using an external company called Source BioScience (Source 
BioScience, Nottingham, UK) and samples were prepared at a concentration of 
100ng/µl prior to sending in accordance with the companies guidelines. 
2.6 In vitro tumour cell functional assays 
2.6.1 Bone matrix extract (BME) preparation for functional assays 
BME was employed in tumour functional assays to generate an in vitro bone-like 
environment. BME was prepared using fresh human bone tissues obtained post hip 
replacement. Bones were crushed at ice cold temperature prior to processing using a 
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Bone Mill (Splerings Orthopaedics B.V., The Netherlands) and subsequently a 
BioRuptor (Wolf Laboratories, York, UK) to solubilise and extract matrix proteins in 
PBS buffer. This was prepared, aliquoted and used previously in (Davies and Jiang, 
2010). For functional assays in section 4 and 5, an aliquot of stock BME (at 
concentration 2mg/ml) was removed from the freezer and allowed to thaw at room 
temperature. BME was required at a final concentration of 50µg/ml and 100µg/ml. 
This was done by making a working concentration of 100µg/ml and 200µg/ml (2x 
concentrated) which was subsequently diluted 1:1 with prostate cancer cells (PC-3 or 
LNCaP cells). The volume made was dependant on the functional assay and number 
of wells required. 
2.6.2 FAK inhibitor treatment to determine inhibitor concentration 
Prostate cancer cells were pre-seeded to approximately 60% confluence into 6 well 
plates one day prior to FAK treatment. PC-3 cells were treated overnight with four 
separate FAK inhibitor (CAS4506-66-5) (Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany) concentrations to determine optimal concentration for 
functional assay testing. The concentrations chosen were 100nM, 500nM, 1µM and 
5µM. FAK inhibitor solutions were made up in DMEM medium with sufficient 
volume for each concentration. The following day, protein was extracted as in 
section 2.4.1 but with a reduced volume of lysis buffer (100µl). Protein 
concentration was determined as in section 2.4 and samples were stored at -20°C 
until required for functional assays. 
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2.6.3 Src inhibitor (dasatinib) treatment to determine inhibitor concentration 
The same procedure was employed for determining optimal inhibitor concentration 
of dasatinib as in section 2.6.2. The chosen inhibitor concentrations were 100nM, 
500nM and 1µM. Following treatment, protein was extracted as in section 2.4.1 but 
with a reduced volume of lysis buffer (100µl). Protein concentration was determined 
as in section 2.4 and samples were stored at -20°C until required for functional 
assays. 
2.6.4 FAK inhibitor preparation for functional assays 
FAK inhibitor was prepared at final concentrations of 1µM and 5M. This 
concentration was chosen following treatment to PC-3 cells overnight followed by 
Western Blot (see Chapter6). This deduced optimal inhibition of FAK Y397 in both 
cell lines. The stock inhibitor was stored at 10mM concentration and diluted 1:1000 
to give a working concentration of 10M, then diluting by half depending on volume 
requirements for appropriate functional assays required. 
2.6.5 Src inhibitor (dasatinib) preparation for functional assays 
Dasatinib inhibitor (Axon1392) (Axon Medchem, Groningen, Netherlands) was 
prepared at a final concentration of 500nM. This concentration was chosen following 
treatment to PC-3 and LNCaP cells overnight followed by Western Blot (see Chapter 
7). This deduced optimal inhibition of Src Y419 in both cell lines. The stock 
inhibitor was stored at concentration 1mM and diluted 1:1000 to give a working 
concentration of 1M, then diluting by half depending on volume requirements for 
appropriate functional assays required. 
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2.6.6 In vitro tumour cell proliferation assay 
Cell proliferation was measured using an in vitro tumour proliferation assay. Cells 
were seeded into a 96-well plate (Nunc, Fisher Scientific, Leicestershire, UK) at 
3000 and 10,000 cells per well in 200μl of cell medium for PC-3 and LNCaP, 
respectively. In total, three plates were seeded to obtain proliferation readings at time 
points of Day 1, Day 3 and Day 5. Plates were seeded approximately 16 hours prior 
to the start of the first time point (Day 1). Cell proliferation of each sample was then 
compared at Day 3 and Day 5 time points and compared to the control (Day 1). For 
each experiment, samples were run in triplicate. After each incubation period (Day 1, 
3 or 5), cells were fixed in 4% formalin for 10 minutes before staining for 10 
minutes with 0.5% (w/v) crystal violet in distilled water. The plates were washed 
with water and the cells extracted using 10% acetic acid (v/v). Absorbance was 
measured at a wavelength of 540nm on an ELx800 plate reading spectrophotometer 
(Bio-Tek, Wolf laboratories, York, UK). The percentage of cell proliferation was 
determined using the following equation: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒
=  
𝐷𝑎𝑦 3 𝑜𝑟 5 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝐷𝑎𝑦 1 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝐷𝑎𝑦 1 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
 × 100 
The doubling time of PC-3 and LNCaP Wild-Type cells is 25hrs and 60hrs 
respectively (ATCC). Doubling time of PC-3/LNCaP
pEF6/EPLIN EXP 
was established at 
Day 5. This was done using the following equation: 
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 =  
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝐷𝑎𝑦 1 𝑎𝑛𝑑 𝐷𝑎𝑦 5 (ℎ𝑟𝑠) − log(2)
log(𝐷𝑎𝑦 5 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡) − log(𝐷𝑎𝑦 1 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡)
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In addition to untreated PC-3 and LNCaP cells, cell proliferation assay were 
performed in the presence of BME and FAK inhibitor. Use of BME was performed 
to establish the effects on cell proliferation in an in vitro bone-like environment, and 
the FAK inhibitor was used to establish the effect of FAK inhibition in conjunction 
with EPLINα over expression on PC-3 and LNCaP cells. 
2.6.7 In vitro tumour cell matrigel invasion assay 
The invasive capacity of the cells used in this study was assessed using an in vitro 
tumour cell Matrigel invasion assay. The assay measures the capability of cells to 
penetrate and invade through an artificial basement membrane created using 
Matrigel (MatrigelTM, BD Bioscience,Oxford, UK). Cell culture inserts containing 
8µM pores were placed into a 24-well plate and coated in 50µg Matrigel. A solution 
of Matrigel was initially made of concentration 0.5mg/ml in Serum Free Media 
(SFM) and 100μl was added to each of the inserts and allowed to dry in an incubator 
at 55˚C for 2-3 hours. Once dry, the inserts were rehydrated in 100μl of SFM for 30 
minutes. The media was then aspirated and the cells were seeded in the inserts on top 
of the basement membrane. Cells were seeded in 200μl at 15,000 for PC-3 cells and 
60,000 for LNCaP cells in each well. Once cells were seeded, 500µl of cell media 
was added to the well (outside of the insert) to support invading cells. The plates 
were then incubated for 3 days at 37˚C with 5% CO2. Following the incubation 
period, the inserts were rinsed and subject to cleaning inside of the insert using 
cotton buds to remove excess media and non-invaded cells. The cells which had 
invaded through the pores and penetrated the Matrigel were fixed in 500µl formalin 
solution for 10 minutes before staining in 0.5% crystal violet (w/v) in distilled water. 
Inserts were left overnight to dry before being visualized under the microscope under 
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X20 objective magnification. Of each insert, 4 random fields were counted and an 
average taken to evaluate cellular invasion of each sample. In addition to untreated 
PC-3 and LNCaP cells, cellular invasion was assessed in the presence of BME and 
an FAK inhibitor. Use of BME was performed to establish the effects on cellular 
invasion in an in vitro bone-like environment, and the FAK inhibitor was used to 
establish the effect of FAK inhibition in conjunction with EPLINα overexpression on 
PC-3 and LNCaP cells. 
2.6.8 In vitro cell-matrix adhesion assay 
The adhesive capacity of the cells used in this study was assessed using an in vitro 
tumour cell Matrigel adhesion assay. Matrigel was made using a concentration of 
0.05mg/ml in SFM and 100µl added to the wells of a 96-well plate. The plates were 
allowed to dry in the oven at 55˚C for 2-3 hours. Once dry, the inserts were 
rehydrated in 100μl of SFM for 30 minutes. The media was then aspirated and the 
cells were seeded in the inserts on top of the basement membrane. Cells were seeded 
in 200μl at varying density for varying incubation times depending on cell line as 
indicated in Table 2.7. 
Table 2.7 In vitro cell-matrix adhesion assay conditions 
Cell line Cell seed density Incubation time 
PC-3  40,000 45 minutes  
LNCaP 60,000 60 minutes  
 
LNCaP cell lines were incubated longer to ensure sufficient cellular attachment for 
measurement. Incubations were done at 37˚C with 5% CO2. After the incubation 
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period, the medium was aspirated and cells fixed in 4% formalin for 10 minutes 
before being stained in 0.5% crystal violet (w/v) in distilled water. The number of 
adherent cells were counted from 4 random fields per well, with 3 triplicate wells per 
sample, under a microscope at X20 objective magnification. In addition to untreated 
PC-3 and LNCaP cells, cellular adhesion was assessed in the presence of BME and 
an FAK inhibitor. Use of BME was performed to establish the effects on cellular 
adhesion in an in vitro bone-like environment, and the FAK inhibitor was used to 
establish the effect of FAK inhibition in conjunction with EPLINα overexpression on 
PC-3 and LNCaP cells. 
2.6.9 In vitro scratch/wound healing assay 
Cellular migration was evaluated across a wounded surface of a confluent monolayer 
of PC-3 cells. PC-3 cells were seeded at a seeding density of 100,000 cells per well 
in a 24 well plate the day before the scratch assay was planned to commence. Upon 
reaching a confluent monolayer, the cells were vertically scraped using a 10µl 
pipette tip, creating a wound. The cell media was then removed and fresh media 
and/or treatment was added to the PC-3 cells. Photos were taken on a Leica DM IRB 
microscope (Leica GmbH, Bristol, UK) at x20 magnification and designated as 0 
hour. Cell plates were placed back in the incubator to keep a constant temperature of 
37°C and further photographs were taken at 1 hour intervals, over a course of 4 
hours. Cell migration was analysed using ImageJ software by measuring the distance 
between the two wounded fronts of each well at 4 separate points per incubation. 
The distance between the migrating fronts at each 1 hour time point was determined 
by comparing the time point to Time 0, and subtracting the distance between the two 
fronts at the specific intervals with the original time point. The cellular migration of 
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PC-3 cells transfected with the pEF6 plasmid the EPLINα overexpression plasmid 
was determined, in addition to treatments used for the experiment. In addition to 
untreated PC-3 cells, cellular migration was assessed in the presence of BME and an 
FAK inhibitor. Use of BME was performed to establish the effects on cellular 
migration in an in vitro bone-like environment, and the FAK inhibitor was used to 
establish the effect of FAK inhibition in conjunction with EPLINα overexpression on 
PC-3. 
2.6.10 In vitro transwell migration assay 
A transwell migration assay was performed on LNCaP cells to assess cellular 
migration. Unlike PC-3 cells, LNCaP cells are less adherent and thus a scratch assay 
wasn’t suitable. The assay measures the capability of cells to migrate through cell 
culture inserts containing 8m pores. Cells were seeded in 200μl at a density of 
60,000 LNCaP cells in each well. A chemoattractant media of was used to ensure 
suitable migration through the pores (2% FCS on top of the inserts, 10% FCS in the 
wells). The plates were then incubated for 3 days at 37˚C with 5% CO2. Following 
the incubation period, the inserts were washed and blotted with cotton buds to 
remove excess media. The cells which had migrated through the pores and were 
fixed in 500µl formalin solution for 10 minutes before staining in 0.5% crystal violet 
(w/v) in distilled water. Inserts were left overnight to dry before being visualized 
under the microscope under X20 magnification. Of each insert, 4 random fields were 
counted and an average taken to evaluate cellular migration of each sample. In 
addition to untreated LNCaP cells, cellular migration was assessed in the presence of 
BME and an FAK inhibitor. Use of BME was performed to establish the effects on 
cellular migration in an in vitro bone-like environment, and the FAK inhibitor was 
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used to establish the effect of FAK inhibition in conjunction with EPLINα 
overexpression on LNCaP cells. 
2.6.11 In vitro co-culture invasion assay with human osteoblasts 
This assay was set up in a similar way to the in vitro Matrigel invasion assay as 
described in section 2.6.7; however this included the incubation with human 
hFOB1.19 osteoblast cells, to determine the impact of EPLINα overexpression on 
cellular invasion in an in vitro bone-like environment. hFOB1.19 cells were seeded 
at a seeding density of 40,000 cells per well in a 24 well plate one day prior to the 
start of the experiment.  PC-3/LNCaP
pEF6
 and PC-3/LNCaP
EPLIN EXP
 cells were 
seeded in inserts pre-covered with a layer of Matrigel as in section 2.6.7. PC-3 cells 
were seeded at 15,000 cells per insert, and LNCaP at 60,000 cells per insert in 200µl. 
Inserts containing PC-3 or LNCaP cells were then transferred to the 24 well plates 
pre-seeded with human osteoblasts, and to a plate containing no osteoblasts. The 
plates were then placed in the incubator and left for 3 days. Following the 
incubation, plates were fixed in formalin and stained using crystal violet before 
being visualised on the microscope. Cellular invasion was compared for PC-
3/LNCaP
pEF6
 and PC-3/LNCaP
EPLIN
 
EXP
 cells +/- osteoblasts. In addition to untreated 
PC-3 and LNCaP cells, cellular invasion was assessed in the presence of BME and 
an FAK inhibitor. Use of BME was performed to establish the effects on cellular 
invasion in an in vitro bone-like environment, and the FAK inhibitor was used to 
establish the effect of FAK inhibition in conjunction with EPLINα overexpression on 
PC-3 and LNCaP cells. 
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2.7  Data analysis for KinexusTM protein microarray 
The protein microarray determined the change in expression of certain molecules in 
response to EPLINα overexpression in PC-3 cells. Protein samples for PC-3pEF6 and 
PC-3
EPLIN EXP
 were prepared and quantified as described in section 2.4.3 before being 
sent to Kinexus Bioinformatics, Canada for processing and analysis. The Kinexus 
microarray utilises several key parameters for data analysis and these include 1) 
Globally Normalised Signal Intensity, 2) Z ratio and 3) % Change From Control 
(CFC). The Globally Normalised Signal intensity is calculated by totalling the net 
signal median values for a particular sample. The Z ratio is a comparison between 
two Z scores, by dividing the Z score differences by the standard deviation of all the 
differences in the comparison. A Z ratio greater than 1.64 is considered statistically 
significant for a molecule which has showed upregulation (in response to EPLINα 
overexpression) and a Z ratio less than -1.64 is considered statistically significant for 
a molecule that is downregulated (in response to EPLINα overexpression). The 
%CFC is a percentage calculation for a change in normalised signal intensity from 
the specified control. If a molecule is upregulated from the specified control, it will 
have a positive %CFC, and if a molecule is downregulated from the specified 
control, it will have a negative %CFC. This method has been described previously in 
(Owen et al., 2016).  
2.8 Statistical analysis 
Statistical analysis was performed using the SigmaPlot 11 statistical software 
package (Systat Software Inc., London, UK). Comparison between test groups was 
performed using a two sample, two tailed t-test or a Mann Whitney U test depending 
on data parameters. All experiments were carried out a minimum of three 
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independent times. Values of p < 0.05 were regarded as statistically significant. All 
figures annotated using *, ** or *** indicate p<0.05, p<0.01 and p<0.001 
respectively. 
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3.1 Introduction 
Gene dysregulation or loss is a primary indicator for potential association in disease 
progression in molecular biology and is frequently used as a tool for identifying 
cancer-related genes. EPLIN is widely expressed in various tissues including the 
kidney, placenta, ovaries, spleen, heart and prostate, however, EPLIN expression 
markedly diminishes during cancer progression (Maul and Chang, 1999). This loss 
was first identified in 1999 where the EPLINα isoform was downregulated or lost in 
various cancers, including oral, breast and prostate cancer (Maul and Chang, 1999). 
In later years this lead to various research groups evaluating EPLIN as a potential 
marker in cancer progression and as a possible therapeutic target. In prostate cancer 
specifically, subsequent publications have demonstrated a progressive loss of EPLIN 
in more advanced staged cancers, in addition to EPLIN loss being associated with 
pro-metastatic features including EMT transition, and has clinical implications 
linking to prognosis  (Sanders et al., 2011, Zhang et al., 2011). EPLIN has key links 
to the globular protein actin and has been shown to have actin binding capacity 
within its structure (Maul et al., 2003), and although this indicates EPLIN may have 
roles in cell movement and migration, the direct function of EPLIN remains elusive. 
This chapter aims to gain a further understanding of the expression profile of EPLIN 
in human prostate cancer, utilising prostate cancer cell lines and clinical prostate 
cancer tissue representative of various stages of prostate cancer progression to 
determine if EPLIN loss correlated with metastatic capacity and aggressiveness. 
Additionally, plasmid constructs were generated including the EPLINα full length 
expression sequence (for EPLINα overexpression) to gain further insight into the cell 
function and mechanism of action of manipulated EPLINα expression. EPLINα 
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expression plasmids were transfected into PC-3 and LNCaP cell lines, and verified 
for overexpression by PCR and Western Blotting. These stably transfected cells were 
used in later chapters of this thesis for cell functional and mechanistic investigations. 
The current chapter explores the expression profile of EPLIN in a range of cell lines 
and prostate tissues and describes the generation of these expression plasmids and 
EPLINα manipulated cell lines in addition to the verification of EPLINα 
overexpression at both transcript and protein level. 
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3.2 Material and methods 
3.2.1 Materials 
All primers used were manufactured and provided by Sigma (Sigma Aldrich, 
Gillingham, UK). Antibodies and primer sequences used for this study are listed in 
section 2.1.2 and 2.1.3. 
3.2.2 Cell lines 
The human prostate cancer cell lines PC-3, LNCaP, VCaP, DU-145 and CA-HPV-
10, immortalised ‘normal’ prostate cell line PZ-HPV-7 and a human osteoblast cell 
line hFOB1.19 were used for this study. For cell line media and incubation 
conditions, please see section 2.2. 
3.2.3 RNA extraction and cDNA synthesis 
RNA extraction was carried out on cells according to TRI reagent protocol (Sigma-
Aldrich, Dorset, UK). Reverse transcription was carried out using GoScript™ 
Reverse Transcription System (Promega, UK). For full procedure please refer to 
section 2.3.3. 
3.2.4 Polymerase Chain Reaction (PCR) 
PCR was carried out on cDNA from PC-3, LNCaP, VCaP, DU-145, PZ-HPV-7, CA-
HPV-10 and hFOB1.19. Levels of EPLINα and EPLINβ transcript were established. 
For full procedure please refer to section 2.3.4. 
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3.2.5 Real-Time Quantitative Polymerase Chain Reaction (RT-QPCR) 
RT-QPCR was performed using Precision Q-PCR 2X qPCR Mastermix (Primer 
Design, UK). Quantitative PCR data were analysed and normalised to the 
housekeeping gene, GAPDH. Primer sequences used for this study are listed in 
section 2.1.2. For the full procedure, please refer to section 2.3.6. 
3.2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting 
Protein expression was established by SDS-PAGE and Western Blotting. This was 
done using an OmniPAGE VS10 vertical electrophoresis system (OminPAGE, Wolf 
Laboratories, York, UK) and a SD10 SemiDry Maxi System blotting unit (Wolf 
Laboratories, York, UK) for electroblotting. Protein was detected using SNAP i.d.® 
2.0 Protein Detection System (Merck Millipore Ltd., Feltham, UK). For full 
procedure please refer to section 2.4. 
3.2.7 Generation of full length EPLINα overexpression plasmid 
Amplification of the EPLINα coding sequence was carried out using a Platinum® 
PCR SuperMix kit (Thermo Fisher Scientific,USA) using primers capable of 
amplifying the full length sequence of human EPLINα from PZ-HPV-7 cell line 
cDNA. Full length EPLINα was cloned into a pEF6/V5-His TOPO® TA cloning 
vector and extracted and verified. For full procedure please refer to section 2.5. 
3.2.8 Transfection of pEF6/V5-HIS TOPO TA vector containing EPLINα 
overexpression plasmids into prostate cancer cell lines  
pEF6/V5-HIS TOPO TA vectors containing EPLIN overexpression plasmid or 
empty pEF6/V5-HIS TOPO TA vector were used to transfect PC-3 or LNCaP cells 
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by electroporation. Following transfection cells were selected for 6-14 days (6 days 
for LNCaP, 14 days for PC-3) in appropriate cell line media containing 5μg/ml 
Blasticidin S (Melford, Suffolk, UK). Cells were subsequently maintained in 
0.5μg/ml Blasticidin S. For full procedure please refer to section 2.5.5. 
3.2.9 EPLIN expression analysis in prostate cancer tissues and related 
secondary tissues 
EPLIN expression was evaluated in clinical prostate cancer using two TMA’s 
labelled HPro-Ade96Sur-01 and PR8011a (see section 2.4.11). IHC analysis was 
performed on sections of normal prostate and prostate cancer tissue. For full 
procedure please refer to sections 2.4.11 and 2.4.12. Patient/sample information for 
sections present on the TMA’s is shown in Table 2.5 and Table 2.6. 
3.2.10 Statistical analysis 
Statistical comparisons were made between different groups using a two sample, two 
tailed t-test or a Mann Whitney U test dependant on data normality using SigmaPlot 
11 software. All experiments were carried out a minimum of three independent times 
and p < 0.05 regarded as statistically significant. 
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3.3 Results 
3.3.1 Expression profile of EPLIN in prostate cancer cells 
EPLIN expression was evaluated in prostate cancer, normal prostate and bone like 
cells lines by RT-PCR, Q-PCR and Western blotting (Figure 3.1A-C). EPLIN 
transcript was expressed in all cell lines with highest levels in CA-HPV-10, PZ-
HPV-7 and hFOB1.19, high levels were also observed in the DU-145 prostate cancer 
cell line. EPLINβ transcript was expressed at low levels and remained relatively 
consistent throughout the cell lines. Lowest levels of EPLIN transcript were seen in 
more aggressive cell lines PC-3, LNCaP and VCaP. Given the relatively consistent 
levels of EPLINβ transcript within all samples, PC-3, LNCaP and VCaP also had 
lowest levels of EPLINα expression. For Q-PCR analysis, EPLIN remained highly 
expressed in CA-HPV-10, and had low transcript expression in PC-3, DU-145, 
LNCaP and VCaP (Figure 3.1B). Samples were normalised to the CA-HPV-10 
sample for Q-PCR data analysis. EPLIN transcript was significantly reduced in PC-3 
(p=0.003), DU-145 (p=0.005), LNCaP (p=<0.001) and VCaP (p=0.002) when 
compared to EPLIN expression in CA-HPV-10. A similar EPLIN profile was seen 
during the protein analysis, with high expression of EPLINα and β in CA-HPV-10 
and hFOB1.19 and moderate expression of EPLINα in PZ-HPV-7. Low EPLINα 
expression was seen for DU-145 and VCaP, whilst EPLINβ was negative was these 
cell lines. For PC-3 and LNCaP, both EPLIN isoforms were negative (Figure 3.1C). 
GAPDH was run alongside each PCR, Q-PCR and Western Blot reaction as a 
control. 
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Figure 3.1– EPLIN expression profile in prostate cancer cells lines.  
(A) PCR analysis of prostate cell lines showing EPLINα, EPLINβ and GAPDH 
transcript expression. (B) q-PCR analysis of EPLIN transcript in prostate cell lines. 
Samples were normalised and compared to the CA-HPV-10 cell line. Error bars 
represent SE of the mean. (C) Western Blot protein analysis of EPLIN protein in 
prostate cell lines. GAPDH was used alongside each experiment as a control. Gel 
images and graphs are representative of n=3 repeats for each experiment. ** = 
p<0.01, *** = p<0.001. Statistical test performed for this analysis was a two sample, 
two tailed t-test using SigmaPlot software. 
  
 Chapter III 
147 
 
 
3.3.2 Generation of EPLINα overexpression plasmid 
To assess the effect of increased or sustained EPLINα expression on prostate cancer 
cell characteristics, a plasmid was constructed which included the EPLINα full 
length coding sequence (Figure 3.2). EPLINα transcript was initially derived and 
isolated from PZ-HPV-7 cell cDNA previously shown to express human EPLIN. 
Primers known to target a region of EPLINα (EPLIN F8/EPLIN R8) were also used 
alongside as a positive control, and produced a PCR band of 878bp, confirming the 
presence of EPLIN in PZ-HPV-7 (Figure 3.2B). Primers targeting the full EPLINα 
CDS were utilised to isolate a 1.8kb band using a high fidelity PCR procedure before 
progressing onto cloning steps (Figure 3.2C).  EPLINα expression sequences were 
then cloned into a pEF6/V5-His TOPO® TA vector and transformed into competent 
E.coli cells. Colonies were selected from plates and the orientation of the insert was 
checked by PCR using plasmid specific primers (T7F and BGHR) and EPLIN 
specific primers (F8 and R8). ‘Correct orientation’ PCR reactions produced strong 
bands at approximately 2kb (T7F vs BGHR) and 1.1kb (T7F vs EPLIN R8) and 
‘incorrect orientation’ PCR reactions produced no band (T7F vs EPLIN F8/ (-)).  
This confirmed presence of the human EPLINα sequence and correct orientation in 
the plasmid. Further sequence analysis was implemented by sequencing the plasmid 
and confirmed presence of EPLINα when comparing the sequencing product to the 
mRNA structure of EPLINα using a NCBI reference sequence (Figure 3.2E). These 
plasmids were then used for subsequent transfection procedures to mammalian 
prostate cancer cell lines. 
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Figure 3.2 EPLINα overexpression plasmid generation and verification.  
(A) Geneflow HighRanger 1kb DNA Ladder. (B) Confirmation of EPLINα 
expression and primer suitability in PZ-HPV-7 cell line. Bands at 1.8kb represent the 
full CDS of EPLINα that were amplified by primers targeting the start and end of the 
EPLINα sequence. Bands at approximately 878bp represent a region of EPLINα 
recognised by EPLIN-specific primers F8 and R8. PCR reactions run in duplicate. 
(C) PCR reaction using High Fidelity PCR kit to generate full EPLINα coding 
sequence for cloning reaction. (D) EPLINα full CDS region. Primers used for PCR 
amplification highlighted in bold. (E) PCR amplification of plasmids following 
cloning and plasmid extraction utilising EPLIN-specific primers (F8 and R8) and 
vector-specific primers (T7F). Positive orientation of sequence indicated by 1.1kb 
band in T7F vs EPLIN R8 whereas a negative result in T7F vs EPLIN F8 represents 
the absence of incorrectly orientated sequences. (F) Sequence chromatogram of 
sequencing products following sequencing from Source Biosciences. Start region of 
EPLINα mRNA depicted alongside start region of sequencing product. 
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3.3.3 Transfection of EPLINα expression sequence into PC-3 cells and 
verification of stable transfectants 
Following successful plasmid extraction, the mammalian prostate cancer cell line 
PC-3 was transfected with the EPLINα expression plasmid by electroporation. This 
was subsequently named PC-3
EPLIN EXP
. Plasmid control cells were generated by 
transfecting PC-3 Wild-Type cells with an empty pEF6 plasmid which was 
designated PC-3
pEF6
.  After electroporation and recovery, the cells were subjected to 
selection in Blasticidin S (5µg/ml) for 14 days. Following selection periods, RNA 
and protein were extracted from each cell line and verified for successful 
incorporation of the plasmid and enhancement of EPLIN expression. Successful 
forced expression was confirmed using PCR and Western Blotting (Figure 3.3). 
EPLIN transcript (P<0.001) and protein expression (P=0.004) was significantly 
increased in cells containing the EPLINα expression plasmid compared to cells 
containing empty pEF6 vector following semi-quantitative analysis of band 
intensities. PC-3
pEF6 
cells had comparable EPLIN expression to PC-3 Wild-Type 
cells, displaying low levels of EPLIN transcript expression and negligible EPLIN 
protein expression (data not shown). The EPLINβ isoform increased at the protein 
level (Figure 3.3C) but this increase was not seen at the transcript level (Figure 
3.3A). GAPDH was used as a housekeeping gene/protein for both PCR and Western 
Blotting reactions and for standardizing levels of cDNA and protein within the 
samples. 
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Figure 3.3 EPLINα overexpression in PC-3 cells.  
(A) EPLIN and EPLINβ PCR reaction. EPLINα transcript was substantially 
enhanced in PC-3
EPLIN EXP
 cells compared to PC-3
pEF6
 cells. (B) Semi-quantitative 
analysis of EPLINα band intensity from PCR reaction demonstrated a significant 
enhancement of EPLINα expression in PC-3EPLIN EXP cells compared to PC-3pEF6 
cells (C) EPLINα and EPLINβ Western Blot reaction. The EPLINα isoform was 
markedly increased in PC-3
EPLIN EXP 
cells compared to PC-3
pEF6
 (D) Semi-
quantitative analysis of EPLINα band intensity from Western Blot reaction 
demonstrated a significant enhancement of EPLINα expression in PC-3EPLIN EXP  
cells compared to PC-3
pEF6
 cells. Samples normalised to GAPDH for all 
experiments. Representative images shown, semi-quantitative analysis shows mean 
values of n=3 repeats. Error bars represent SE of the mean. ** = p<0.01, *** = 
P<0.001. Statistical test performed for semi-quantitative analysis was a two sample, 
two tailed t-test using SigmaPlot software.  
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3.3.4 Transfection of EPLINα expression sequence into LNCaP cell line and 
verification of stable transfectants 
Following successful plasmid extraction, the mammalian prostate cancer cell line 
LNCaP was transfected with the EPLINα expression plasmid by electroporation. 
This was subsequently named LNCaP
EPLIN EXP
. A control was used by transfecting 
LNCaP Wild-Type cells with an empty pEF6 plasmid control which was designated 
LNCaP
pEF6
. After electroporation and recovery the cells were subjected to a selection 
period in Blasticidin S (5µg/ml) for 6 days. Following selection periods, RNA and 
protein were extracted from each cell line and verified successful incorporation of 
the plasmid and enhancement of EPLIN expression using PCR and Western Blotting 
(Figure 3.4). Transfection of LNCaP cells with the EPLINα expression plasmid 
enhanced transcript expression of EPLIN, and to a lesser extent, EPLINβ (Figure 
3.4A), though the overexpression of EPLIN transcript in LNCaP
EPLIN EXP
 compared 
to LNCaP
pEF6
 did not quite reach statistical significance following semi-quantitative 
band analysis. For protein analysis, EPLINα was significantly increased in cells 
containing the EPLINα expression plasmid compared to cells containing empty 
pEF6 vector (P=0.047) (Figure 3.4D). LNCaP
pEF6 
cells had comparable EPLIN 
expression to LNCaP Wild-Type cells, displaying low EPLIN transcript expression 
and negligible EPLIN protein expression (data not shown). An increase in the 
EPLINβ isoform was also seen at protein level in LNCaP (Figure 3.4C). GAPDH 
was used as a housekeeping gene/protein for both PCR and Western Blotting 
reactions and standardized levels of cDNA and protein within the samples. 
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Figure 3.4 EPLINα overexpression in LNCaP cells.  
(A) EPLIN and EPLINβ PCR reaction in LNCaPpEF6 and LNCaPEPLIN EXP cells. (B) 
Semi-quantitative analysis of EPLIN band intensity from PCR reaction 
demonstrating slight increase in EPLIN expression in LNCaP
EPLIN EXP
 cells 
compared to LNCaP
pEF6
 cells. (C) EPLINα and EPLINβ Western Blot reaction. The 
EPLINα isoform was markedly increased in LNCaPEPLIN EXP cells compared to 
LNCaP
pEF6
. (D) Semi-quantitative analysis of EPLINα band intensity from Western 
Blot reaction demonstrated a significant enhancement of EPLINα expression in 
LNCaP
EPLIN EXP
 cells compared to LNCaP
pEF6
 cells. Semi-quantitative analysis 
carried out using Image J software. Samples normalised to GAPDH for all 
experiments. Representative images shown, semi-quantitative analysis shows mean 
values of n=3 repeats. Error bars represent SE of the mean. * = p<0.05. Statistical 
test performed for semi-quantitative analysis was a two sample, two tailed t-test 
using SigmaPlot software.  
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3.3.5 Expression analysis of EPLIN transcript levels in PCa tissues using the 
Gene Expression Omnibus (GEO) repository  
EPLIN expression in prostate cancer tissue has been previously evaluated where 
similar trends were seen to prostate cell line data demonstrated in this study. Using 
GEO profiles extracted from NCBI, EPLIN continually scored lower in cancerous 
tissue compared to normal prostate, with significant reductions in highly metastatic 
cancer tissues across cohorts (Figure 3.5). For the GDS2865 / 217892_s_at cohort, 
highly metastatic cancer tissue scored significantly lower for EPLIN expression than 
poorly metastatic (p<0.05) cancer tissue (Figure 3.5A). For the GDS1439 / 
222457_s_at cohort, metastatic prostate cancer tissue scored significantly less for 
EPLIN compared to Benign Prostate Tissue (p<0.01) and Primary Prostate Cancer 
(p<0.001) (Figure 3.5B). A similar trend was seen for the GDS1439 / 217892_s_at 
GEO profile where metastatic prostate cancer tissue scored significantly less for 
EPLIN compared to Benign Prostate Tissue (p<0.05) and Primary Prostate Cancer 
(p<0.01) (Figure 3.5C). 
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Figure 3.5 Gene Expression Omnibus (GEO) profiles of EPLIN score values 
from various cancer cohorts extracted from NCBI.  
(A) Profile GDS2865 / 217892_s_at; EPLIN score value in poorly metastatic tissue 
and highly metastatic tissue. (B) Profile GDS1439 / 222457_s_at; EPLIN score 
value in benign prostate tissue, primary prostate cancer and metastatic prostate 
cancer. (C) Profile GDS1439 / 217892_s_at; EPLIN score value in benign prostate 
tissue, primary prostate cancer and metastatic prostate cancer. Statistical test 
performed for analysis was a two sample, two tailed t-test using SigmaPlot software.  
 Chapter III 
156 
 
3.3.6 Expression analysis of EPLIN in prostate cancer tissues 
EPLIN expression was evaluated in clinical prostate cancer tissue using two TMAs 
(Figure 3.6). Several clinical parameters were evaluated for EPLIN staining in terms 
of cancer progression, these included cancer tissue vs. normal, cancer stage, Gleason 
score, chronic inflammation, cancers in adjacent to prostate tissue and cancer type 
(hyperplasia and adenocarcinoma). In the first TMA (HPro-Ade96Sur-01), EPLIN 
expression was reduced in cancer tissue compared to normal tissue (Figure 3.7). 
EPLIN expression in normal tissue was predominately expressed in the epithelial 
portion of the sections. EPLIN expression was also reduced in higher stage cancers, 
specifically stage III and IV compared to stage II (Figure 3.8). A reduction of EPLIN 
expression was also seen with increasing Gleason score samples, with EPLIN 
downregulation observed in Gleason 8, 9 and 10, compared to Gleason 6 and 7 
(Figure 3.9), though none of these trends reached statistical significance. In the 
second TMA (PR8011a), EPLIN expression was significantly reduced in patients 
with prostate cancer hyperplasia (p=<0.001) and adenocarcinoma (p=0.005) 
compared to normal prostate tissue (Figure 3.10). EPLIN was also highly expressed 
in the epithelial portion of normal tissue sections. A significant reduction in EPLIN 
expression was also seen in hyperplasia samples compared to adjacent prostate tissue 
(p=0.003). A general reduction in EPLIN expression was also seen between adjacent 
tissue and adenocarcinoma, and between normal prostate tissue and chronic 
inflammation, though these didn’t quite reach statistical significance (p=0.054 for 
adjacent tissue vs. adenocarcinoma; p=0.071 for normal prostate tissues vs. chronic 
inflammation). No significant differences were seen in EPLIN expression between 
normal prostate tissues and adjacent prostate tissue (p=0.422) (Figure 3.10). 
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Figure 3.6 TMA slides used for IHC analysis of EPLIN staining.  
(A) Photograph taken of TMA1; HPro-Ade96Sur-01. (B) Photograph taken of 
TMA2; PR8011a.  
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Figure 3.7 EPLIN IHC staining in normal prostate tissue and cancer tissue 
from TMA1 (HPro-Ade96Sur-01).  
(A) Representative images of EPLIN IHC staining from normal (n=8) and prostate 
cancer (n=36) samples at X10 and X20 objective magnification. Representative 
images are grid numbers G9 (Normal) and C8 (Cancer). Refer to Table 2.5 for full 
details. (B) Boxplot representations of (A) showing Median, Q1 and Q3 staining 
intensity. Whiskers represent minimum and maximum staining intensity. Staining 
intensity was determined by three independent operators using 0, 1, 2 and 3 as 
scoring intensities before taking an average of each score. The larger the number 
between 0-3, indicates the degree of brown protein staining.  
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Figure 3.8 EPLIN IHC staining in cancer samples of Stage II, III and IV from 
TMA1 (HPro-Ade96Sur-01).  
(A) Representative images of EPLIN IHC staining from cancer samples of Stage II 
(n=7), III (n=26) and IV (n=3) at X10 and X20 objective magnification. 
Representative images are grid numbers B5 (Stage II), C7 (Stage III) and B11 (Stage 
IV). Refer to Table 2.5 for full details.  (B) Boxplot representations of (A) showing 
Median, Q1 and Q3 staining intensity. Box plot data shows Stage II (n=7) vs. 
combined Stage III and IV (n=29). Whiskers represent minimum and maximum 
staining intensity. Staining intensity was determined by three independent operators 
using 0, 1, 2 and 3 as scoring intensities before taking an average of each score. The 
larger the number between 0-3, indicates the degree of brown protein staining.
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Figure 3.9 EPLIN IHC staining in cancer samples Gleason 6, 7, 8, 9 and 10 from TMA1 (HPro-Ade96Sur-01).  
(A) Representative images of EPLIN IHC staining from cancer samples of Gleason 6 (n=1), 7 (n=13), 8 (n=6), 9 (n=14) and 10 (n=2) at 
X10 and X20 objective magnification. Representative images are grid numbers D5 (Gleason 6), B4 (Gleason 7), D12 (Gleason 8), A9 
(Gleason 9) and E5 (Gleason 10). Refer to Table 2.5 for full details.  (B) Boxplot representations of (A) showing Median, Q1 and Q3 
staining intensity. Box plot data shows combined Gleason 6/7 (n=14) vs. combined Gleason 8/9/10 (n=22). Whiskers represent 
minimum and maximum staining intensity. Staining intensity was determined by three independent operators using 0, 1, 2 and 3 as 
scoring intensities before taking an average of each score. The larger the number between 0-3, indicates the degree of brown protein 
staining. 
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Figure 3.10 EPLIN IHC staining in normal prostate tissue, tissue with adjacent cancers, chronic inflammation, hyperplasia and 
adenocarcinoma from TMA2 (PR8011a).  
(A) Representative images of EPLIN IHC staining from normal prostate tissue (n=8), tissue with adjacent cancers (n=6), chronic 
inflammation (n=6), hyperplasia (n=26) and adenocarcinoma (n=30) at X20 and X40 objective magnification.  Representative images 
are grid numbers H3 (Normal Prostate), G8 (Adjacent Tissue), G4 (Chronic Inflammation), F10 (Hyperplasia) and C3 
(Adenocarcinoma). Refer to Table 2.6 for full details.  (B) Boxplot representations of (A) showing Median, Q1 and Q3 staining 
intensity. Staining intensity was determined by three independent operators using 0, 1, 2 and 3 as scoring intensities before taking an 
average of each score. The larger the number between 0-3, indicates the degree of brown protein staining. Whiskers represent minimum 
and maximum staining intensity. ** = p<0.01 and *** = p<0.001. Comparison between test groups was performed using a Mann 
Whitney U test. 
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3.4 Discussion 
This study aimed to create an expression profile for EPLIN in human prostate 
cancer, utilising prostate cancer cell lines and clinical prostate cancer tissue. EPLIN 
was initially identified as a protein with differential expression between normal and 
HPV immortalized oral keratinocytes (Chang et al., 1998) and this study sought to 
build on previous work utilising further prostate cancer cell lines and tissue. The 
initial cell line screen determined that EPLIN is differentially expressed in prostate 
cancer cell lines at the transcript level, with lowest expression in PC-3, LNCaP and 
VCaP. This notion was also comparable to protein data, where EPLIN was negative 
for both PC-3 and LNCaP. On the other hand, EPLIN transcript and protein was 
strongly expressed in the PZ-HPV-7 and CA-HPV-10 cell lines. This suggests that 
EPLIN is lost progressively as prostate cancer develops and becomes more 
aggressive, as PC-3, LNCaP and VCaP are cell lines derived from an aggressive 
form of prostate cancer which has metastasised, whereas PZ-HPV-7 is derived from 
normal prostate tissue, and CA-HPV-10 is derived from a non-metastatic 
adenocarcinoma. EPLINβ was expressed equivalently at low levels at the transcript 
level for all cell lines tested, however was negative for all prostate cell lines except 
for CA-HPV-10. These findings for EPLIN expression in prostate cancer concur 
with previous studies using PC-3, DU-145 and LNCaP models where EPLIN 
expression was low or abolished compared to non-cancerous controls (Maul and 
Chang, 1999). This is the first known study where the VCaP model has been used to 
evaluate EPLIN expression in prostate cancer and demonstrates comparable 
expression to the PC-3 and LNCaP models, supporting the concept that EPLIN is 
lost as prostate cancer progresses, as VCaP is a metastatic derived cell line from 
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vertebral metastases and is a more aggressive form of cancer compared to CA-HPV-
10 and PZ-HPV-7 (Korenchuk et al., 2001). It’s interesting to note that the lowest 
EPLIN expression profile was seen in cell lines derived from secondary bone sites 
(PC-3, VCaP), or secondary regions in the vicinity of bone sites (LNCaP), 
suggesting EPLIN expression may be at its weakest when in a most aggressive form 
of metastasised bone cancer.  This potential relationship between EPLIN and 
development of bone metastasis will be investigated further in later chapters. 
To evaluate EPLIN expression in clinical cancer, the global transcriptome database 
GEO was searched for EPLIN expression in various cancers. Analyses of three 
independent sets of microarray data on clinical prostate cancer demonstrated that 
metastatic and highly metastatic cancer correlated with markedly low EPLIN scores. 
Further to this, EPLIN expression was determined in two separate TMA 
experiments. EPLIN expression was markedly reduced in cancer samples compared 
to normal, and EPLIN loss correlated with increasing cancer stage and Gleason 
score. EPLIN expression was also reduced in cancer tissue samples with hyperplasia 
and adenocarcinoma with highly significant reductions compared to normal prostate 
tissue. This emphasises the importance of EPLIN expression in cancer progression 
and further suggests a cumulative loss of EPLIN in more aggressive prostate cancer 
types. This substantiates previous work evaluating EPLIN expression in clinical 
cancer, and demonstrates a potential use of EPLIN in diagnostic/prognostic testing of 
prostate cancer development and progression (Sanders et al., 2011, Jiang et al., 2008, 
Zhang et al., 2011, Liu et al., 2016). Interestingly, in the second TMA study, EPLIN 
was reduced in samples with chronic inflammation compared to normal prostate, 
which may also suggest a novel association of EPLIN expression in immune 
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response in cancer. Though, due to low sample number, this must be considered with 
caution and requires validation. In addition to low sample number, there are possible 
issues which could affect the level of protein staining in the tissues and these include 
antibody performance issues, processing, and embedding or antigenicity/antigen 
retrieval issues. This could help explain the reasons for poor staining of the sections. 
This TMA was also purchased commercially; therefore the ability to modify 
processing of the samples was unavailable. Further work is therefore required using 
a larger sample number and additional degrees of prostate cancer aggressiveness. 
Lastly, this study successfully generated a plasmid construct containing a full length 
EPLIN expression sequence for overexpression work in later chapters. Plasmids 
were transfected into PC-3 and LNCaP cells and EPLIN expression was verified by 
PCR and Western Blotting. In these two cell lines, EPLIN was successfully 
overexpressed and showed significant increase in EPLINα expression in both PC-3 
and LNCaP cells transfected with the expression plasmid compared to plasmid 
control cells, thus establishing suitable cell models for later chapters evaluating cell 
function in relation to manipulated EPLINα expression and potential mechanisms of 
action. Following EPLINα overexpression, PC-3 cells tended to show a more 
flattened, cobblestone morphology, opposed to a more spherical morphology of 
control pEF6-transfected PC-3 cells. LNCaP cells remained relatively unchanged 
morphologically following transfection. Changes in morphology following 
manipulated EPLINα expression has been previously seen using osteosarcoma cells, 
where cells became more spindle forming with cytoplasmic extensions (Maul and 
Chang, 1999). Both PC-3 and LNCaP cells overexpressing EPLINα also required 
longer incubations times for cells to be detached using trypsin, suggesting changes in 
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cell-matrix interaction with increased EPLINα and changes to cell adhesion. This 
will be discussed further in later chapters. Notably from this analysis, EPLINβ 
expression also increased alongside EPLINα overexpression. The reason for this is 
unknown; however it could be due to a potential stabilising effect of increased 
EPLINα on EPLINβ. As no significant increase was seen at the transcript level of 
EPLINβ for either PC-3 or LNCaP (Figure 3.3/Figure 3.4), this effect on EPLINβ 
must be acting post-transcriptionally. Little work has been presented and focused on 
the relationship between EPLINα and EPLINβ expression in cancer (Sanders et al., 
2010, Jiang et al., 2008, Liu et al., 2012a) nor has EPLINβ been comprehensively 
evaluated for implication in cancer in the literature, so it’s difficult to decipher if this 
increase is specific to prostate cancer cell lines PC-3 and LNCaP, or is a regulatory 
effect in other cell systems. On a side note, we have overexpressed the EPLINα 
isoform in the pancreatic cancer cell line PANC-1 previously, and no subsequent 
increase in EPLINβ was seen (unpublished, data not shown), therefore it may be that 
this increase is specific to prostate cancer cell lines. Lastly, this increase of EPLINβ 
cannot be directly from the expression plasmid itself, as EPLIN sequenced plasmid 
products contains only EPLINα promoter regions and everything upstream of the 
EPLINα promoter and hence, the start of EPLINβ sequence is missing from the 
sequenced plasmid.  
Based on the findings of this study, it supports the conclusion that EPLIN is 
downregulated or lost in prostate cancer, with largest reductions in expression of 
aggressive cancer cell lines or aggressive metastatic prostate cancer tissue. As other 
studies have reported, this demonstrates the potential of EPLIN as a prognostic 
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marker protein and could be used to envisage the aggressive nature of prostate 
cancer. 
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4 Chapter IV: Functional 
impact of EPLINα 
expression in a 
osteolytic PC-3 cell 
model of prostate cancer 
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4.1 Introduction 
With the discovery of EPLIN loss in cancer, a key research area emerged to 
elucidate its role in carcinogenesis and progression. Although there are indications of 
functional links of EPLIN to actin dynamics (Maul et al., 2003), the functional role 
of EPLIN in cancer development remains elusive. Several studies have illustrated 
that manipulation of the EPLINα isoform may have potential for cancer therapy and 
treatment, where enhanced EPLINα expression proved to be advantageous in 
suppressing metastatic characteristics including cellular invasion, adhesion, 
proliferation and motility, whereas inhibition of EPLINα expression resulted in a 
more aggressive phenotype  across a number of cancer types (Sanders et al., 2011, 
Jiang et al., 2008, Liu et al., 2012a, Liu et al., 2016). In addition to EPLIN’s 
association to actin, there are highlighted links to various other signalling molecules 
including paxillin and FAK (Sanders et al., 2010).  The majority of work carried out 
on the molecular characteristics of EPLIN in prostate cancer biology has utilised the 
classical prostate cell line PC-3 and this chapter aims to further explore EPLIN’s role 
using this cell model. In this chapter, PC-3 cells previously transfected with a 
EPLINα overexpression plasmid (see Chapter 3) were used to evaluate any 
functional importance of EPLINα by employing a number of in vitro functional 
techniques. In addition, cells were treated BME, and used in a co-culture osteoblast 
model, in order to highlight any change in metastatic potential of cells when in a 
bone like environment and to evaluate any potential role for EPLIN in establishment 
or development of bone metastasis. The aim of this chapter is to further explore the 
importance of EPLINα in the PC-3 osteolytic model of prostate cancer and to 
evaluate potential roles for EPLINα in regulating bone metastasis in vitro.  
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4.2 Material and methods 
4.2.1 Materials 
All primers used were manufactured and provided by Sigma-Aldrich (Dorset, UK). 
Antibodies and primer sequences used for this study are listed in section 2.1.2 and 
2.1.3. For this section, BME was used in in vitro functional assays. For preparation 
and dilution conditions, please see section 2.6.1. 
4.2.2 Cell lines 
The prostate cancer cell line PC-3 was used for this section of the study. PC-3 cells 
were cultured in DMEM as described in section 2.2. For the co-culture invasion 
assay with human osteoblasts, hFOB1.19 cells were used with a specialist medium 
of DMEM without phenol red supplemented with 10% FCS, 1% antibiotics and 
0.3mg/ml G418. 
4.2.3 In vitro tumour cell proliferation assay 
Cells were seeded into 96 well plates for varying incubation times to evaluate cell 
proliferation. Absorbance was measured to determine cell number and proliferation 
rate. The proliferation of both control PC-3
pEF6
 cells and PC-3
EPLIN EXP
 cells was 
determined in addition to any treatments used. For full procedure please refer to 
section 2.6.6. 
4.2.4 In vitro tumour cell Matrigel adhesion assay 
Cells were seeded into a 96 well plate which was pre-covered with layer of Matrigel. 
Following an appropriate incubation period, the number of cells that had adhered to 
the artificial basement membrane was counted. The adhesion of both control PC-
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3
pEF6
 cells and PC-3
EPLIN EXP
 cells was determined in addition to any treatments used. 
For full procedure please refer to section 2.6.8. 
4.2.5 In vitro tumour cell invasion assay 
Cells were seeded into 24 well plates containing cell culture inserts coated with a 
Matrigel layer. Following a 3 day incubation period, the number of cells which had 
penetrated and invaded the artificial basement membrane was stained and visualised 
on the microscope. The invasive capacity of both control PC-3
pEF6
 cells and PC-
3
EPLIN EXP
 cells was determined in addition to any treatments used. For full procedure 
please refer to section 2.6.7. 
4.2.6 In vitro tumour migration/wound healing assay 
Cells were seeded into 24 well plates one day prior to day of experiment ensuring 
sufficient cells to reach a confluent monolayer. A wound healing assay was 
performed over four hours and photos were taken at each one hour interval. 
Migratory potential both control PC-3
pEF6
 cells and PC-3
EPLIN EXP
 cells was then 
determined. For full procedure please refer to section 2.6.9 
4.2.7 In vitro co-culture invasion assay with human osteoblasts 
Human osteoblast hFOB1.19 cells were seeded into 24 well plates one day prior to 
the beginning of the experiment to ensure sufficient confluence. Once seeded, an 
invasion assay was set up as in section 2.6.7. Cell invasion was determined in both 
control PC-3
pEF6
 cells and PC-3
EPLIN EXP
 cells in an in vitro bone environment in 
presence of human osteoblasts. For full procedure please see section 2.6.11 
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4.2.8 Statistical analysis 
Statistical comparisons were made between different groups using a two sample, two 
tailed t-test or a Mann Whitney U test dependant on data normality. SigmaPlot 11.00 
software was used to conduct statistical analysis and p < 0.05 regarded as 
statistically significant  
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4.3 Results  
4.3.1 Effect of EPLINα overexpression on PC-3 cell proliferation 
The functional effect of EPLINα overexpression was determined in the osteolytic 
PC-3 cell line using an in vitro tumour cell proliferation assay. Forced EPLINα 
expression significantly reduced the cell proliferation of PC-3 cells at Day 3 
(p=0.005) and at Day 5 (p=0.023), when comparing PC-3
EPLINEXP
 and PC-3
pEF6
 cells 
(Figure 4.1A). The approximate doubling time of PC-3
pEF6 
cells at Day 5 was 35 
hours. The approximate doubling time of PC-3
EPLIN EXP 
cells at Day 5 was 41 hours. 
The effect of BME, at 50µg/ml and 100µg/ml concentrations, was also determined in 
both PC-3
pEF6 
and PC-3
EPLINEXP 
cells to deduce the potential effect of EPLINα 
expression on cell proliferation in an in vitro bone-like environment (Figure 4.1B/C). 
BME had no apparent effect on PC-3 cell proliferation for both PC-3
pEF6
 and PC-
3
EPLIN EXP 
cells at either concentration tested (50µg/ml and 100µg/ml).  
 Chapter IV 
174 
 
 
Figure 4.1 Cell proliferation assay in PC-3 cells.  
(A) Average cell proliferation (% change from Day 1) of PC-3
pEF6 
(pEF6) and PC-
3
EPLIN EXP 
(EPLIN EXP) cells at 3 day and 5 day time points. (B) Effect of BME at 
50µg/ml and 100µg/ml concentrations upon PC-3
pEF6 
(pEF6)
 
cells at 3 day and 5 day 
time points (% change from Day 1). (C) Effect of BME at 50µg/ml and 100µg/ml 
concentrations upon PC-3
EPLIN EXP 
(EPLIN EXP) cells at 3 day and 5 day time points 
(% change from Day 1). BME was added to tumour cell functional assays to 
represent an in vitro bone-like environment. Mean of three independent repeats 
(n=3) are shown. Error bars represent SE of the Mean. * = p<0.05, ** = p<0.01. 
Statistical analysis was performed using a two sample, two tailed t-test using 
SigmaPlot software. 
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4.3.2 Effect of EPLINα overexpression on tumour cell invasion 
The capability for PC-3
pEF6
 and PC-3
EPLINEXP
 cells to invade surrounding tissue was 
evaluated using an in vitro Matrigel invasion assay (Figure 4.2). Forced EPLINα 
expression in PC-3
EPLINEXP
 cells caused a significant decrease in cellular invasion 
(p=0.048) (Figure 4.2A/B). The effect of BME, at 50µg/ml and 100µg/ml 
concentrations, was also determined in both PC-3
pEF6 
and PC-3
EPLINEXP 
cells to 
deduce the potential effect of EPLINα expression on cell invasion in an in vitro 
bone-like environment (Figure 4.2C/D). BME had no apparent effect on PC-3 cell 
invasion for PC-3
pEF6
 and PC-3
EPLIN EXP 
cells at either concentration tested (50µg/ml 
and 100µg/ml). 
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Figure 4.2 Cellular invasion assay in PC-3 cells.  
(A) Average cell invasion of PC-3
pEF6
 and PC-3
EPLIN EXP
 cells through Matrigel over 
a 3 day incubation period. (B) Representative microscope image of PC-3
pEF6
 (pEF6) 
and PC-3
EPLIN EXP
 (EPLIN EXP) cell invasion images taken at X20 objective 
magnification. (C) Effect of BME addition at 50µg/ml and 100µg/ml concentrations 
on the invasiveness of PC-3
pEF6 
cells. (D) Effect of BME addition at 50µg/ml and 
100µg/ml concentrations on the invasiveness of PC-3
EPLIN EXP
 cells.  BME was 
added to tumour cell functional assays to represent an in vitro bone-like 
environment. Mean of three independent repeats (n=3) are shown. Error bars 
represent SE of the Mean. * = p<0.05. Statistical analysis was performed using a two 
sample, two tailed t-test using SigmaPlot software. 
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4.3.3 Effect of EPLINα overexpression on tumour cell adhesion 
The ability of PC-3
pEF6
 and PC-3
EPLINEXP
 cells to adhere to the matrix was evaluated 
using an in vitro Matrigel adhesion assay. Forced expression of EPLINα caused a 
significant increase in the cells ability to adhere to the cell matrix (P=0.034) (Figure 
4.3A/B). The effect of BME at 50µg/ml and 100µg/ml concentrations was also 
determined in both PC-3
pEF6 
and PC-3
EPLINEXP 
cells to deduce the potential effect of 
EPLINα expression on adhesion in an in vitro bone-like environment (Figure 
4.3C/D). BME had no apparent effect on PC-3 cell adhesion for PC-3
pEF6
 and PC-
3
EPLIN EXP 
cells at either concentration tested (50µg/ml and 100µg/ml). 
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Figure 4.3 Cellular adhesion assay in PC-3 cells.  
(A) Average cell adhesion of PC-3
pEF6
 and PC-3
EPLIN EXP
 cells to Matrigel matrix. 
(B) Representative microscope image of PC-3
pEF6
 (pEF6) and PC-3
EPLIN EXP
 (EPLIN 
EXP) cell adhesion, images taken at X20 objective magnification. (C) Effect of BME 
addition, at 50µg/ml and 100µg/ml concentration, on matrix adhesion of PC-3
pEF6 
cells. (D) Effect of BME addition, at 50µg/ml and 100µg/ml concentration, on 
matrix adhesion of PC-3
EPLIN EXP
 cells.  BME was added to tumour cell functional 
assays to represent an in vitro bone-like environment. Mean of three independent 
repeats (n=3) are shown. Error bars represent SE of the Mean. * = p<0.05. Statistical 
analysis was performed using a two sample, two tailed t-test using SigmaPlot 
software. 
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4.3.4 Effect of EPLINα overexpression on tumour cell migration using a 
scratch/wound healing assay 
To determine the effect of EPLINα expression on cell migration, an in vitro 
scratch/wound healing assay was performed on PC-3
pEF6 
cells and PC-3
EPLINEXP 
cells 
(Figure 4.4). Cell migration was measured at 4 time points (1 hour, 2 hours, 3 hours 
and 4 hours) and compared to a control at Time 0 (0 hour). EPLINα overexpression 
resulted in a significant decrease in cell migration at the 2 hour time point (p=0.011), 
3 hour time point (p=0.004) and the 4 hour time point (p=0.005), with highly 
significant reductions in cell migration being seen at the later time points (Figure 
4.4A/B). The effect of BME, at 50µg/ml and 100µg/ml concentrations, was also 
determined in both PC-3
pEF6 
and PC-3
EPLINEXP 
cells to deduce the potential effect of 
EPLINα expression on cell migration in an in vitro bone environment (Figure 
4.4C/D). In PC-3
pEF6 
cells, BME had no apparent effect on PC-3
pEF6
 cell migration at 
either concentration tested (50µg/ml and 100µg/ml). In PC-3
EPLINEXP 
cells, the lower, 
50µg/ml, BME concentration enhanced the migration rate of PC-3
EPLINEXP 
cells 
throughout each time point; with a significant increase in cellular migration at the 2 
hour time point (p=0.043), in comparison to the untreated PC-3
EPLIN EXP
. The higher, 
100µg/ml BME concentration had no significant effects on PC-3
EPLINEXP 
cells at any 
time point tested when compared to untreated PC-3
EPLIN EXP 
cells (Figure 4.4D). 
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Figure 4.4 Cell migration assay in PC-3 cells.  
(A) Average cell migration of PC-3
pEF6
 and PC-3
EPLIN EXP
 cells over 4 hours. (B) 
Representative images of PC-3
pEF6
 (pEF6) and PC-3
EPLIN EXP
 (EPLIN EXP) wounds 
at initial and end points, images taken at X10 objective magnification. (C) Effect of 
BME addition, at 50µg/ml (BME 50) and 100µg/ml (BME 100) concentration, on 
the migration rates of PC-3
pEF6 
cells. (D) Effect of BME addition, at 50µg/ml (BME 
50) and 100µg/ml (BME 100) concentration, on the migration rates of PC-3
EPLIN EXP
 
cells. BME was added to tumour cell functional assays to represent an in vitro bone-
like environment. Mean of three independent repeats (n=3) are shown. Error bars 
represent SE of the Mean. * = p<0.05, ** = p<0.01. Statistical test performed for 
analysis was a two sample, two tailed t-test using SigmaPlot software.  
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4.3.5 Effect of EPLINα overexpression on cell invasion using a co-culture 
human osteoblast model 
To further determine the effect of EPLINα overexpression in the bone environment, 
cell invasion was established in the presence of human hFOB1.19 osteoblasts in an 
in vitro co-culture assay (Figure 4.5). Two 24 well plates were set up, one cultured 
with osteoblasts and the other without osteoblasts and Matrigel coated transwell 
inserts (containing 8µm pores) were placed over the top of the empty wells and those 
containing hFOB1.19 osteoblast cells in a similar fashion to that in the invasion 
assay. The presence of osteoblasts generally increased cellular invasion for both PC-
3
pEF6
 and PC-3
EPLINEXP
 cells. For the PC-3
pEF6 
cells, presence of osteoblasts 
significantly increased cellular invasion (P<0.001 vs. mono-cultured PC-3
pEF6
 cells). 
For PC-3
EPLINEXP
 cells, presence of osteoblasts slightly increased invasion, however 
the change was not significant (p=0.400), suggesting EPLINα expression may 
protect against pro-invasive signals secreted by osteoblasts at the bone environment. 
EPLINα overexpression significantly reduced cellular invasion in absence of 
osteoblasts (p=<0.001) when compared to the equivalent PC-3
pEF6
 group. When 
osteoblasts were present, EPLINα overexpression reduced cellular invasion, however 
this didn’t reach significance when compared to PC-3pEF6 cells (in presence of 
osteoblasts) (p=0.100) (Figure 4.5A/B). The effect of 50µg/ml BME was also 
determined in both PC-3
pEF6 
and PC-3
EPLINEXP 
cells, for osteoblast positive and 
osteoblast negative culture conditions. In PC-3
pEF6 
cells, BME enhanced cell 
invasion for osteoblast positive and osteoblast negative culture conditions, with the 
highest amount of cell invasion seen in conditions where both osteoblasts and BME 
were present (Figure 4.5C). Although BME treatment increased cellular invasion 
when compared to PC-3
pEF6 
cells, this increase was not statistically significant 
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(p=0.094 for osteoblast negative condition, p=0.730 for osteoblast positive 
condition). In PC-3
EPLIN EXP 
cells, a similar trend was seen, where BME increased 
cell invasion when compared to untreated controls, with highest invasion seen in the 
presence of osteoblasts (Figure 4.5D). Although BME treatment increased cellular 
invasion when compared to PC-3
EPLINEXP 
cells, this increase was not statistically 
significant (p=0.204 for osteoblast negative condition, p=0.229 for osteoblast 
positive condition). 
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Figure 4.5 Co-culture invasion assay with human hFOB1.19 osteoblasts and 
PC-3 cells.  
(A) Average cell invasion of PC-3
pEF6
 and PC-3
EPLIN EXP
 cells with and without 
osteoblasts. (B) Representative images, taken at X20 objective magnification, of 
invaded PC-3
pEF6
 (pEF6) and PC-3
EPLIN EXP
 (EPLIN EXP) cells following culture in 
the presence or absence of hFOB1.19 osteoblasts. (C) Effect of 50µg/ml BME 
addition on the invasiveness of PC-3
pEF6 
cells cultured with and without osteoblasts. 
(D) Effect of 50µg/ml BME addition on the invasiveness of PC-3
EPLIN EXP
 cells 
cultured with and without osteoblasts. BME was added to tumour cell functional 
assays to represent an in vitro bone-like environment +/- human osteoblasts. Mean of 
three independent repeats (n=3) are shown. Error bars represent SE of the Mean. ** 
= p<0.01, *** = p<0.001. Statistical test performed for semi-quantitative analysis 
was a two sample, two tailed t-test using SigmaPlot software.  
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4.4 Discussion 
This study has demonstrated the functional impact of EPLINα expression using an 
osteolytic cell line model, PC-3. The functional effect of EPLINα overexpression 
was established in PC-3 by employing various in vitro functional assays. EPLINα 
overexpression resulted in a less aggressive PC-3 phenotype in terms of cell 
proliferation, invasion and migration. Forcing EPLINα expression led to PC-3 cells 
displaying reduced invasiveness, proliferation rates and motility. EPLINα expression 
was also associated with enhanced matrix-adhesion of PC-3 cells to Matrigel. These 
functional effects agree with previous reports in prostate cancer (Sanders et al., 
2011), breast cancer (Jiang et al., 2008), oesophageal cancer (Liu et al., 2012a) and 
ovarian cancer (Liu et al., 2016) that EPLINα expression is able to influence various 
cell functions and demonstrates a key role for EPLINα in regulating cancer 
progression as a tumour suppressive molecule.  The enhanced adhesive ability of 
PC-3 cells overexpressing EPLINα also strengthens the putative link to FAK, as 
FAK is an established molecule for inducing focal adhesion via integrin signalling 
(Guan, 1997), and this is a relationship which will be explored in more detail in 
Chapter 6 of this thesis.  
As EPLINα appears to have an anti-proliferative effect in PC-3 cells by the three day 
time point, which concurs with previous reports (Sanders et al., 2011), it’s important 
to note that any other cellular effect visualised with a similar time point (for example 
the tumour invasion assay in Figure 4.2), could also be attributed, in part, to this anti-
proliferative effect.  
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In addition to untreated PC-3
pEF6
 and PC-3
EPLIN EXP
cells, in vitro tumour functional 
assays were carried out in presence of BME, to establish any effects EPLINα may 
have on cell function in a bone-like environment. BME contains proteins extracted 
from human femoral bones and thus provides a molecular environment for cancer 
cells when used in functional tests. BME appeared to have no significant effect on 
cell proliferation, adhesion, invasion or migration in PC-3
pEF6
 and PC-3
EPLIN EXP
 
cells. Notably, BME caused a slight increase in cell proliferation of PC-3
pEF6
 control 
cells but not PC-3
EPLIN EXP
 cells and a reduction of cell invasion of PC-3
pEF6
 control 
cells but not PC-3
EPLIN EXP
 cells. Further, an increase in matrix-adhesion of both PC-
3
pEF6
 and PC-3
EPLIN EXP
 cells was seen in response to BME addition. Interestingly, 
BME appeared to increase cell migration of PC-3
EPLIN EXP
 cells in earlier stages of 
the experiment compared to untreated PC-3
EPLIN EXP
 cells, with a significant increase 
at the 2 hour time point, yet PC-3
pEF6
 cells were unresponsive to BME. Lastly, in 
order to further elucidate if the potential tumour suppressive effect of EPLINα has 
any potential in the bone environment and in the development of bone metastasis, an 
in vitro co-culture model was established using PC-3 cells and human hFOB1.19 
osteoblasts with and without BME. PC-3 cells with forced EPLINα expression were 
capable of significantly reducing cell invasion outside the bone-like environment. 
Whereas untreated PC-3
pEF6
 cells were highly invasive, and at their most aggressive 
within a bone-like environment, PC-3
EPLIN EXP
 cells displayed no significant 
difference when they moved from a non-bone-like environment to a bone-like 
environment. Currently, there are no published articles that have examined the 
impact of EPLIN in regards to the homing of prostate cancer cells to the bone or in 
the development of bone metastasis. This early study highlighted some subtle 
differences in how PC-3
pEF6
 and PC-3
EPLIN EXP
 cells responded to BME, though these 
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were generally not significant. Furthermore, it has demonstrated that EPLINα 
overexpression may be capable of reducing the pro-invasive effect brought about by 
the presence of osteoblasts. Hence the current data suggests that EPLINα may have 
some role in regulating the responsiveness of PC-3 cells to factors present within the 
bone matrix or secreted by bone cells present in the environment and may thus play a 
role in cancer dissemination or establishment in such environments.  
Collectively, this study addresses the functional importance of EPLINα in prostate 
cancer, specifically utilising an osteolytic cell line model and has identified early 
indications of EPLINα biology in a bone-like environment. To compliment this data, 
further functional and mechanistic evidence is required from additional models of 
prostate cancer to provide and clarify EPLIN’s role in cancer progression. The 
following chapter of this thesis will examine the impact of EPLINα overexpression 
in the LNCaP cell line, a model suggested forming mixed osteolytic/osteoblastic 
metastasis. 
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5 Chapter V: Functional 
impact of EPLINα 
expression in a mixed 
osteoblastic/osteolytic 
LNCaP cell model of 
prostate cancer 
  
 Chapter V 
188 
 
5.1 Introduction 
Previous reports have utilised the “classic” PC-3 cell line to demonstrate the 
functional anti-cancer effects of EPLIN (Sanders et al., 2011, Maul and Chang, 
1999). Whilst a previous study has explored the functional impact of EPLIN in 
LNCaP using an in vitro invasion assay (Zhang et al., 2011), a comprehensive study 
elucidating EPLINα’s potential exploiting the LNCaP model is yet to be undertaken. 
The LNCaP model is an androgen-dependant model of prostate cancer utilising 
metastatic prostate cancer cells derived from the left supraclavicular lymph node of 
human prostatic adenocarcinoma (Horoszewicz et al., 1983). Prostate cancer cells 
nearly always form osteoblastic lesions when metastasised to bone, unlike breast, 
kidney and lung cancer cells which tend to form osteolytic lesions (Logothetis and 
Lin, 2005). PC-3 cells tend to form osteolytic lesions, whereas LNCaP cells form a 
mixture of osteoblastic and osteolytic lesions. LNCaP cells are therefore useful for 
evaluating prostate cancer in the laboratory due to the close association of the 
clinical disease. Importantly, a key aim of this thesis was to evaluate any potential 
links EPLINα may have on the establishment of bone metastases, therefore making 
the LNCaP cell line useful for functional analysis. In this chapter, LNCaP cells that 
were previously transfected with the EPLINα overexpression plasmid (see Chapter 
3) were used in various in vitro functional techniques to assess the effect of forced 
EPLINα expression on cancer cell characteristics in a mixed osteolytic/osteoblastic 
cell model. These functional assays were carried out in presence of BME to provide 
a bone-like environment for the cancer cells. The aims of this chapter is to deduce if 
forced EPLINα expression can influence LNCaP cells and potentially mitigate the 
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characteristics associated with metastatic cancer cells within this mixed 
osteoblastic/osteolytic prostate cancer cell model. 
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5.2 Material and methods 
5.2.1 Materials 
All primers used were manufactured and provided by Sigma-Aldrich (Dorset, UK). 
Antibodies and primer sequences used for this study are listed in section 2.1.2 and 
2.1.3. BME was prepared and used as described in Section 2.6.1. 
5.2.2 Cell lines 
The human prostate cancer cell line LNCaP and the human hFOB1.19 osteoblast cell 
line were used for this section of the study. LNCaP cells were cultured in RPMI-
1640 media. For the co-culture invasion assay with human osteoblasts, hFOB1.19 
cells were used with a specialist medium of DMEM without phenol red 
supplemented with 10% FCS, 1% antibiotics and 0.3mg/ml G418. 
5.2.3 Polymerase Chain Reaction (PCR) 
PCR was carried out on cDNA previously reverse transcribed from LNCaP RNA. 
EPLIN expression was determined in LNCaP
pEF6
 cDNA and LNCaP
EPLIN EXP
 cDNA. 
For full procedure please refer to section 2.3.4. 
5.2.4 SDS PAGE and Western Blotting 
Western blotting was carried out on LNCaP protein extracted from cells previously 
transfected with the pEF6 vector or the EPLINα expression plasmid. EPLIN protein 
levels were determined and changes in expression were evaluated. For full procedure 
please refer to section 2.4. 
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5.2.5 In vitro tumour cell proliferation assay 
Cells were seeded into quadruplicate 96 well plates for varying incubation times to 
evaluate cell proliferation as described in section 2.6.6. Absorbance was measured to 
determine cell number and proliferation rate. The proliferation rates of both control 
LNCaP
pEF6 
cells and LNCaP
EPLIN
 
EXP
 cells were determined in addition to any 
treatments used. For full procedure please refer to section 2.6.6. 
5.2.6 In vitro tumour cell Matrigel adhesion assay 
Cells were seeded into a 96 well plate which was pre-covered with layer of Matrigel 
(5µg). Following an incubation period, the number of cells that had adhered to the 
artificial basement membrane was fixed, stained and counted. The adhesion 
capacities of both control LNCaP
pEF6 
cells and LNCaP
EPLIN
 
EXP
 cells were 
determined in addition to any treatments used. For full procedure please refer to 
section 2.6.8. 
5.2.7 In vitro tumour cell invasion assay 
Cells were seeded into 24 well plates containing cell culture inserts, containing 8µm 
pores, with a Matrigel layer (50µg). Following a 3 day incubation period, the number 
of cells which had penetrated and invaded the artificial basement membrane was 
fixed, stained and visualised on the microscope. The invasive capacities of both 
control LNCaP
pEF6 
cells and LNCaP
EPLIN
 
EXP
 cells were determined in addition to 
any treatments used. For full procedure please refer to section 2.6.7. 
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5.2.8 In vitro tumour transwell migration assay 
A transwell migration assay was performed using cell culture inserts, containing 
8µm pores utilising a chemoattractant cell medium .Cell migration was visualised by 
counting and measuring the number of cells that migrated through the 8µm pores of 
the cell culture inserts after a 3 day incubation period on the microscope. The 
migration capacities of both control LNCaP
pEF6 
cells and LNCaP
EPLIN
 
EXP
 cells were 
determined in addition to any treatments used. For full procedure please refer to 
section 2.6.10. 
5.2.9 In vitro co-culture invasion assay with human osteoblasts 
Human osteoblast hFOB1.19 cells were seeded into 24 well plates one day prior to 
the beginning of the experiment to ensure sufficient confluence. Once seeded, an 
invasion assay was set up as in section 2.6.7. Cell invasion was determined in both 
control LNCaP
pEF6 
cells and LNCaP
EPLIN
 
EXP
 cells in an in vitro bone environment in 
presence of human osteoblasts. For full procedure please see section 2.6.11. 
5.2.10 Statistical analysis 
Statistical comparisons were made between different groups using a two sample, two 
tailed t-test or a Mann Whitney U test dependant on data normality. SigmaPlot 11 
software was used to conduct statistical analysis and p < 0.05 regarded as 
statistically significant.  
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5.3 Results 
5.3.1 Effect of EPLINα overexpression on LNCaP cell proliferation  
The functional effect of EPLINα overexpression was determined in the LNCaP cell 
line using an in vitro tumour cell proliferation assay. Forced EPLINα expression in 
LNCaP cells displayed a similar trend to PC-3 cells with a reduction of cell 
proliferation  in LNCaP
EPLIN EXP
 compared to  LNCaP
pEF6
 cells, at both day 3 
(p=0.114) and day 5 (p=0.329) time points, however this reduction didn’t reach 
significance (Figure 5.1A). The approximate doubling time of LNCaP
pEF6 
cells at 
Day 5 was 40 hours. The approximate doubling time of LNCaP
EPLIN EXP 
cells at Day 
5 was 62 hours. The effect of BME, at 50µg/ml and 100µg/ml concentrations, was 
also determined in both LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells to deduce the potential 
effect of EPLINα expression on cell proliferation in an in vitro bone-like 
environment (Figure 5.1B/C). BME had no apparent effect on LNCaP cell 
proliferation for both LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells at either concentration 
tested (50µg/ml and 100µg/m l).   
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Figure 5.1 Cell proliferation assay in LNCaP cells.  
(A) Average cell proliferation of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells at 3 day and 5 
day time points (% change from Day 1). (B) Effect of BME addition, at 50µg/ml 
(BME 50) and 100µg/ml (BME 100) concentrations, to LNCaP
pEF6 
cells at 3 day and 
5 day time points (% change from Day 1). (C) Effect of BME addition, at 50µg/ml 
(BME 50) and 100µg/ml (BME 100) concentrations, to LNCaP
EPLIN EXP
 cells at 3 
day and 5 day time points (% change from Day 1). BME was added to tumour cell 
functional assays to represent an in vitro bone-like environment. Mean of three 
independent repeats (n=3) are shown. Error bars represent SE of the Mean. 
Statistical test performed for analysis was a two sample, two tailed t-test using 
SigmaPlot software. 
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5.3.2 Effect of EPLINα overexpression on LNCaP cell invasion 
The invasive capability of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells was evaluated using 
an in vitro Matrigel invasion assay (Figure 5.2). Forced EPLINα expression in 
LNCaP
EPLIN EXP
 cells caused a reduction in cellular invasion, however this didn’t 
reach significance (p=0.194) (Figure 5.2A/B). The effect of BME, at 50µg/ml and 
100µg/ml concentrations, was also determined in both LNCaP
pEF6 
and LNCaP
EPLIN 
EXP 
cells to deduce the potential effect of EPLINα expression on cell invasion in an 
in vitro bone-like environment. BME had no apparent effect on LNCaP cell invasion 
for LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells at either concentration tested (50µg/ml and 
100µg/ml). 
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Figure 5.2 Cell invasion assay in LNCaP cells.  
(A) Average cell invasion of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells following 3 day 
incubation. (B) Representative microscope image of LNCaP
pEF6
 (pEF6) and 
LNCaP
EPLIN EXP
 (EPLIN EXP) cell invasion, images taken at X20 objective 
magnification. (C) Effect of BME addition, at 50µg/ml and 100µg/ml 
concentrations, on the invasiveness of LNCaP
pEF6 
cells. (D) Effect of BME addition, 
at 50µg/ml and 100µg/ml concentrations, on the invasiveness of LNCaP
EPLIN EXP
 
cells. BME was added to tumour cell functional assays to represent an in vitro bone-
like environment. Mean of three independent repeats (n=3) are shown. Error bars 
represent SE of the Mean. Statistical test performed for analysis was a two sample, 
two tailed t-test using SigmaPlot software.  
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5.3.3 Effect of EPLINα overexpression on LNCaP cell adhesion 
The ability of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells to adhere to the Matrigel matrix 
was evaluated using an in vitro Matrigel adhesion assay. Forced expression of 
EPLINα caused a significant increase in the cells ability to adhere to the cell matrix 
(P=0.006) (Figure 5.3A/B). The effect of BME, at 50µg/ml and 100µg/ml 
concentrations, was also determined in both LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells to 
deduce the potential effect of EPLINα expression on matrix-adhesion in an in vitro 
bone-like environment (Figure 5.3C/D). In LNCaP
pEF6 
cells, BME had no apparent 
effect on LNCaP cell adhesion for LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells at either 
concentration tested (50µg/ml and 100µg/ml). For LNCaP
EPLIN EXP 
cells, no apparent 
change was seen at the lower concentration of BME tested (50µg), but a significant 
increase in cellular adhesion was seen for the higher concentration (100µg) tested. 
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Figure 5.3 Cell adhesion assay in LNCaP cells.  
(A) Average cell adhesion of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells. (B) 
Representative microscope image of LNCaP
pEF6
 (pEF6) and LNCaP
EPLIN EXP
 (EPLIN 
EXP) cell adhesion, images taken at X20 objective magnification. (C) Effect of BME 
addition, at 50µg/ml and 100µg/ml concentrations, on the cell-matrix adhesion of 
LNCaP
pEF6 
cells. (D) Effect of BME addition, at 50µg/ml and 100µg/ml 
concentrations, on the cell-matrix adhesion of LNCaP
EPLIN EXP
 cells. BME was added 
to tumour cell functional assays to represent an in vitro bone-like environment. Mean 
of three independent repeats (n=3) are shown. Error bars represent SE of the Mean. * 
= p<0.05, *** = p<0.001. Statistical test performed for analysis was a two sample, 
two tailed t-test using SigmaPlot software.  
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5.3.4 Effect of EPLINα overexpression on LNCaP cell transwell migration  
To assess the effect EPLINα exerts on tumour cell migration in the LNCaP cell line, 
an in vitro transwell migration assay was undertaken (Figure 5.4). Forced EPLINα 
expression reduced the ability of LNCaP cells to migrate through the pores of the 
transwell inserts and reduced cell migration when compared to LNCaP
pEF6 
cells, 
however this didn’t reach significance (p=0.381) (Figure 5.4A/B). To establish if the 
presence of a bone-like environment effected cell migration and/or EPLINα’s effect 
on cell migration, the assay was carried out in presence of BME at a concentration of 
50µg/ml (Figure 5.4C). BME had no apparent effect on LNCaP cell migration for 
LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells at concentration 50µg BME.  
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Figure 5.4 Transwell cell migration assay in LNCaP cells.  
(A) Average cell migration of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells. (B) 
Representative images of LNCaP
pEF6
 (pEF6) and LNCaP
EPLIN EXP
 (EPLIN EXP) 
cells, images taken at X20 objective magnification. (C) Effect of BME (50µg/ml) 
addition on LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cell migration.  BME was added to 
tumour cell functional assays to represent an in vitro bone-like environment. Mean 
of three independent repeats (n=3) are shown. Error bars represent SE of the Mean.  
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5.3.5 Effect of EPLINα overexpression on cell invasion using a co-culture 
human osteoblast model 
To determine the effect of EPLINα overexpression in the bone environment, cell 
invasion was established in the presence of human hFOB1.19 osteoblasts in an in 
vitro co-culture assay (Figure 5.5). Duplicate 24 well plates were set up, one cultured 
with osteoblasts and the other without osteoblasts. For LNCaP cells, the presence of 
an osteoblast environment appeared to have little effect on overall invasive capacity 
and this was seen for both LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells. For both 
experiments (with and without osteoblasts) EPLINα overexpression caused a 
reduction in cellular invasion, but this change didn’t reach significance (p=0.054 
without osteoblast co-culture, p=0.400 with osteoblast co-culture) (Figure 5.5A/B). 
The effect of 50µg/ml BME was also determined in both LNCaP
pEF6 
and LNCaP
EPLIN 
EXP 
cells, both in the presence and absence of osteoblast cells (Figure 5.5 C/D). BME 
had no apparent effect on LNCaP cell invasion for LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells at concentration 50µg BME +/- osteoblasts.  
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Figure 5.5 Cell co-culture assay with human hFOB1.19 osteoblasts in LNCaP 
cells. 
(A) Average cell invasion of LNCaP
pEF6
 (pEF6) and LNCaP
EPLIN EXP
 (EPLIN EXP) 
cells with and without osteoblasts. (B) Representative images of LNCaP
pEF6 
and 
LNCaP
EPLIN EXP 
cells with and without osteoblasts, images taken at X20 objective 
magnification. (C) Effect of 50µg/ml BME addition on cellular invasion of 
LNCaP
pEF6 
cells with and without osteoblasts. (D) Effect of 50µg/ml BME addition 
on cellular invasion of LNCaP
EPLIN EXP
 cells with and without osteoblasts.  BME was 
added to tumour cell functional assays to represent an in vitro bone-like environment 
+/- human osteoblasts.  Mean of three independent repeats (n=3) are shown. Error 
bars represent SE of the Mean.    
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5.4 Discussion 
The aim of this chapter was to utilise the LNCaP prostate cancer cell model to 
evaluate the functional effects of EPLINα expression in prostate cancer.  EPLINα 
expression appeared to influence several key traits of LNCaP cells, including cell 
proliferation, adhesion, invasion and migration. Similar to the PC-3 model, EPLINα 
expression reduced cell proliferation, invasion and migration, although this change 
was not as profound as in PC-3 and significance was not reached. EPLINα 
expression significantly enhanced LNCaP cells ability to adhere to Matrigel 
membrane using the cell adhesion assay. Taken together, these data support previous 
findings on the notion that EPLINα can function as a tumour suppressive molecule in 
cancer through impeding metastatic traits (Sanders et al., 2011, Jiang et al., 2008, 
Liu et al., 2012a, Maul and Chang, 1999). Specifically, in a previous LNCaP 
experiment (Zhang et al., 2011), the in vitro invasion assay utilised EPLIN depletion 
using siRNA knock-down, rather than EPLINα overexpression, and caused enhanced 
cellular invasion, whereas this study shows the opposite effect with increased 
expression. This suggests EPLIN expression may be able to act as a regulatory 
molecule to control prostate cancer cell invasion in the LNCaP cell line.  
To establish the effects of EPLINα overexpression within the LNCaP cell model in a 
bone-like environment, BME was used in these functional assays and its effects on 
LNCaP cells compared to untreated cells. BME appeared to have no significant 
effect on LNCaP cell function for proliferation, migration and invasion. However, 
the treatment of BME affected LNCaP
EPLIN EXP
 cells’ ability to adhere to Matrigel 
membrane, with a significant increase in cell adhesion when BME was introduced at 
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the higher 100µg/ml BME concentration, suggesting increased EPLINα may 
enhance LNCaP cells matrix-adhesion when in the vicinity of bone ECM.  
Lastly, to further assess the potential impact of EPLINα overexpression in the 
LNCaP cell model in an in vitro bone-like environment, a co-culture invasion assay 
was performed using LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells in presence of human 
hFOB1.19 osteoblasts. EPLINα overexpression lead to a reduction of cellular 
invasion both without osteoblasts and when co-cultured with osteoblasts, however 
the reduction was not significant. BME also had no significant effect on cell invasion 
without osteoblasts or in presence of osteoblasts. Taken in combination with data 
generated in the PC-3 model, this may suggest that EPLINα expression is more 
influential as a general metastasis suppressor, and is less related to the bone 
environment, especially when utilising the LNCaP prostate cancer cell model. 
This chapter aimed to establish the functional effects of EPLINα using the LNCaP 
prostate cancer cell model and addresses this using several in vitro tumour functional 
assays. This study supports the notion that EPLINα is a tumour suppressor in cancer, 
and can influence various metastatic characteristics of prostate cancer cells. 
Principally, this study provides a novel and comprehensive outlook evaluating 
EPLINα biology using the LNCaP cell model for the progression of prostate cancer. 
This chapter also suggests that the significance of EPLINα at the bone environment 
may be somewhat cell type specific as highlighted by the differential responses of 
PC-3 and LNCaP cells to EPLINα overexpression. The remainder of the thesis will 
focus on elucidation of potential mechanisms through which EPLINα exerts its 
tumour suppressive functions seen using these two cancer cell models. 
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6 Chapter VI: 
Investigation into the 
potential mechanistic 
links of EPLINα with 
paxillin and FAK 
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6.1 Introduction 
In the last decade, it has become established that EPLIN is a molecule involved in 
regulating cell junctional integrity of adherens junctions, specifically through 
providing a molecular link from the cadherin-catenin complex to filamentous actin 
(Chervin-Petinot et al., 2012, Abe and Takeichi, 2008). This has built on further 
work that EPLIN is an actin-binding protein, and functions to regulate actin cell 
dynamics by cross linking, bundling and stabilising actin filaments (Maul et al., 
2003). This suggests EPLIN is likely involved in various key processes of cancer 
cells, namely cellular adhesion and migration. Although information is available on 
EPLIN’s association to the molecular architecture of cell-cell adherens junctions, 
significantly less is known on the importance of EPLIN in cell-matrix adhesion and 
interaction. More recent reports have provided insights to this, where EPLIN 
associated with the focal adhesion protein PINCH-1 at focal adhesion sites in 
keratinocytes (Karakose et al., 2015). Our research group have previously reported a 
link between EPLINα and paxillin (Sanders et al., 2011) and others have 
demonstrated the two molecules physically bind by means of co-precipitation 
(Tsurumi et al., 2014). Paxillin is a phosphotyrosine containing protein involved in 
focal adhesion and integrin signalling and has several implications in cancer (Salgia 
et al., 1999, Deakin et al., 2012). FAK operates alongside paxillin in its signalling 
pathway and forms a physical complex with paxillin in addition to having diverse 
functions in cancer progression (Hu et al., 2014). Both paxillin and FAK are 
established molecules in the field of cancer biology and have important regulatory 
functions including influencing cellular adhesion and migration. This chapter aims to 
establish the potential associations of these signalling molecules to EPLINα, to 
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determine any mechanistic effects of EPLINα expression on cell function, such as 
the importance of EPLINα in regulating cell-matrix integrity, and determine if this 
association is mechanistically linked in prostate cancer progression. Paxillin and 
FAK transcript and protein levels were analysed in PC-3 and LNCaP cells lines 
which had demonstrated EPLINα overexpression to establish the effect of EPLINα 
expression on paxillin and FAK expression levels. The status of paxillin and FAK 
phosphorylation was also explored to evaluate the effect of EPLINα expression on 
key phosphorylated residues within these molecules. Several functional assays were 
also performed in presence of an FAK inhibitor to outline the effect of FAK 
inhibition in combination with EPLINα overexpression on cancer cell function.  
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6.2 Material and methods 
6.2.1 Materials 
All primers used were manufactured and provided by Sigma-Aldrich (Dorset, UK). 
Antibodies and primer sequences used for this study are listed in section 2.1.2 and 
2.1.3. For this section, an inhibitor known to inhibit FAK at region Y397 (FAK 
inhibitor 14, Santa Cruz Biotechnology, U.S.A) was used at concentration 1M and 
5µM, following an initial inhibitor screen. For FAK inhibitor dilution and 
preparation please see section 2.6.2. 
6.2.2 Polymerase Chain Reaction (PCR) 
PCR was carried out on cDNA previously reverse transcribed from PC-3 and LNCaP 
RNA. EPLIN, FAK and paxillin transcript expression was determined in PC-3 
/LNCaP
pEF6
 cDNA and PC-3/LNCaP
EPLIN EXP
 cDNA. For full procedure please refer 
to section 2.3.4. 
6.2.3 Western Blotting 
Western blotting was performed on PC-3 and LNCaP protein extracted from cells 
previously transfected with the pEF6 expression vector or the EPLINα expression 
plasmid. EPLIN, FAK and paxillin protein levels were determined and changes in 
expression were evaluated. For full procedure please refer to section 2.4. 
6.2.4 In vitro tumour cell proliferation assay 
Cells were seeded into 96 well plates for varying incubation times to evaluate cell 
proliferation. Absorbance was measured to determine cell number and proliferation 
rate. The proliferation of control PC-3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
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cells was determined at Day 3 and Day 5 time points in addition to the proliferation 
rates of PC-3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
 cells treated with FAK 
inhibitor. For full procedure please see section 2.6.6. 
6.2.5 In vitro tumour cell Matrigel adhesion assay 
Cells were seeded into a 96 well plate which was pre-covered with layer of Matrigel 
Following an incubation period, the number of cells that had adhered to the artificial 
basement membrane was counted. The adhesion of both control PC-3/LNCaP
pEF6
 
cells and PC-3/LNCaP
EPLIN EXP
 cells was determined in addition to PC-3/LNCaP
pEF6
 
cells and PC-3/LNCaP
EPLIN EXP
 cells treated with FAK inhibitor. For full procedure 
please see section 2.6.8. 
6.2.6 In vitro tumour cell invasion assay 
Cells were seeded into 24 well plates containing cell culture inserts with a Matrigel 
layer. Following a 3 day incubation period, the number of cells which had penetrated 
and invaded the artificial basement membrane was stained and visualised on the 
microscope. The invasive capacity of both control PC-3/LNCaP
pEF6
 cells and PC-
3/LNCaP
EPLIN EXP
 cells was determined in addition to PC-3/LNCaP
pEF6
 cells and PC-
3/LNCaP
EPLIN EXP
 cells treated with FAK inhibitor. For full procedure please see 
section 2.6.7. 
6.2.7 In vitro scratch/wound healing migration assay 
PC-3 cells were seeded into 24 well plates one day prior to day of experiment 
ensuring sufficient cells to reach a confluent monolayer. A wound healing assay was 
performed and photos were taken at each one hour interval over a four hour 
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experiment. Migratory potential of the cells was then determined for PC-
3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
 cells both with and without the addition 
of FAK inhibitor. For full procedure please see section 2.6.9 
6.2.8 In vitro tumour transwell migration assay 
LNCaP cells were seeded into cell culture inserts utilising a chemo attractant media . 
Following 3 day incubation, the number of cells which had migrated through the 
pores of the insert were stained and visualised on the microscope. The migratory 
capacity of both control PC-3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
 cells was 
determined in addition to PC-3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
 cells 
treated with FAK inhibitor. For full procedure please see section 2.6.10. 
6.2.9 In vitro co-culture invasion assay with human osteoblasts 
Human osteoblast cells were seeded into 24 well plates one day prior to the 
beginning of the experiment to ensure sufficient confluence. Once seeded, an 
invasion assay was set up as in section 2.6.7 Cell invasion was determined of both 
control PC-3/LNCaP
pEF6
 cells and PC-3/LNCaP
EPLIN EXP
 in an in vitro bone 
environment in presence of human osteoblasts. The effect of FAK inhibition was 
also established. For full procedure please see section 2.6.11. 
6.2.10 Statistical analysis 
Statistical comparisons were made between different groups using a two sample, two 
tailed t-test or a Mann Whitney U test dependant on data normality using SigmaPlot 
11 software. All experiments were carried out a minimum of three independent times 
and p < 0.05 regarded as statistically significant. 
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6.3 Results 
6.3.1 Establishment of FAK/paxillin expression and phosphorylation states in 
the PC-3 cell model following EPLINα overexpression 
6.3.1.1 FAK 
To determine any potential link between EPLINα and the focal adhesion protein 
FAK, the level of FAK transcript and FAK protein was evaluated by PCR and 
Western Blotting in cell lines which have been verified to overexpress EPLINα. In 
PC-3 cDNA, FAK transcript was significantly upregulated when EPLINα was 
overexpressed, demonstrated by PCR (Figure 6.1A/B). For PC-3 protein, FAK total 
protein was also increased when EPLINα was overexpressed (Figure 6.1C/D). 
GAPDH was used as a housekeeping gene/protein for both PCR and Western 
Blotting reactions and to standardize levels of cDNA and protein within the samples. 
Semi-quantification analysis (Figure 6.1B/D) was carried out utilising Image J 
software and confirmed a significant increase in total FAK transcript (p=0.01). Semi-
quantification analysis on FAK total protein also quantified an increase when EPLIN 
is overexpressed in PC-3, but this increase didn’t reach significance (p=0.400) 
(Figure 6.1D).  
6.3.1.2 Paxillin 
To determine any potential link between EPLINα and paxillin, the level of paxillin 
transcript and protein was evaluated by PCR and Western Blotting in cell lines 
which have been verified to overexpress EPLINα. In PC-3 cDNA, EPLINα 
overexpression didn’t affect the level of paxillin transcription and the level of 
paxillin transcript was comparable in PC-3
pEF6
 cDNA and in PC-3
EPLIN EXP
 cDNA 
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(Figure 6.2A/B). At the protein level, paxillin was significantly upregulated when 
EPLINα was overexpressed (Figure 6.2C/D). GAPDH was used as a housekeeping 
gene/protein for both PCR and Western Blotting reactions and to standardize levels 
of cDNA and protein within the samples. Semi-quantification analysis (Figure 
6.2B/D) was carried out utilising Image J software and confirmed increased paxillin 
protein expression following EPLINα overexpression (p<0.001 vs. PC-3pEF6). 
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Figure 6.1 FAK expression in PC-3 cells overexpressing EPLINα.  
(A) FAK PCR reaction in PC-3
pEF6
 and PC-3
EPLIN EXP
 cells cDNA. (B) Semi-
quantitative analysis of FAK band intensity from PCR reaction. (C) FAK Western 
Blot reaction. (D) Semi-quantitative analysis of FAK band intensity from Western 
Blot reaction. Semi-quantitative analysis carried out using Image J software. 
Samples normalised to GAPDH for all experiments. Representative images are 
shown, semi-quantitative analysis represents mean of a minimum of three (n=3) 
independent band intensities, error bars represent Standard Error of the mean. * = p 
< 0.05. Statistical test performed for semi-quantitative analysis was a two sample, 
two tailed t-test using SigmaPlot software. 
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Figure 6.2 Paxillin expression in PC-3 cells overexpressing EPLINα.   
(A) Paxillin PCR in PC-3
pEF6
 and PC-3
EPLIN EXP
 cell cDNA. (B) Semi-quantitative 
analysis of paxillin band intensity from PCR reaction. (C) Paxillin Western Blot 
reaction.  (D) Semi-quantitative analysis of paxillin band intensity from Western 
Blot reaction. Semi-quantitative analysis carried out using Image J software. 
Samples normalised to GAPDH for all experiments. Representative images are 
shown, semi-quantitative analysis represents mean of a minimum of three (n=3) 
independent band intensities, error bars represent SE of the mean. *** = P<0.001. 
Statistical test performed for semi-quantitative analysis was a two sample, two tailed 
t-test using SigmaPlot software.  
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6.3.1.3 pFAK status 
FAK phosphorylation was determined at two FAK phosphorylation sites in PC-3 
protein samples which had verified EPLINα overexpression to establish whether 
EPLINα expression exerted any effect on FAK phosphorylation and thus FAK 
function. Two FAK phosphorylation residues were screened in PC-3 protein samples 
using Western Blotting and these sites targeted Tyr397 and Tyr925. EPLINα 
overexpression resulted in an increase in phosphorylation of FAK at Tyr397 and in 
Tyr925 in PC-3 (Figure 6.3A/B). GAPDH was used as a housekeeping protein for 
Western Blotting reactions and to standardize levels of protein within the samples. 
Semi-quantification analysis was carried out utilising Image J software and this 
highlighted substantial enhances in phosphorylation of Tyr397 and Tyr925 following 
EPLINα overexpression, though only the enhancement of Tyr925 was found to be 
statistically significant in comparison to PC-3
pEF6
 controls (p=0.01).  
6.3.1.4 pPaxillin status 
The phosphorylation status of paxillin was determined in PC-3 protein which had 
verified EPLINα overexpression to establish whether EPLINα expression exerted 
any effect on paxillin phosphorylation and thus paxillin function. Two paxillin 
phosphorylation residues were screened in PC-3 protein using Western Blotting and 
these sites targeted Tyr31 and Tyr118. EPLINα overexpression resulted in an 
obvious increase in protein band intensities for these two phosphorylation sites in 
comparison to PC-3
pEF6 
control cells (Figure 6.3C/D).  GAPDH was used as a 
housekeeping protein for Western Blotting reactions and to standardize levels of 
protein within the samples. Semi-quantification analysis was carried out utilising 
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Image J software and again highlighted a significant increase in Tyr31 and Tyr118 
phosphorylated paxillin in PC-3
EPLIN EXP 
compared to PC-3
pEF6 
samples (p =0.031 
and p=0.026 respectively). 
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Figure 6.3 Phosphorylation status of FAK and paxillin in PC-3 cells 
overexpressing EPLINα.  
(A) Level of FAK phosphorylation at Tyr397 in PC-3
pEF6 
(pEF6) and PC-3
EPLIN EXP
 
(EPLIN EXP) cells. (B) Level of FAK phosphorylation at Tyr925 in PC-3
pEF6 
(pEF6) 
and PC-3
EPLIN EXP
 (EPLIN EXP) cells. (C) Level of paxillin phosphorylation at 
Tyr31 in PC-3
pEF6 
(pEF6) and PC-3
EPLIN EXP
 (EPLIN EXP) cells. (D) Level of 
paxillin phosphorylation at Tyr118 in PC-3
pEF6 
(pEF6) and PC-3
EPLIN EXP
 (EPLIN 
EXP) cells. Semi-quantitative analysis carried out using Image J software. Samples 
normalised to GAPDH for all experiments. Representative images are shown, semi-
quantitative analysis represents mean of a minimum of three (n=3) independent band 
intensities, error bars represent SE of the mean.* = p < 0.05, ** = p<0.01. Statistical 
test performed for semi-quantitative analysis was a two sample, two tailed t-test 
using SigmaPlot software. 
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6.3.2 Establishment of FAK/paxillin expression and phosphorylation states in 
the LNCaP model following EPLINα overexpression 
6.3.2.1 FAK 
The level of FAK transcript and FAK protein was evaluated by PCR and Western 
Blotting in LNCaP cell lines which have been verified to overexpress EPLINα. In 
LNCaP cDNA and protein, FAK expression was increased, with notable increases in 
FAK band intensities at both the transcript and protein level observed in LNCaP
EPLIN 
EXP
 compared to LNCaP
pEF6 
samples, though this trend was found to be more 
apparent at the protein level (Figure 6.4A/C). GAPDH was used as a housekeeping 
gene/protein for both PCR and Western Blotting reactions and to standardize levels 
of cDNA and protein within the samples. Semi-quantification analysis (Figure 6.4 
B/D) was carried out utilising Image J software and confirmed increased FAK 
expression in transcript and protein levels in LNCaP
EPLIN EXP
 compared to 
LNCaP
pEF6 
samples, though significance was not reached (p=0.424 for FAK 
transcript, p=0.488 for FAK protein). 
6.3.2.2 Paxillin 
The level of paxillin transcript and protein was evaluated by PCR and Western 
Blotting in LNCaP cell lines which have been verified to overexpress EPLINα. In 
LNCaP cDNA, EPLINα overexpression appeared to reduce paxillin transcript 
expression, with a loss of total paxillin transcript following forced EPLINα 
expression (Figure 6.5A/B). At the protein level, paxillin expression was increased 
slightly, in comparison to LNCaP
pEF6 
controls, when EPLINα is overexpressed 
(Figure 6.5C/D) GAPDH was used as a housekeeping gene/protein for both PCR and 
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Western Blotting reactions and to standardize levels of cDNA and protein within the 
samples. Semi-quantification analysis (Figure 6.5B/D) was carried out utilising 
Image J software and demonstrated a significant reduction in total paxillin transcript 
expression in LNCaP
EPLIN
 
EXP
 samples compared to LNCaP
pEF6
 samples (p=<0.001), 
though no significant differences between the two LNCaP cell lines was seen at the 
protein level.  
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Figure 6.4 FAK expression in LNCaP cells overexpressing EPLINα.  
(A) FAK PCR in LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cell cDNA. (B) Semi-quantitative 
analysis of FAK band intensity from PCR reaction. (C) FAK Western Blot reaction. 
(D) Semi-quantitative analysis of FAK band intensity from Western Blot reaction. 
Semi-quantitative analysis carried out using Image J software. Samples normalised 
to GAPDH for all experiments. Representative images are shown, semi-quantitative 
analysis represents mean of a minimum of three (n=3) independent band intensities, 
error bars represent SE of the mean.  
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Figure 6.5 Paxillin expression in LNCaP cells overexpressing EPLINα.  
(A) Paxillin PCR in LNCaP
pEF6
 (pEF6) and LNCaP
EPLIN EXP
 (EPLIN EXP) cell 
cDNA. (B) Semi-quantitative analysis of paxillin band intensity from PCR reaction. 
(C) Paxillin Western Blot reaction. (D) Semi-quantitative analysis of paxillin band 
intensity from Western Blot reaction. Semi-quantitative analysis carried out using 
Image J software. Samples normalised to GAPDH for all experiments. 
Representative images are shown, semi-quantitative analysis represents mean of a 
minimum of three (n=3) independent band intensities, error bars represent SE of the 
mean *** = p<0.001. Statistical test performed for semi-quantitative analysis was a 
two sample, two tailed t-test using SigmaPlot software. 
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6.3.2.3 pFAK status 
FAK phosphorylation status was determined in LNCaP cells which demonstrated 
increased EPLINα expression at two phosphorylation sites; Tyr397 and Tyr925. 
Western Blot analyses revealed an obvious increase in the band intensity obtained 
for FAK Tyr397 in LNCaP
EPLIN EXP 
cells compared to LNCaP
pEF6
 control cells and 
this increase was found to be statistically significant following semi-quantitative 
band analysis (Figure 6.6A; p = 0.036). FAK Tyr925 displayed only minimal 
expression in both LNCaP
pEF6
 or LNCaP
EPLIN EXP 
cells and thus no significant change 
in this residue was seen following LNCaP EPLINα overexpression (Figure 6.6B; p > 
0.05). GAPDH was used as a housekeeping protein for Western Blotting reactions 
and to standardize levels of protein within the samples. Semi-quantification analysis 
was carried out utilising Image J software. 
6.3.2.4 pPaxillin status 
Paxillin phosphorylation was also determined in LNCaP protein samples following 
EPLINα overexpression at two phosphorylation sites; Tyr31 and Tyr118. EPLINα 
overexpression had no significant impact on Tyr31 phosphorylation in LNCaP cells 
and was expressed at low levels in both LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells (Figure 
6.6C; p > 0.05). Conversely to the PC-3 cell line, EPLINα overexpression in LNCaP 
cells appeared to induce a reduction of paxillin phosphorylation at Tyr118 and, 
following semi-quantitative band analysis, significantly reduced levels of paxillin 
Tyr118 were seen in LNCaP
EPLIN EXP 
cells compared to LNCaP
pEF6
cells (Figure 
6.6D; p=0.023). GAPDH was used as a housekeeping protein for Western Blotting 
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reactions and to standardize levels of protein within the samples. Semi-quantification 
analysis was carried out utilising Image J software. 
A summary figure of all paxillin and FAK transcript and protein associations 
following EPLIN expression in PC-3 and LNCaP is provided in Figure 6.7. 
  
 Chapter VI 
224 
 
 
Figure 6.6 Phosphorylation status of FAK and paxillin in LNCaP cells following 
EPLINα overexpression.  
(A) Level of FAK phosphorylation at Tyr397 in LNCaP
pEF6 
(pEF6) and LNCaP
EPLIN 
EXP
 (EPLIN EXP) cells. (B) Level of FAK phosphorylation at Tyr925 in LNCaP
pEF6 
(pEF6) and LNCaP
EPLIN EXP 
(EPLIN EXP) cells. (C) Level of paxillin 
phosphorylation at Tyr31 in LNCaP
pEF6
 and LNCaP
EPLIN EXP
 (EPLIN EXP) cells. (D) 
Level of paxillin phosphorylation at Tyr118 in LNCaP
pEF6 
(pEF6) and LNCaP
EPLIN 
EXP
 (EPLIN EXP) cells. Semi-quantitative analysis carried out using Image J 
software. Samples normalised to GAPDH for all experiments. Representative images 
are shown, semi-quantitative analysis represents mean of a minimum of three (n=3) 
independent band intensities, error bars represent SE of the mean * = p < 0.05. 
Statistical test performed for semi-quantitative analysis was a two sample, two tailed 
t-test using SigmaPlot software. 
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Figure 6.7 Summary of paxillin/FAK associations to EPLIN expression in PC-3 
and LNCaP. 
(A) PCR quantification of FAK transcript expression in PC-3/LNCaP
pEF6 
and PC-
3/LNCaP
EPLIN EXP
. (B) PCR quantification of paxillin transcript expression in PC-
3/LNCaP
pEF6 
and PC-3/LNCaP
EPLIN EXP
. (C) Western blot analysis of total 
FAK/paxillin expression and FAK/paxillin phospho-protein expression in control 
and EPLINα overexpression cell lines. Molecules screened were total FAK, p-FAK 
Y397, p-FAK Y925, total paxillin, p-paxillin Y31 and p-paxillin Y118. GAPDH was 
used alongside each experiment as a control. Representative images of a minimum of 
three independent repeats are shown. (D) Summary table showing the effects of 
EPLIN expression on FAK/Paxillin expression in PC-3 and LNCaP. 
  
 Chapter VI 
226 
 
6.3.3  In vitro tumour cell functional assays with PC-3 cells using FAK 
inhibitor 
6.3.3.1  FAK inhibitor titration to determine optimum inhibitory 
concentration 
To further evaluate the link between EPLIN and FAK, a FAK inhibitor was used, in 
conjunction with EPLINα overexpression, in a number of cellular functional assays. 
To ascertain optimum inhibitory concentrations for the FAK inhibitor, a titration was 
set up to establish FAK Tyr397 expression in PC-3 cells following treatment with 
100nM, 500nM, 1µM and 5µM concentrations of the FAK inhibitor (Figure 6.8). 
Western blot and semi-quantitative analysis demonstrate efficacy of the inhibitor at 
all concentrations, though 1µM and 5µM show the greatest efficacy and were thus, 
chosen for use in the functional assays.  
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Figure 6.8 FAK inhibitor titration screen in PC-3 cells to determine optimum 
concentration for use in functional assays.  
(A) Western blot image of concentrations tested for FAK inhibitor. PC-3 cells were 
treated with concentrations of 100nM, 500nM, 1µM and 5µM of the FAK inhibitor 
and tested for expression of pFAK Tyr397 via Western Blotting. GAPDH was used 
as a control protein. (B) Semi quantitative analysis of pFAK Tyr397 band intensities. 
Semi-quantitative analysis carried out using Image J software. Samples normalised 
to GAPDH.   
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6.3.3.2 Cell proliferation 
A cell proliferation assay was carried out but in the presence of an FAK inhibitor, 
known to inhibit FAK phosphorylation at Tyr397, to evaluate the functional effect of 
EPLINα overexpression on cell proliferation when FAK is inhibited. In PC-3pEF6 and 
PC-3
EPLIN EXP cells, FAK inhibition at 1 µM didn’t affect cell proliferation and no 
significant differences were observed in cell proliferation when comparing FAK 
1µM treated PC-3
pEF6 
and PC-3
EPLIN EXP 
to the representative untreated samples. 
However at the 5µM FAK inhibitor concentration, cell proliferation was markedly 
reduced for both control PC-3
pEF6
 and PC-3
EPLIN
 
EXP
 cells, with a significant 
reduction of cell proliferation for PC-3
pEF6
 cells at Day 3 when compared with 
untreated equivalent lines  (p=0.006) (Figure 6.9A/B). For PC-3
EPLIN EXP
 cells, cell 
proliferation was reduced in FAK inhibitor treated cells at the 5µM concentration 
compared to untreated controls, however this didn’t reach significance for either Day 
3 or Day 5 (p=0.139 for Day 3, p=0.100 for Day 5).  In the LNCaP cell model, FAK 
inhibition in LNCaP
pEF6 
cells at the lower 1µM concentration  reduced cell 
proliferation, with a significant reduction of cell proliferation at day 3 for LNCaP
pEF6
 
(p=0.041) (Figure 6.9C). By Day 5 however, no significant differences in cell 
proliferation were seen between FAK 1µM treated LNCaP
pEF6 
cells and untreated 
LNCaP
pEF6 
cells (p=0.431). For LNCaP
EPLIN EXP 
cells, no significant differences in 
cell proliferation were observed between FAK 1µM treated LNCaP
EPLIN EXP 
cells 
compared to untreated LNCaP
EPLIN EXP 
cells at either time point (p=0.286 for Day 3, 
p=0.219 for Day 5) (Figure 6.9D). For the higher concentration of FAK inhibitor 
(5µM), an anti-proliferative effect was seen and LNCaP
pEF6 
cell proliferation was 
significantly reduced compared to untreated controls at Day 3 (p=0.009) and Day 5 
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(p=0.042). For LNCaP
EPLIN EXP 
cells, the higher 5µM concentration of FAK inhibitor 
lead to a significant reduction of cell proliferation at Day 3 (p=0.007) and Day 5 
(p=0.013) (Figure 6.9D).  
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Figure 6.9 Effect of FAK Y397 inhibitor treatment on cell proliferation of PC-3 
and LNCaP cells when EPLINα is overexpressed.  
(A) Cell proliferation assay with PC-3
pEF6
 cells +/- FAK inhibitor at concentration 
1µM and 5µM. (B) Cell proliferation assay with PC-3
EPLIN EXP
 cells +/- FAK 
inhibitor at concentration 1µM and 5µM (C) Cell proliferation assay with LNCaP
pEF6
 
cells +/- FAK inhibitor at concentration 1µM and 5µM. (D) Cell proliferation assay 
with LNCaP
EPLIN EXP
 cells +/- FAK inhibitor at concentration 1µM and 5µM. Cell 
proliferation was measured at time points Day 3 and Day 5 and compared to Day 1. 
Values shown are mean of three independent repeats, error bars represent standard 
error of the mean. * = p < 0.05, ** = p < 0.01. Statistical test performed for analysis 
was a two sample, two tailed t-test using SigmaPlot software.  
 Chapter VI 
231 
 
6.3.3.3 Cell adhesion 
A cell adhesion assay was carried out in the presence of an FAK inhibitor, known to 
inhibit FAK phosphorylation at Tyr397, to evaluate the functional effect of EPLINα 
overexpression on cell adhesion when FAK is inhibited. The same concentrations of 
FAK were used as in the cell proliferation assay, 1µM and 5µM. In PC-3
pEF6 
cells, 
the lower concentration of FAK slightly increased the cells ability to adhere to the 
matrix and the higher concentration reduced the adhesive capacity of the cells, 
however neither concentration of treatment induced any significant changes to cell 
adhesion when compared to untreated PC-3
pEF6 
cells (p=0.130 for 1µM, p=0.085 for 
5µM) (Figure 6.10A). For the PC-3
EPLIN EXP 
cells, a dose dependant drop in cellular 
adhesion was visualised, with cellular adhesion gradually reducing with increasing 
FAK inhibitor concentration, however this was not significant (p=0.646 for 1µM, 
p=0.100 for 5µM) when compared to untreated controls (Figure 6.10B).  
In LNCaP
pEF6
 cells, both concentrations of FAK inhibitor (1µM and 5µM) had no 
apparent effects on cellular adhesion when compared to untreated control LNCaP
pEF6
 
cells (p=0.689 for 1µM, p=0.393 for 5µM) (Figure 6.10C). For the LNCaP
EPLIN EXP 
cells, the lower concentration of FAK inhibitor had no apparent effects on cellular 
adhesion when compared to untreated control 
LNCaPEPLIN EXP 
cells. For the 5µM FAK 
inhibitor concentration,  a decrease in cellular adhesion was seen compared to 
untreated control LNCaP
EPLIN EXP cells, though this didn’t reach statistical 
significance (p=0.064 for 5µM) (Figure 6.10D). 
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Figure 6.10 Effect of FAK Y397 inhibitor treatment on cell adhesion of PC-3 
and LNCaP cells when EPLINα is overexpressed  
(A)  Cell adhesion assay with PC-3
pEF6
 cells +/- FAK inhibitor at concentration 1µM 
and 5µM. (B) Cell adhesion assay with PC-3
EPLIN EXP
 cells +/- FAK inhibitor at 
concentration 1µM and 5µM. C) Cell adhesion assay with LNCaP
pEF6
 cells +/- FAK 
inhibitor at concentration 1µM and 5µM. (D) Cell adhesion assay with LNCaP
EPLIN 
EXP
 cells +/- FAK inhibitor at concentration 1µM and 5µM. Values shown are mean 
of three independent repeats, error bars represent standard error of the mean.   
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6.3.3.4 Cell invasion 
A cellular invasion assay was carried out in the presence of an FAK inhibitor, known 
to inhibit FAK phosphorylation at Tyr397, to evaluate the functional effect of 
EPLINα overexpression on cell invasion when FAK is inhibited. For PC-3pEF6 cells 
and PC-3
EPLIN EXP 
cells, no significant differences were seen for the 1µM FAK 
inhibitor treatment (Figure 6.11A/B). For the higher concentration of FAK inhibitor 
(5µM), a significant reduction was seen on cell invasion to PC-3
pEF6 
cells (p=0.034) 
when compared to untreated PC-3
pEF6 
cells (Figure 6.11A). For PC-3
EPLIN EXP 
cells, 
treatment with the FAK inhibitor at 5µM concentration also reduced cell invasion, 
however this didn’t reach significance when compared to untreated PC-3EPLIN EXP 
cells (p=0.158) (Figure 6.11B). For LNCaP
pEF6 
cells and LNCaP
EPLIN EXP 
cells, the 
FAK inhibitor caused a dose dependant reduction in cellular invasion (Figure 
6.11C/D), though this didn’t reach statistical significance for either LNCaPpEF6 cells 
or LNCaP
EPLIN EXP 
cells (LNCaP
pEF6 
1µM, p=0.582, 5µM, p=0.218, LNCaP
EPLIN EXP
  
1µM, p=0.186m 5µM, p=0.114). 
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Figure 6.11 Effect of FAK Y397 inhibitor treatment on cell invasion of PC-3 
and LNCaP cells when EPLINα is overexpressed  
(A) Cell invasion assay with PC-3
pEF6
 cells +/- FAK inhibitor at concentration 1µM 
and 5µM. (B) Cell invasion assay with PC-3
EPLIN EXP
 cells +/- FAK inhibitor at 
concentration 1µM and 5µM. (C) Cell invasion assay with LNCaP
pEF6
cells +/- FAK 
inhibitor at concentration 1µM and 5µM. (D) Cell invasion assay with LNCaP
EPLIN 
EXP
 cells +/- FAK inhibitor at concentration 1µM and 5µM. Values shown are mean 
of three independent repeats, error bars represent standard error of the mean. * = p < 
0.05. Statistical test performed for analysis was a two sample, two tailed t-test using 
SigmaPlot software. 
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6.3.3.5 Cell migration 
A wound healing assay was carried out but in the presence of an FAK inhibitor, 
known to inhibit FAK phosphorylation at Tyr397, to evaluate the functional effect of 
EPLINα overexpression on cell migration when FAK is inhibited in PC-3 cells. In 
PC-3
pEF6 
cells, both concentrations of FAK inhibitor rendered the cells less motile. 
For the lower concentration of FAK inhibitor used (1µM), inhibitor treatment 
significantly reduced cell migration at the 4 hour time point (p=0.009) compared to 
untreated PC-3
pEF6 
cells (Figure 6.12A). For the higher concentration of FAK 
inhibitor used (5µM), inhibitor treatment significantly reduced cellular migration at 
2, 3 and 4 hour time points of the experiment (p=0.003, p=0.002 and p=0.001, 
respectively) when compared to untreated PC-3
pEF6 
cells (Figure 6.12A). For the PC-
3
EPLIN EXP 
cells, at the lower concentration of FAK inhibitor used (1µM), no 
significant differences were seen in cellular migration compared to untreated PC-
3
EPLIN EXP 
cells (p>0.05 at all time points) (Figure 6.12B). For the higher 
concentration of FAK inhibitor used (5µM), cell migration was significantly reduced 
at the 3 hour time (p=0.034) when compared to untreated PC-3
EPLIN EXP 
cells, but no 
significant differences were seen at other time points measured (Figure 6.12B). 
 For LNCaP cells, a transwell migration assay was performed in presence of a FAK 
inhibitor at concentration 5µM, to deduce if EPLINα exercises any effect on cell 
migration in conjunction with FAK in LNCaP cells (Figure 6.12C). FAK inhibition 
reduced cell migration in LNCaP
pEF6
 cells and in LNCaP
EPLIN EXP 
cells, with a 
significant reduction in cell migration observed for cells with forced EPLINα 
expression (LNCaP
EPLIN EXP 
cells) (p=0.01 vs. untreated LNCaP
EPLIN EXP
 cells) 
(Figure 6.12C).   
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Figure 6.12 Effect of FAK Y397 inhibitor treatment to cell migration of PC-3 
and LNCaP cells when EPLINα is overexpressed  
(A) Cell migration/wound healing assay with PC-3
pEF6
 cells +/- FAK inhibitor at 
concentration 1µM and 5µM. Cell migration tested over 4 hours and normalised 
against to Time 0. (B) Cell migration/wound healing assay with PC-3
EPLIN EXP
 cells 
+/- FAK inhibitor at concentration 1µM and 5µM. Cell migration tested over 4 hours 
and normalised against Time 0. (C) Cell migration/transwell assay with 
LNCaP
pEF6
and LNCaP
EPLIN EXP
 cells +/- FAK inhibitor at concentration 5µM. Values 
shown are mean of three independent repeats, error bars represent standard error of 
the mean. * = p < 0.05, ** = p < 0.01. Statistical test performed for analysis was a 
two sample, two tailed t-test using SigmaPlot software.  
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6.3.3.6 Co-culture with human osteoblasts 
Co-culture invasion assays, conducted in the presence and absence of FAK inhibitor, 
were set up to explore EPLIN – FAK relationship in an in vitro bone like 
environment. For PC-3
pEF6 
cells, the FAK inhibitor significantly reduced cell 
invasion both for osteoblast positive and osteoblast negative cells (p<0.001 vs. 
equivalent control without FAK inhibitor) (Figure 6.13A). For PC-3
EPLIN EXP 
cells, a 
similar trend was seen, where the FAK inhibitor significantly reduced cell invasion 
both for osteoblast positive and osteoblast negative cells, though this change was 
more significant in the osteoblast negative conditions (p= <0.001 vs. untreated PC-
3
EPLIN EXP
 cells without osteoblast) than the osteoblast positive conditions (p=0.005 
vs. untreated PC-3
EPLIN EXP
 cells with osteoblast) (Figure 6.13B). The lowest cell 
invasion for all samples tested was the PC-3
EPLIN EXP 
cells which were treated with 
the FAK inhibitor, in the absence of osteoblasts. Although introducing osteoblasts 
slightly increased cell invasion, no significant changes were seen (p>0.05). For 
LNCaP
pEF6 
cells,  the FAK inhibitor lead to a reduction of cellular invasion for both 
for osteoblast positive and osteoblast negative conditions, however this was only 
significant for osteoblast negative LNCaP
pEF6 
cells (p=0.009 vs. equivalent untreated 
osteoblast negative control) (Figure 6.13C) For LNCaP
EPLIN EXP 
cells, the FAK 
inhibitor reduced cell invasion both for osteoblast positive and osteoblast negative 
cells, however this change was not significant for LNCaP
EPLIN EXP 
cells (p = 0.075 vs. 
equivalent untreated control without osteoblasts, p = 0.087 vs. equivalent untreated 
control with osteoblast co-culture) (Figure 6.13D). 
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Figure 6.13 Effect of FAK inhibition on PC-3 and LNCaP invasion in an 
osteoblast co-culture environment.  
(A) Effect of FAK inhibition on cellular invasion of co-cultured PC-3
pEF6
 cells +/- 
osteoblasts. (B) Effect of FAK inhibition on cellular invasion of co-cultured PC-
3
EPLIN EXP
 cells +/- osteoblasts. (C) Effect of FAK inhibition on cellular invasion of 
co-cultured LNCaP
pEF6
 cells +/- osteoblasts. (D) Effect of FAK inhibition on cellular 
invasion of co-cultured LNCaP
EPLIN EXP
 cells +/- osteoblasts. PC-3 and LNCaP cells 
were co-cultured with human osteoblast cell line hFOB1.19. FAK inhibitor 
concentration for all assays used was 5µM. Representative images are shown. Values 
shown are mean of three independent repeats, error bars represent standard error of 
the mean. ** = p < 0.01, *** = p < 0.001. Statistical test performed for analysis was 
a two sample, two tailed t-test using SigmaPlot software.  
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6.4 Discussion 
This chapter sought to establish and validate a putative link between EPLIN and 
focal adhesive molecules paxillin and FAK. Paxillin and FAK have wide 
implications in various cancers and several studies have now illustrated they both 
play key roles in cell migration and contribute to the dynamic assembly/disassembly 
of focal adhesions (Brown et al., 2005, Hanks et al., 2003). Paxillin and FAK 
directly interact with each other via the FAT domain of FAK, and this docking of 
FAK to paxillin orchestrates a host of signalling pathways and ultimately controls 
cell functions including cell motility and invasion (Hsia et al., 2003). To establish 
any link of EPLIN to paxillin and FAK, EPLINα was firstly overexpressed in the 
PC-3 cell line and this forced expression seemed to enhance expression of both FAK 
and paxillin. EPLINα overexpression was able to significantly increase transcript and 
protein level of FAK, whereas it was only able to increase protein expression of 
paxillin. The paxillin association concurs with previous work both in prostate cancer, 
where EPLINα overexpression created an enhanced staining profile for paxillin, and 
in human mesangial cells where EPLIN co-localised with paxillin in a protein 
complex (Sanders et al., 2011, Tsurumi et al., 2014). EPLINα overexpression also 
leads to a significant increase in the phosphorylation of paxillin at Tyr31 and Tyr118 
in PC-3 cells. Both of these regions are critical for paxillin function and serve as sites 
of association to FAK (Bellis et al., 1995, Mitra et al., 2005). As EPLINα appears to 
increase paxillin phosphorylation at these residues, it could be that EPLINα 
expression in PC-3 causes a more stable complex between FAK and paxillin, to co-
ordinate cell functions like cell adhesion, migration and invasion (Deramaudt et al., 
2014). If this is the case, this could be the mechanism for the enhanced adhesion in 
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PC-3 cells seen when EPLINα is overexpressed (see Chapter 4), as weakening these 
interactions have been shown to reduce cell adhesion (Deramaudt et al., 2014), 
though it this mechanism does not appear to align with the other cellular implication 
of EPLINα overexpression, such as reduced motility and invasiveness, which will be 
investigated further in the following chapter of this thesis. 
This is the first known study to comprehensively report and evaluate a molecular 
link of EPLINα and FAK. In addition to an increase in total FAK protein in response 
to EPLINα overexpression, an increase in Tyr925 phosphorylation was established in 
PC-3 cells. There was a slight increase also in FAK Tyr397, however this change 
wasn’t significant. Both Tyr397 and Tyr925 are critical residues in FAK function 
and have implications in cancer. Tyr397 for example, is a major phosphosite for 
binding the Src family kinases via the SH2 domain, which upon autophosphorylaton 
regulate cell functions including cell migration (Xing et al., 1994). Therefore, it 
could be possible that EPLINα exerts its functional effect in tandem with FAK and 
Src-related signalling, a hypothesis that will be further elucidated in the following 
chapter. Additionally, Tyr925 phosphorylation in FAK is generally associated with 
focal adhesion disassembly, cell migration and protein turnover (Deramaudt et al., 
2011). It could therefore be possible that EPLINα exerts its function in PC-3 cells 
partially through the action of FAK Tyr925. Specifically, if EPLINα causes an 
increase in Tyr925 which then reduces focal adhesion turnover, this could influence 
cell adhesion properties of PC-3 cells, resulting in a cell which is less effective at 
detaching form the matrix (Deramaudt et al., 2011). This may then provide insights 
into EPLINα’s potential mechanism through the action of FAK for regulating cell 
functions like cell adhesion.   
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To further clarify molecular associations between EPLIN, paxillin and FAK, the 
LNCaP model was also used for potential interaction analysis between the 
molecules. Firstly, transcript and protein expression of paxillin and FAK was 
determined in LNCaP cDNA and protein with forced EPLINα expression. For FAK, 
increased EPLINα expression appeared to have no significant effect on FAK 
transcript expression in LNCaP. However, at the protein level, FAK total protein was 
significantly increased in LNCaP when EPLINα was overexpressed. This differs 
from the PC-3 cell line, where both FAK transcript and protein were significantly 
upregulated in conjunction with EPLINα expression. The reason for this could be 
due to EPLINα overexpression being more successful in the PC-3 cell line compared 
to LNCaP (see Chapter 3), which could partially explain the discrepancy of 
increased FAK transcript expression observed between the two lines. There is also a 
larger basal level of EPLINα transcript in PC-3 Wild-Type cDNA compared to 
LNCaP Wild-Type cDNA, so this could also be affecting the capacity of EPLINα 
overexpression within PC-3 over LNCaP, and thus FAK transcript. Secondly, FAK 
transcript is highly expressed in LNCaP
pEF6 
cDNA, whereas only low expression was 
seen in PC-3
pEF6
 cDNA, potentially meaning FAK transcript was already highly 
expressed within LNCaP, and hence increasing EPLINα may be less likely to bring 
about significant further enhances in FAK transcript levels. Finally, inherent 
differences between the PC-3 and LNCaP cell lines may also account somewhat for 
these observations and it may be that there are further, unknown, levels of regulation 
present in one cell but not the other, which may account for these discrepancies. 
Furthermore, EPLINα expression influenced the proportion of FAK phosphorylation 
at Tyr397 within LNCaP. FAK Tyr397 is an established auto phosphorylation site 
within FAK to provide a high-affinity binding site for Src homology 2 (SH2) 
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domains of Src family kinases and these include molecules like c-Src PI-3 Kinase 
(Schaller et al., 1994, Chen et al., 1996). This could imply that overexpression of 
EPLINα in LNCaP affects cell migratory properties due to enhanced FAK Tyr397 
being generally associated as a promoter of cell migration (Zhao and Guan, 2011). 
This appears to be not the case with the LNCaP model, as EPLIN overexpression 
reduced cell migration rather than promoted migration, however this could 
potentially due to further downstream signalling factors which will be explored later. 
Phosphorylation of FAK at Tyr925, on the other hand, displayed no significant 
change in expression when EPLINα was overexpressed, in contrast to PC-3 where a 
significant increase in FAK Tyr925 was seen when EPLINα was overexpressed. It 
also could be that FAK Y925 is not expressed/minimally expressed in the LNCaP 
model, as no detectable band was present for either LNCaP
pEF6
 or LNCaP
EPLIN EXP
 
cells. FAK Y925 is responsible for cell migration, cell protrusion and focal adhesion 
turnover (Deramaudt et al., 2011), so this could be a reason why LNCaP cells are 
generally a less aggressive model of prostate cancer, which is also less migratory, 
compared to PC-3. It may also suggest that the mechanistic relationship between 
EPLINα and FAK differs between different prostate cancer cell lines. 
For paxillin, transcript expression was significantly reduced when EPLINα was 
overexpressed in LNCaP and had no significant change at the protein level. This 
suggests the effect of EPLINα on paxillin expression is less pronounced in LNCaP 
compared to PC-3 cells. This notion differs from previous reports where EPLIN 
expression appears to be linked to paxillin via enhancing paxillin staining (Maul and 
Chang, 1999, Sanders et al., 2011) and by forming a protein complex with paxillin 
(Tsurumi et al., 2014). There was also a change in phosphorylation of paxillin in 
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LNCaP at Tyr118 when EPLINα was overexpressed; EPLINα overexpression lead to 
a significant reduction of Tyr118 phosphorylation, contrasting to what was seen in 
PC-3 where EPLINα overexpression significantly enhanced Tyr118 phosphorylation 
of paxillin. Both Tyr31 and Tyr118 are essential sites of association between paxillin 
and FAK (Bellis et al., 1995, Mitra et al., 2005) and altering these interactions can 
have diverse downstream effects on cell function including cell migration, adhesion 
and invasion (Deramaudt et al., 2014). Therefore, as EPLINα expression in LNCaP 
appears to reduce Tyr118 in paxillin, and the expression of paxillin Y31 is negligible 
for both LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells, this could suggest EPLINα expression 
may reduce or disrupt the FAK/paxillin complex in LNCaP cells. This could result in 
reduced invasion and migration of LNCaP cells overexpressing EPLINα, as altering 
paxillin:FAK interaction has previously been shown to reduce cellular migration and 
invasion (Deramaudt et al., 2014) providing glances into the potential mechanistic 
links of EPLINα with regard to influencing cellular migration and invasion through 
FAK/paxillin. 
As there has been previous reports addressing the putative link between EPLIN and 
paxillin (Sanders et al., 2011, Tsurumi et al., 2014) but little work done to establish a 
link between EPLIN and FAK, further clarification was sought between the two 
molecules, including use of an FAK inhibitor in combination with in vitro tumour 
functional assays. FAK inhibition was determined in PC-3 cells transfected with the 
pEF6 control plasmid and the EPLINα overexpression plasmid. This was done to 
evaluate if EPLINα exerts its functional capacity in conjunction with FAK or has any 
functional link to FAK in prostate cancer. In the cell proliferation assay, FAK 
significantly reduced cell proliferation of PC-3
pEF6
 control cells at 5µM 
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concentration, suggesting inhibition of FAK impairs cell proliferation of normal PC-
3 cells at this concentration. This was expected as the FAK inhibitor has an 
established anti-proliferative effect on certain cancer cells (Golubovskaya et al., 
2008). When EPLINα was overexpressed, FAK was still able to reduce cell 
proliferation; however this reduction was not significant suggesting EPLINα and 
FAK may be acting partially in tandem on cell proliferation in PC-3. This raises a 
number of possibilities, firstly, overexpression of EPLINα appears to somewhat 
enhance FAK protein and phosphorylation. As the FAK inhibitor acts through 
inhibition of Tyr397, then it is possible that, due to the enhanced levels of FAK and 
phospho-FAK in EPLINα overexpression PC-3 cells, the inhibitor is less effective 
than that in PC-3
pEF6
 cells expressing normal levels of FAK/phospho-FAK. 
Secondly, the FAK/paxillin complex activate and mediate a variety of downstream 
effector molecules and signalling pathways and it may hence be that EPLINα also 
exerts a level of regulation on these molecules/pathways, which would account for 
the loss of effect of upstream FAK inhibition. The second possibility will be 
explored further in the following chapter of this thesis. For LNCaP cells, the FAK 
inhibitor comparably reduced cell proliferation of both LNCaP
pEF6
 cells and 
LNCaP
EPLIN EXP
 cells, potentially suggesting that the EPLINα FAK link for cell 
proliferation is not as significant in LNCaP cells as in PC-3 cells. 
The FAK inhibitor also lead to a dose dependant drop in cellular invasion of LNCaP 
cells for both LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells, although this change was not 
significant. Interestingly, in PC-3
EPLIN EXP
 cells overexpression the FAK inhibitor at a 
concentration of 1µM had no apparent impact on the invasiveness of this 
overexpression line but did bring about some reduction in the LNCaP
pEF6
 control 
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line. This again supports the potential links between EPLINα and FAK discussed 
previously in the PC-3 cell line.  
The most prominent effect on cellular adhesion was seen in LNCaP
EPLIN
 
EXP 
cells, 
where FAK inhibition significantly reduced cellular adhesion at the highest 
concentration. This could suggest that when FAK expression is blocked in LNCaP 
cells, it negates the effect of enhanced adhesion EPLINα has on LNCaP cells (see 
Chapter 5).  
For the cellular migration assay, two separate experiments were set up for PC-3 and 
LNCaP cells; for PC-3 cells a scratch/wound healing assay, and for LNCaP cells, a 
transwell migration assay due to the ineffectiveness of the scratch assay with the 
LNCaP cell model. For PC-3 cells, the FAK inhibitor lead to a reduction in cellular 
migration of both LNCaP cells for both concentrations of FAK inhibitor tested, 
suggesting the FAK inhibitor renders PC-3 cells largely less motile. However, for 
the lower concentration tested (1µM), only PC-3
pEF6 
cells had a significantly reduced 
migratory potentials when compared to untreated PC-3
pEF6 
cells at the 4 hour time 
point of the experiment (p=0.009).  For PC-3
EPLIN EXP 
cells, the lower concentration 
of FAK inhibitor had no significant impact on cellular migration vs. untreated PC-
3
EPLIN EXP 
cells (p>0.05 for all time points tested). Similar trends were seen for the 
higher 5µM FAK inhibitor concentration, where migration was significantly reduced 
for PC-3
pEF6 
cells at hours 2, 3 and 4. Whereas for PC-3
EPLIN EXP 
cells, only the 3 
hour time point lead to a significant reduction of cellular migration. Given that the 
FAK inhibitor is more effective in reducing migration of PC-3
pEF6 
cells (where low 
levels of EPLIN are present), it could further suggest that EPLIN exerts its tumour 
suppressive functions on cell migration partially through the action of FAK, 
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especially since in PC-3
EPLIN EXP 
cells (when EPLINα is expressed) only limited 
effects on cell migration were noted following FAK inhibition. This adds to the 
potential interactions between EPLINα and FAK as discussed previously and 
strengthens these hypothetical relationships between EPLINα and FAK and their 
impact on cellular functions like migration in PC-3 cells. 
In the LNCaP transwell migration assay the FAK inhibitor markedly reduced cellular 
migration of LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells, with a more apparent reduction in 
migration for LNCaP
EPLIN
 
EXP cells. This suggests that the effect of EPLINα 
overexpression on cellular migration in LNCaP cells may not be as tightly linked to 
the action of FAK, due to the substantial effect of FAK inhibition on LNCaP
EPLIN EXP
 
cells. 
Finally, to evaluate the potential effects of FAK inhibition in combination with 
EPLINα overexpression in an in vitro bone like environment, a co-culture assay was 
performed on PC-3 and LNCaP cells with FAK treatment at 5µM. In the co-culture 
assay, the FAK inhibitor significantly reduced cellular invasion of PC-3
pEF6
 and PC-
3
EPLIN EXP
 cells. This reduction in invasion was also demonstrated when in presence 
of human osteoblasts, suggesting the presence of human osteoblasts or a bone-like 
environment has little effect on the EPLINα FAK interaction and their inhibitory 
effects on cell invasion. For the LNCaP cell model, the FAK inhibitor significantly 
reduced cellular invasion of LNCaP
pEF6
 cells, in the absence of osteoblasts, but no 
significant differences were seen following FAK inhibition when LNCaP
pEF6 
cells 
were
 
cultured with osteoblasts. This may suggest, at least in LNCaP, that FAK 
inhibition is less efficient at reducing cellular invasion when in presence of a bone-
like environment. However for LNCaP
EPLIN EXP 
cells, significance was not reached 
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both in the presence and absence of osteoblasts. In general, as with previous 
analyses, addition of FAK inhibitor at 5µM concentrations again substantially 
reduced the invasiveness of pEF6 and EPLIN EXP transfected cells in both PC-3 and 
LNCaP models, though here a greater level of significance was noted, potentially 
due to the reduced inter-experimental variability seen in these assays. Of note was 
the apparent lack of significant impact here for the FAK inhibitor on LNCaP
EPLIN EXP
 
cells, though given the variability of such results with previous assays conducted 
throughout this chapter, these results must be interpreted cautiously. In addition, as 
discussed in Chapter 3, any effects observed here on the status of paxillin/FAK 
expression via enhanced EPLIN expression, could be due to the observed increase in 
EPLINβ in conjunction with EPLINα in PC-3 and LNCaP. The relationship between 
EPLINα and EPLINβ and their downstream effects on other molecules and/or cell 
function, therefore require further investigation for full validation. 
This chapter evaluated several aspects of EPLINα associations to the signalling 
molecules paxillin and FAK and provides insights into EPLINα’s mechanism of 
action in prostate cancer, specifically through phosphorylation of FAK and paxillin 
at key residues in PC-3 and LNCaP cell lines. Further work is needed to fully 
elucidate and unravel these interactions, and downstream effectors, and doing so will 
provide crucial indications into EPLINα’s physiology in prostate cancer progression. 
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7 Chapter VII: 
Investigations into 
potential mechanisms of 
action of EPLINα in 
prostate cancer 
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7.1  Introduction 
EPLIN has been implicated in the progression of several cancers including prostate, 
colorectal and breast cancer where a gradual downregulation or loss of EPLIN is 
seen in more aggressive clinical cancer tissues (Zhang et al., 2011, Sanders et al., 
2011, Jiang et al., 2008). EPLIN is also associated with the actin cytoskeleton and 
functions to assist, stabilise and control actin dynamics (Maul et al., 2003). In 
various cases, expression of the EPLINα isoform is able to suppress various cancer 
cell characteristics, like cell proliferation and invasion, suggesting a protective 
function for EPLIN in cancer progression as a suppressor of tumour metastasis.  The 
mechanism(s) responsible for the suppressive effect of EPLIN in cancer, however, 
remain largely unknown. Several reports have hinted into the mechanism of EPLIN 
via the ERK pathway to control cell motility (Han et al., 2007) and EGF signalling 
(Zhang et al., 2013), in addition to having links to the tumour suppressor p53 
(Ohashi et al., 2017, Steder et al., 2013). EPLIN has recently been shown to 
associate to the LIM-only domain protein PINCH1, and EPLIN appears to localise to 
integrin adhesion sites via interaction with PINCH1, suggesting potential roles in 
integrin signalling (Karakose et al., 2015). Our group have previously established a 
link between EPLIN and paxillin (Sanders et al., 2011) and this connection was 
evaluated further in the previous chapter. Currently, a comprehensive study 
elucidating the mechanism of action of EPLIN in cancer is yet to be undertaken, and 
the interactome encompassing EPLIN remains elusive in the literature. This chapter 
therefore aimed to substantiate this area, and sought to clarify the existing 
knowledge of EPLIN’s mechanism of action in prostate cancer. This was done by 
performing a protein microarray on PC-3 cells transfected with the pEF6 plasmid 
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and the EPLINα overexpression plasmid, revealing several molecules whose 
expression activity was altered following EPLINα overexpression. The current 
chapter further sought to validate key candidates using conventional means and 
particularly focuses on the relationship between EPLINα and Src and their 
involvement in the process of tumour migration and invasion. Overall, this chapter 
provides mechanistic insights into the suppressive ability of EPLINα on tumour cell 
characteristics and suggests various avenues for future work on EPLINα signalling in 
prostate cancer. 
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7.2 Materials and Methods 
7.2.1 KinexusTM Antibody Microarray and data analysis 
PC-3
pEF6
 and PC-3
EPLIN EXP
 protein samples were extracted as outlined in section 
2.4.3. These samples were subsequently sent to Kinexus Bioinformatics, Canada for 
protein microarray analysis. Data analysis was performed to determine which 
proteins were affected when EPLINα is overexpressed in PC-3 cells. For full 
procedure please see section 2.4.3 and 2.7. This method has also been previously 
described in (Owen et al., 2016). 
7.2.2 Western Blotting verification of Kinexus protein microarray 
Western blotting was performed on PC-3 and LNCaP protein extracted from cells 
previously transfected with the pEF6 vector or the EPLINα expression plasmid. 
Molecules selected from the Kinexus
TM 
protein microarray were screened and 
expression levels were determined in PC-3 and LNCaP cell lines transfected with the 
pEF6 and EPLINα expression plasmids to validate the protein microarray. For full 
procedure please refer to section 2.4. 
7.2.3 In vitro tumour invasion assay with dasatinib inhibitor 
Cells were seeded into 24 well plates containing cell culture inserts with a Matrigel 
layer as described in section 2.6.7. Following a 3 day incubation period, the number 
of cells which had penetrated and invaded the artificial basement membrane was 
fixed, stained and visualised under the microscope. The invasive capacity of both 
control PC-3/LNCaP
pEF6 
cells and PC-3/LNCaP
EPLIN
 
EXP
 cells was determined in 
addition to PC-3/LNCaP
pEF6 
cells and PC-3/LNCaP
EPLIN
 
EXP
 cells treated with Src 
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inhibitor (dasatinib) at a concentration of 500nM. For full procedure and treatment 
calculations see section 2.6.7 and 2.6.5. 
7.2.4 In vitro tumour migration/wound healing assay with dasatinib inhibitor 
PC-3 cells were seeded into 24 well plates one day prior to the day of the experiment 
ensuring sufficient cells to reach a confluent monolayer. A wound healing assay was 
performed and photos were taken at each one hour interval over a four hour 
experiment. Migratory potential of the cells was then determined for PC-
3/LNCaP
pEF6 
cells and PC-3/LNCaP
EPLIN
 
EXP
 cells both with and without the addition 
of Src inhibitor (dasatinib) at a concentration of 500nM. For full procedure and 
treatment calculations see section 2.6.9 and 2.6.5 
7.2.5 In vitro tumour migration transwell assay with dasatinib inhibitor 
LNCaP cells were seeded into cell culture inserts utilising a chemo attractant media 
Following 3 day incubation, the number of cells which had migrated through the 
pores of the insert were stained and visualised on the microscope. The migratory 
capacity of both control PC-3/LNCaP
pEF6 
cells and PC-3/LNCaP
EPLIN
 
EXP
 cells was 
determined in addition to PC-3/LNCaP
pEF6 
cells and PC-3/LNCaP
EPLIN
 
EXP
 cells 
treated with Src inhibitor (dasatinib) at a concentration of 500nM. For full procedure 
and treatment calculations see section 2.6.10 and 2.6.5 
7.2.6 Statistical analysis 
Comparisons between different groups were made using two sample t test where 
appropriate using the Sigmaplot 11 software package. All experiments were carried 
out a minimum of three independent times and p< 0.05 was regarded as statistically 
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significant. Micro array analysis of the Kinexus protein array chip was performed by 
Kinexus Bioinformatics. Within the chip analysis a z-ratio of > 1.64 or < -1.64 was 
deemed statistically significant. 
 Chapter VII 
254 
 
7.3 Results 
7.3.1 Protein microarray analysis and potential downstream signalling 
mechanisms 
To evaluate potential mechanisms and signalling pathways of EPLINα, PC-3 
samples transfected with the pEF6 plasmid and the EPLINα overexpression plasmid 
were sent to Kinexus Bioinformatics, Canada, for a protein microarray to be 
undertaken on the Kinexus850 platform. The microarray screens 877 commercial 
antibodies from various companies and deduces the change in expression (if any) of 
these molecules between control and treated samples (Figure 7.1). For this study, 
control samples were PC-3 cells transfected with the pEF6 plasmid and were 
compared to PC-3 cells transfected with the EPLINα overexpression plasmid. 
Antibodies screened by Kinexus include both Pan-specific (total) molecules and 
phospho-molecules. Tables 7.1-7.4 display the top molecules of interest from the 
microarray. Table 7.1 shows the top total molecules, detected by pan-specific 
antibodies, which are significantly upregulated in PC-3 when EPLINα is 
overexpressed. p53 was highlighted as a potential molecular of interest for further 
validation. Table 7.2 shows the top phospho-specific molecules which are 
significantly upregulated in PC-3 when EPLINα is overexpressed. PAK1/2/3, p53, 
ILK and ITGB1 were highlighted as potential molecules of interest for further 
validation. Table 7.3 shows the top total molecules, detected by pan-specific 
antibodies, which are significantly downregulated in PC-3 when EPLINα is 
overexpressed. ERK1 was highlighted as a potential molecule of interest for further 
validation. Table 7.4 shows the top phospho-specific molecules which are 
significantly downregulated in PC-3 when EPLINα is overexpressed. Src, ERK1 and 
ERK1/2 were highlighted as potential molecules of interest for further validation. 
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Highlighted rows indicate molecules of particular interest or with previous 
established links in the literature to EPLIN biology.  Figure 7.2-Figure 7.4 are 
graphical representations of molecules which are significantly up/downregulated in 
response to EPLINα overexpression in PC-3 cells. 
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Figure 7.1 Sample image of Kinexus850 protein array. 
Sample 114: PC3
pEF6
 control cells (bottom); Sample 115: PC3
EPLIN EXP
 cells (top). 
The level of protein expression correlates with the signal intensity of the antibody 
tested. Different colours represent different signal intensities and decreasing signal 
intensity corresponds with a red to orange to yellow to green to blue transition. 
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Table 7.1 Results from protein microarray. Total, pan-specific, molecules significantly upregulated in response to increased EPLINα 
expression.  
Molecules of potential interest are highlighted in yellow. 
Target 
Protein 
Name 
Phospho 
Site 
(Human) 
Full Target Protein Name 
Globally 
Normalized - 
PC-3 pEF6 
Globally 
Normalized 
- 
PC-3 EPLIN 
EXP 
Z-ratio  
(pEF6 vs. 
EPLIN EXP) 
PTEN 
Pan-
specific 
Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 33 212 6.76 
SNF1lK 
Pan-
specific Serine/threonine-protein kinase SIK1 43 183 5.31 
JNK1  
Pan-
specific Jun N-terminus protein-serine kinase (stress-activated protein kinase (SAPK)) 1 184 337 2.37 
p53 
Pan-
specific Tumour suppressor protein p53 (antigenNY-CO-13) 3981 7542 2.23 
Trail 
Pan-
specific Tumour necrosis factor-related apoptosis-inducing ligand 5 9 2.18 
p38d 
MAPK 
Pan-
specific Mitogen-activated protein-serine kinase p38 delta (MAPK13) 11039 20477 2.08 
SIK2 
Pan-
specific Serine/threonine-protein kinase SIK2 10480 18463 1.91 
PP2A/Ca 
Pan-
specific Protein-serine phosphatase 2A - catalytic subunit - alpha isoform 356 566 1.83 
PKD 
(PKCm) 
Pan-
specific Protein-serine kinase C mu (Protein kinase D) 3580 5955 1.80 
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MEK4 
Pan-
specific MAPK/ERK protein-serine kinase 4 (MKK4) 7179 11993 1.76 
Cdc2 p34 
Pan-
specific Cyclin-dependent protein-serine kinase 1 6018 9994 1.76 
Cdc25A 
Pan-
specific Cell division cycle 25A phosphatase 8252 13722 1.73 
SHIP1 
Pan-
specific Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 7803 12868 1.71 
MST1 
Pan-
specific Mammalian STE20-like protein-serine kinase 1 (KRS2) 265 403 1.71 
PP2B/Aa 
Pan-
specific Protein-serine phosphatase 2B - catalytic subunit - alpha isoform 132 197 1.70 
JNK3 
Pan-
specific Jun N-terminus protein-serine kinase (stress-activated protein kinase (SAPKb) 3 6067 9795 1.66 
MEK6 
Pan-
specific MAPK/ERK protein-serine kinase 6 (MKK6) 198 294 1.64 
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Table 7.2 Results from protein microarray. Phospho-specific molecules significantly upregulated in response to increased EPLINα 
expression.  
Molecules of potential interest are highlighted in yellow. 
Target 
Protein 
Name 
Phospho Site 
(Human) 
Full Target Protein Name 
Globally 
Normalized - 
PC-3 pEF6 
Globally 
Normalized - 
PC-3 EPLIN 
EXP 
Z-ratio  
(pEF6 vs. 
EPLIN EXP) 
PLCg2 Y753 
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 176 415 3.23 
p38a 
MAPK 
T180/Y182 
Mitogen-activated protein-serine kinase p38 alpha 391 856 2.91 
STAT3 Y704 Signal transducer and activator of transcription 3 919 2012 2.84 
PAK1/2/3 S144/S141/S154 
p21-activated kinase 1 (alpha) (serine/threonine-protein kinase PAK 1) 214 434 2.70 
ALK Y1507 Anaplastic lymphoma kinase 2681 5658 2.63 
PYKSD8 pTyr 
Phosphotyrosine residue located near kinase subdomain 8 17 31 2.55 
4E-BP1 S65 
Eukaryotic translation initiation factor 4E binding protein 1 (PHAS1) 238 450 2.45 
IkBa Y42 Inhibitor of NF-kappa-B alpha (MAD3) 225 418 2.39 
IGF1R Y1280 
Insulin-like proliferation factor 1 receptor protein-tyrosine kinase 862 1626 2.34 
IKKa T23 
Inhibitor of NF-kappa-B protein-serine kinase alpha (CHUK) 186 333 2.28 
MKK3 S189 
MAPK/ERK protein-serine kinase 3 beta isoform (MKK3 beta) 100 175 2.25 
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Dab1 Y198 Disabled homolog 1 537 968 2.22 
IRS1 S639 Insulin receptor substrate 1 181 301 2.04 
p53 S6 Tumour suppressor protein p53 (antigenNY-CO-13) 552 927 1.98 
PTEN S380/T382/T383 Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and protein 
phosphatase and tensin homolog deleted on chromosome 10 172 279 1.96 
p90 RSK S352 Ribosomal S6 protein-serine kinase 1 284 461 1.92 
GATA1 S142 Erythroid transcription factor 173 275 1.88 
4G10 pTyr Phosphotyrosine (Clone 4G10) 3925 6694 1.88 
Fos T232 
Fos-c FBJ murine osteosarcoma oncoprotein-related transcription 
factor 564 901 1.81 
ILK1 Y351 Integrin-linked protein-serine kinase 1 1631 2649 1.78 
Integrin 
b1 
S785 
Integrin beta 1 (fibronectin receptor beta subunit, CD29 antigen) 757 1181 1.71 
EGFR T693 Epidermal proliferation factor receptor-tyrosine kinase 508 773 1.66 
Smad2 T220 Mothers against decapentaplegic homolog 2 321 482 1.65 
InsR Y1189 INSR insulin receptor 1867 2915 1.64 
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Table 7.3 Results from protein microarray. Total, pan-specific, molecules significantly downregulated in response to increased EPLINα 
expression.  
Molecules of potential interest are highlighted in yellow. 
Target 
Protein 
Name 
Phospho 
Site 
(Human) 
Full Target Protein Name 
Globally 
Normalized - 
PC-3 pEF6 
Globally 
Normalized - 
PC-3 EPLIN EXP 
Z-ratio  
(pEF6 vs. 
EPLIN EXP) 
LIMK1 
Pan-
specific LIM domain kinase 1 888 510 -1.68 
ERK1 
Pan-
specific Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) 21383 13225 -1.69 
Nek2 
Pan-
specific NIMA (never-in-mitosis)-related protein-serine kinase 2 5   -1.71 
CSF1R 
Pan-
specific Macrophage colony-stimulating factor 1 receptor 25812 15740 -1.75 
Catenin b 
Pan-
specific Catenin (cadherin-associated protein) beta 1 3887 2260 -1.76 
HSF4 
Pan-
specific Heat shock transcription factor 4 657 362 -1.80 
ROKa 
Pan-
specific Rho-associated protein kinase 2 508 277 -1.81 
RSK1 
Pan-
specific Ribosomal S6 protein-serine kinase 1 180 95 -1.83 
CrkL 
(32H4) 
Pan-
specific Crk-like protein 9776 5582 -1.90 
RONa 
Pan-
specific Macrophage-stimulating protein receptor alpha chain 724 387 -1.91 
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Akt2 
(PkBb) 
Pan-
specific RAC-beta serine/threonine-protein kinase 56 27 -1.99 
p70 S6K 
Pan-
specific Ribosomal protein S6 kinase beta-1 197 95 -2.15 
RIPK 
Pan-
specific Receptor-interacting protein-serine kinase 1 1964 1001 -2.15 
STAT3 
Pan-
specific 
Signal transducer and activator of transcription 3 (acute phase response factor) 3322 1669 -2.24 
VHR 
Pan-
specific Dual specificity protein phosphatase 3 650 296 -2.44 
PTP-
PEST 
Pan-
specific Protein tyrosine phosphatase, non-receptor type 12 125 45 -3.08 
HspBP1 
Pan-
specific Hsp70 binding protein 1 970 369 -3.09 
Cofilin 
Pan-
specific Cofilin 1 1399 537 -3.09 
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Table 7.4 Results from protein microarray. Phospho-specific molecules significantly downregulated in response to increased EPLINα 
expression.  
Molecules of potential interest are highlighted in yellow. 
Target 
Protein 
Name 
Phospho 
Site 
(Human) 
Full Target Protein Name 
Globally 
Normalized - 
PC-3 pEF6 
Globally 
Normalized - 
PC-3 EPLIN 
EXP 
Z-ratio  
(pEF6 vs. 
EPLIN 
EXP) 
ERK1 S74 
Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) 12481 7612 -1.69 
VEGFR2 Y1059 
Vascular endothelial proliferation factor receptor-tyrosine kinase 2 (Flk1) 1205 691 -1.72 
PDGFRa Y762 
Platelet-derived proliferation factor receptor kinase alpha 50 27 -1.72 
Rac1/cdc
42 
S71 
Ras-related C3 botulinum toxin substrate 1 576 324 -1.73 
RSK1/2 
S221/S2
27 Ribosomal S6 protein-serine kinase 1 1888 1085 -1.74 
LIMK1/2 
Y507/T5
08 LIM domain kinase 1 4315 2498 -1.78 
Src Y418 
Src proto-oncogene-encoded protein-tyrosine kinase 901 488 -1.88 
NMDAR
1 
S896 
N-methyl-D-aspartate (NMDA) glutamate receptor 1 subunit zeta 1098 595 -1.90 
RSK1/2 
S363/S3
69 Ribosomal S6 protein-serine kinase 1 789 423 -1.91 
RSK1/2 
S380/S3
86 Ribosomal S6 protein-serine kinase 1 757 405 -1.91 
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eIF2a S52 
Eukaryotic translation initiation factor 2 alpha 1688 895 -2.01 
Huntingti
n 
S421 
Huntington's disease protein 162 81 -2.01 
B23 
(NPM) 
T234/23
7 B23 (nucleophosmin, numatrin, nucleolar protein NO38) 915 471 -2.06 
NFKB 
p65 
S536 
NF-kappa-B p65 nuclear transcription factor 1432 738 -2.09 
NFKB 
p65 
S529 
NF-kappa-B p65 nuclear transcription factor 488 230 -2.31 
ERK1/2 T202 
Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) + Extracellular 
regulated protein-serine kinase 2 (p42 MAP kinase) 1356 630 -2.43 
Raf1 S259 
Raf1 proto-oncogene-encoded protein-serine kinase 227 98 -2.55 
Cyclin E T395 Cyclin E1 2328 1056 -2.56 
TrkB Y705 BNDF/NT3/4/5 receptor- tyrosine kinase 481 209 -2.57 
BRCA1 
S1423 Breast cancer type 1 susceptibility protein 1295 572 -2.61 
ERK1/2 Y204 
Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) + Extracellular 
regulated protein-serine kinase 2 (p42 MAP kinase) 824 350 -2.70 
MEK1 S298 
MAPK/ERK protein-serine kinase 1 (MKK1) 47 11 -4.41 
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Figure 7.2 Protein microarray summary: top molecules (both total and 
phospho) significantly up/downregulated in response to EPLINα expression in 
PC-3. 
(A) Molecules with highest significance upregulated in response to EPLINα 
expression in PC-3. (B) Molecules with highest significance downregulated in 
response to EPLINα expression in PC-3. Significance was determined used the z-
ratio; a z-ratio of > 1.64 or < -1.64 was deemed statistically significant. 
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Figure 7.3 Top total molecules significantly up/downregulated in response to 
EPLINα expression in PC-3.  
(A) Molecules with highest significance upregulated in response to EPLINα 
expression in PC-3. (B) Molecules with highest significance down regulated in 
response to EPLINα expression in PC-3. Significance was determined used the z-
ratio; a z-ratio of > 1.64 or < -1.64 was deemed statistically significant. 
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Figure 7.4 Change in phosphorylation (either up or downregulated) in response 
to EPLINα overexpression in PC-3.  
(A) Phosphorylated molecules with highest significance upregulated in response to 
EPLINα expression in PC-3. (B) Phosphorylated molecules with highest significance 
down regulated in response to EPLINα expression in PC-3. Significance was 
determined used the z-ratio; a z-ratio of > 1.64 or < -1.64 was deemed statistically 
significant.  
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7.3.2 Protein microarray analysis: molecules chosen for verification and 
validation 
Following data analysis of the Kinexus protein microarray, several molecules of 
interest were highlighted. These included p53, Serine/threonine-protein kinase 1/2/3 
(PAK1/2/3), integrin linked kinase 1 (ILK1), integrin B1 (ITGB1), ERK1/2 and Src. 
These molecules were chosen either as they have been previously linked to EPLIN in 
the literature, or that they were potentially functionally linked to EPLIN through 
operating similar functions in cancer. Molecules chosen for validation within this 
chapter were ITGB1, ERK1/2 and Src. 
7.3.2.1 Integrin B1 (ITGB1) and Integrin Linked Kinase 1 (ILK1) 
Figure 7.5shows the Kinexus protein microarray results for ITGB1 and ILK1 and the 
subsequent validation of ITGB1 in PC-3 and LNCaP cells. The Kinexus microarray 
probed a number of different integrin receptor related molecules over the entire chip 
and these are highlighted in Figure 7.5A.  ILK1 was shown to be significantly 
upregulated (z-ratio > 1.64) at region Y351 in PC-3
EPLIN EXP
, suggesting enhanced 
ILK phosphorylation in ILK following EPLINα overexpression in PC-3. This region 
however wasn’t validated by Western Blot as no commercial antibodies were 
available for this region at the time of analysis. A significant increase in a S785 
phosphoylation of ITGB1 was indicated with a z-ratio of greater than 1.64 obtained. 
To validate this observation, a commercial antibody, specific for ITGB1 S785, was 
purchased. Unfortunately, the purchased antibody did not show any clear detection 
(data not shown) despite optimisation of conditions and no other suppliers were 
available, hence this phospho site could not be validated at this time. Total ITGB1 
was therefore sourced and tested for expression levels in PC-3 and LNCaP. Total 
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ITGB1 expression was enhanced following EPLINα overexpression in PC-3 cells 
(Figure 7.5B) and this observation was found to be statistically significant following 
semi-quantitative analysis and normalisation against GAPDH (p=0.01). In LNCaP, 
no significant change in ITGB1 expression was visualised between LNCaP
pEF6
 cells 
and LNCaP
EPLIN EXP
 cells. Band intensity was normalised to GAPDH and each was 
tested for n=3 in PC-3 and LNCaP. It’s important to note that total ITBG1 wasn’t 
actually detected in the Kinexus array. However, though S785 of ITGB1 could not 
be validated, there is evidence to suggest EPLINα regulates ITGB1 via enhancing 
total protein content, at least in the PC-3 cell model.  
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Figure 7.5 Protein microarray results: Integrin receptor-related molecules.  
ITGB1 was highlighted as a potential molecule of interest following the protein 
microarray. Specifically the region of S785 was significantly upregulated in response 
to EPLINα overexpression in PC-3. (A) Integrin receptor related-regions screened in 
Kinexus protein microarray. ITGB1 S785 significantly upregulated with z ratio of 
>1.64. (B) ITGB1 protein validation in PC-3 using Western blot analysis. (C) ITGB1 
validation in LNCaP using Western blot analysis. Representative gel images shown 
of n=3 repeats in PC-3 and LNCaP. Significance was determined used the z-ratio; a 
z-ratio of > 1.64 or < -1.64 was deemed statistically significant.  
 Chapter VII 
271 
 
7.3.2.2 Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) 
Following data analysis from the Kinexus protein microarray, ERK1/2 was 
highlighted as a potential molecule of interest for EPLIN association. From the 
microarray, ten regions of ERK1/2 all showed a total loss of Globally Normalised 
Signal Intensity in either total ERK1/2 protein or a loss of phosphorylation of 
ERK1/2 when EPLINα was overexpressed in PC-3 (Figure 7.6A). Interestingly, total 
ERK1 was probed using three separate antibodies within the array and was shown to 
be significantly downregulated, following, EPLINα overexpression in one of the 
tested antibodies, scoring a z value of < -1.64. The other two tested antibodies both 
showed general decreases by these did not fall below the z ratio of -1.64. In addition, 
ERK1 (S74), ERK1/2 (Y204) and ERK1/2 (T202) were all found to be significantly 
downregulated when EPLINα was overexpressed in PC-3 cells with a z ratio of < -
1.64. To validate the Kinexus array, total ERK1/2 and pERK1/2 T202 Y204 
expression was screened in PC-3 and LNCaP cells, however no obvious differences 
were seen between pEF6 and EPLIN EXP transfected cells for either cell line 
(Figure 7.6B/C). This was subsequently confirmed following semi-quantitative 
analysis of band intensity and normalisation against GAPDH, indicating no 
significant differences in expression following EPLINα overexpression in either PC-
3 or LNCaP cells (data not shown).   
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Figure 7.6 Protein microarray results: ERK1/2 expression.  
ERK1/2 was highlighted as a potential molecule of interest following the protein 
microarray. Specifically the region of T202 and Y204 were significantly 
downregulated in response to EPLINα overexpression in PC-3. (A) All ERK1/2 
regions screened in Kinexus protein microarray. ERK1 (Pan-specific), ERK1 (S74), 
ERK1/2 (Y204) and ERK1/2 (T202) were significantly downregulated with z ratio 
of <-1.64. (B) ERK1/2 validation in PC-3. Antibodies for ERK1/2 used: Total 
ERK1/2, and pERK1/2 T202 Y204. (C) ERK1/2 validation in LNCaP. Antibodies 
for ERK1/2 used: Total ERK1/2, and pERK1/2 T202 Y204. Representative gel 
images shown of n=3 repeats in PC-3 and LNCaP. Significance was determined used 
the z-ratio; a z-ratio of > 1.64 or < -1.64 was deemed statistically significant.  
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7.3.2.3 Proto-oncogene Tyrosine-protein kinase (Src) 
Figure 7.7 shows the validation of the Src molecules in PC-3 and LNCaP. The 
Kinexus microarray revealed a significant decrease in the phosphorylation of the 
activation site Y419 of Src following overexpression of EPLINα in PC-3 cells. Also 
present within the microarray chip were several pan-specific probes and the Y529 
phosphorylation site of Src, though no significant differences were seen in the signal 
intensity of such probes with z ratios between 1.64 and -1.64 obtained (Figure 7.7A). 
An antibody was sourced for this region of Y419 and tested for expression levels in 
control and EPLINα overexpression PC-3 and LNCaP cells (Figure 7.7B/C). A 
decrease in band intensity for Src Y419 was seen, which following semi-quantitative 
analysis, was found to be significantly downregulated in PC-3 (data not shown, 
p=0.005) following EPLINα overexpression and validated the Kinexus result. In 
LNCaP cells, a reduction of Src Y419 band intensity was seen in LNCaP
EPLIN EXP
 
cells compared to LNCaP
pEF6 
cells, however this change was not statistically 
significant following semi-quantitative analysis (data not shown, p>0.05). In 
addition to Src Y419, total Src and Src Y530 was also tested. For PC-3 and LNCaP, 
no significant differences were seen in total Src expression, which is in keeping with 
the results of the microarray. Contrary to Src Y419, Src Y530, a common site of 
dephosphorylation, was enhanced following EPLINα overexpression in PC-3 cells 
and this trend was confirmed following semi-quantitative band analysis, highlighting 
a significant increase in PC-3 (data not shown, p=0.027) when EPLINα is 
overexpressed. In LNCaP, Y530 was also increased when EPLINα was 
overexpressed, however the increase didn’t quite reach significance (p=0.068) upon 
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semi-quantitative band analysis (data not shown).  Band intensity was normalised to 
GAPDH and each Src molecule were tested for n=3 in PC-3 and LNCaP.   
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Figure 7.7 Protein microarray results: Src expression.  
Src was highlighted as a potential molecule of interest following the protein 
microarray. Specifically the region of Y419 was significantly downregulated in 
response to EPLINα overexpression in PC-3. (A) All Src regions screened in 
Kinexus protein microarray. Src Y419 significantly downregulated with z ratio of <-
1.64. (B) Src validation in PC-3. Antibodies for Src used: Total Src, pSrc Y419 and 
pSrc Y530. (C) Src validation in LNCaP. Antibodies for Src used: Total Src, pSrc 
Y419 and pSrc Y530. Representative gel images shown of n=3 repeats in PC-3 and 
LNCaP. Significance was determined used the z-ratio; a z-ratio of > 1.64 or < -1.64 
was deemed statistically significant. 
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7.3.3 Functional analysis with Src inhibitor (dasatinib) 
Dasatinib, a Y419 src inhibitor, was employed to further explore the interaction 
between EPLINα and src in PC-3 and LNCaP cells in various functional assays, to 
evaluate if src inhibition affects cancer cell traits in addition to EPLINα 
overexpression. First, PC-3 and LNCaP cells were treated with various dasatinib 
concentrations overnight and screened by Western Blotting with Src Y419 antibody 
to confirm the optimal src concentration for use in in vitro functional assays (Figure 
7.8/Figure 7.9A/B). The optimal concentration chosen was 500nM, as this 
concentration was shown to inhibit src Y419 expression in PC-3 and LNCaP cells. 
Subsequently to this, the chosen src concertation was used in various in vitro tumour 
cell functional assays (Figure 7.8B-E/Figure 7.9C-E).  
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Figure 7.8 Functional assays of PC-3 cells with Src inhibitor (dasatinib).  
(A) Src inhibitor concentration screen in PC-3
pEF6 
(pEF6) and PC-3
EPLIN EXP 
(EPLIN 
EXP) cells
 
to assess optimal inhibitor concentration for functional assays. 
Concentrations tested: 100nM, 500nM and 1000nM. Samples then screened with Src 
Y419 antibody to assess Src activity levels. (B) PC-3 invasion assay with Src 
inhibitor. Representative images of PC-3
pEF6 
(pEF6) and PC-3
EPLIN EXP 
(EPLIN EXP)
 
cells with/without src inhibitor at concentration 500nM. (C) Graphical representation 
of cell invasion of PC-3
pEF6 
and PC-3
EPLIN EXP 
cells with/without src inhibitor. (D) 
PC-3 migration/wound healing assay with Src inhibitor. Representative images of 
PC-3
pEF6 
and PC-3
EPLIN EXP 
cells, at 0 hour and 4 hours of scratch assay, with/without 
src inhibitor. (E) Graphical representation of cell migration of PC-3
pEF6 
and PC-
3
EPLIN EXP 
cells with/without src inhibitor. Graphs represent mean of n=3 repeats and 
errors bars show SE of the mean. * = represents p<0.05, ** = p<0.01, *** = 
p<0.001. Statistical test performed for analysis was a two sample, two tailed t-test 
using SigmaPlot software.  
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7.3.3.1 The effect of src inhibition on cellular invasion 
The effect of src inhibition was determined in PC-3 cells in an in vitro invasion assay 
(Figure 7.8B/C). Dasatinib treatment caused a significant reduction of cellular 
invasion of PC-3
pEF6
 cells (p<0.001). However, for PC-3
EPLIN EXP
 cells, no significant 
differences were seen on cellular invasion when dasatinib was used (Figure 7.8C). 
For untreated (no dasatinib) samples, EPLINα overexpression also caused a 
significant reduction of cellular invasion compared to PC-3
pEF6
 cells (p<0.001). 
Dasatinib was also tested in LNCaP cells in an in vitro invasion assay for LNCaP
pEF6
 
and LNCaP
EPLIN EXP
 cells (Figure 7.9C/D). Dasatinib treatment caused a significant 
reduction of cellular invasion of LNCaP
pEF6
 cells (p=0.016). However, for 
LNCaP
EPLIN EXP
 cells, treatment with dasatinib had no significant effects on cellular 
invasion (Figure 7.9D). For untreated (no dasatinib) samples, EPLINα 
overexpression also caused a significant reduction in cellular invasion compared to 
LNCaP
pEF6
 cells (p=0.015).  
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Figure 7.9 Functional assays of LNCaP cells with Src inhibitor (dasatinib).  
(A) Src inhibitor concentration screen in LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells
 
to 
assess optimal inhibitor concentration for functional assays. Concentrations tested: 
100nM, 500nM and 1000nM. Samples then screened with Src Y419 antibody to 
assess Src activity levels. (B) Semi-quantitative analysis of normalised pSrc Y419 
band intensities from (A). Src Y419 levels normalised to GAPDH. (C) LNCaP 
invasion assay with Src inhibitor. Representative images of LNCaP
pEF6 
and 
LNCaP
EPLIN EXP 
cells with/without src inhibitor. (D) Graphical representation of cell 
invasion of LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells with/without src inhibitor. (E) 
LNCaP transwell migration assay with Src inhibitor. Representative images of 
LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells with/without src inhibitor. (F) Graphical 
representation of cellular migration of LNCaP
pEF6 
and LNCaP
EPLIN EXP 
cells 
with/without src inhibitor. Graphs represent mean of n=3 repeats and errors bars 
show SE of the mean. * = represents p<0.05, *** = p<0.001. Statistical test 
performed for analysis was a two sample, two tailed t-test using SigmaPlot software.  
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7.3.3.2 The effect of src inhibition on cell migration 
In addition to the cellular invasion assay, dasatinib was also used in two in vitro 
migration assays: a scratch/wound healing assay for PC-3 cells, and a transwell 
migration assay for LNCaP cells. For the wound healing assay, dasatinib treatment 
caused a significant reduction of cellular migration of PC-3
pEF6
 cells following a 4 
hour time point (p=0.004) (Figure 7.8E).  For PC-3
EPLIN EXP
 cells, cellular migration 
was also significantly reduced when dasatinib was used at the four hour time point, 
though not to as great an extent (p=0.027) (Figure 7.8E).  For untreated (no 
dasatinib) samples, EPLINα overexpression again caused a significant reduction in 
cellular migration when compared to untreated PC-3
pEF6 
cells (p=0.047) (Figure 
7.8E). Dasatinib was also tested in LNCaP cells in an in vitro transwell migration 
assay for LNCaP
pEF6
 and LNCaP
EPLIN EXP 
cells (Figure 7.9E/F). Dasatinib treatment 
caused a highly significant reduction of cellular migration of LNCaP
pEF6 
cells and 
LNCaP
EPLIN EXP
 cells (p<0.001 compared to respective untreated controls) (Figure 
7.9F). For untreated (no dasatinib) samples, migration was reduced in cells with 
EPLINα overexpression cells compared to LNCaPpEF6 control cells, however this 
change was not significant. 
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7.4 Discussion 
This chapter aimed to substantiate and clarify the existing knowledge on the 
mechanism of action of EPLINα in prostate cancer specifically by evaluating the 
EPLINα interactome using a protein microarray. Prior to this study, information 
regarding the mechanism of EPLIN in cancer was lacking, and few studies have 
comprehensively explored the signalling pathways governing EPLIN’s regulatory 
role in suppressing cancer cell functions like proliferation, migration and invasion. 
This study has highlighted several areas of interest for EPLINα signalling in prostate 
cancer, these include: ERK1/2 signalling, Integrin B1 and integrin receptor-related 
signal and Src signalling pathways.  
The Kinexus protein microarray highlighted an upregulation of several integrin 
receptor-related proteins or phosphorylation events, specifically an increase to ILK1 
at region Y351 and the β component of the integrin receptor; ITGB1 (S785). ILK1 
Y351 was significantly increased in the protein microarray following EPLINα 
overexpression in PC-3. ILK is a signalling protein involved in integrin and actin 
dynamics, has central roles in cellular functions including cellular adhesion, and has 
implications in cancer progression (Legate et al., 2006). Interestingly, ILK forms a 
complex with PINCH1 to co-ordinate various cellular functions, and PINCH1 has 
been previously established as an EPLIN-binding protein (Karakose et al., 2015). 
Given the evidence that EPLIN binds PINCH1 in (Karakose et al., 2015), and the 
evidence in this study which suggests EPLINα expression enhances ILK1 
phosphorylation at Y351, it could be that EPLINα is responsible for regulating 
several components of this integrin signalling complex. This could then potentially 
have diverse implications in cancer, including affecting affinity to the actin 
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cytoskeleton and influencing cellular adhesion and gene transcription (Legate et al., 
2006). Although this was an interesting notion, an antibody specific to the Y351 
region of ILK1 was unavailable at the time of this study, so this phosphorylation and 
association couldn’t be validated in PC-3. 
ITGB1 is a large protein which functions as a receptor protein to bind components of 
the ECM, like collagen, fibronectin and fibrinogen, at the cell membrane and co-
ordinate cell functions though integrin signalling (Gilcrease, 2007). Knock-down 
analysis of ITGB1 has demonstrated a reduction of PCa cellular invasion and 
migration using PC-3 cells (Kurozumi et al., 2016). On the other hand, expression of 
the α5β1 form of the integrin receptor has been associated with proliferation arrest 
and a reduction in cell proliferation (Varner et al., 1995). The phosphorylated form 
of ITGB1 at S785 is associated with increased attachment and inhibition of cell 
spreading and migration (Mulrooney et al., 2001). As EPLINα overexpression in PC-
3 cells induced a significant upregulation of S785 in ITGB1 via the Kinexus protein 
microarray, this could suggest a potential mechanism for EPLINα’s ability to 
influence cellular function in cancer. This will be discussed further in the next 
chapter. It is important to note that an antibody specific to the S785 region of ITGB1 
was unavailable during the time of this study, and all validation work involving 
EPLINα expression and ITGB1 was done using an antibody specific to total ITGB1 
protein. For that reason, these results require further validation and should be 
interpreted with caution.  
In addition to influencing molecules and components associated to integrin receptor 
dynamics, EPLINα overexpression in PC-3 also influenced the activity of several 
ERK molecules. ERK1 total protein and ERK T202/Y204 was significantly 
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downregulated, in the protein microarray, suggesting a loss of ERK1/2 activity when 
EPLINα is overexpressed in PC-3 cells. ERK1/2 functions in cell biology as part of 
the MAPK/ERK pathway which is a huge signalling pathway controlling various 
cellular functions including cell proliferation, proliferation, cell cycle progression, 
invasion, cell survival, and metastatic progression (Dhillon et al., 2007). Activation 
of ERK1/2 is important both physiologically and in cancer, and T202/Y204 are 
established regions for ERK activity, and are responsible for dual activation within 
ERK1/2 (Roskoski, 2012). For example, ERK1/2 activation is associated with cell 
cycle progression and is responsible for induction of positive cell cycle regulatory 
genes, including Cyclin D1, and a reduction of anti-proliferative molecules (Meloche 
and Pouyssegur, 2007). Considering this notion, it may be that when EPLINα is 
expressed in PC-3 cells, it leads to a reduction of ERK1/2 activation at T202/Y204, 
leading to reduced activity and less available cyclin proteins to progress the cell 
cycle, and thus leads to a suppression of cell proliferation. This concept is 
strengthened by the evidenced loss of Cyclin D1 and Cyclin E1 (T395) in the 
Kinexus protein microarray, where Cyclin E1 shows a significant downregulation in 
response to EPLINα overexpression (Table 7.4). Cyclin E1 is crucial for G1 
progression during the cell cycle, so it could be that EPLINα acts through ERK1/2 
signalling to suppress Cyclin E1 and prevent PC-3 cells from leaving the G1 phase 
of the cell cycle (Mazumder et al., 2004). The role of EPLIN in the cell cycle has 
been previously explored, showing EPLIN is crucial for cytokinesis and depletion of 
EPLIN resulted in the formation of multinucleated cells and inefficient clustering 
various proteins like mitotic regulatory  proteins like myosin II, RhoA and Cdc42 to 
the cleavage furrow, signifying cytokinesis failure (Chircop et al., 2009).  EPLIN 
interacts with various proteins at the cleavage furrow of cytokinesis, including 
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supervillin, KIF1 and Arv1 (Smith et al., 2010, Sundvold et al., 2016), further 
highlighting the importance of EPLIN expression for regulating functional cell 
division. 
The Kinexus protein microarray revealed a novel association to the proto-oncogene 
tyrosine-protein kinase, Src. Src (or c-Src; cellular Src) is a key regulatory molecule 
of several signalling pathways and contributes to various cellular functions in cancer 
including cellular adhesion, migration and  invasion (Irby and Yeatman, 2000). Src 
expression  is generally up regulated in cancer and activation through the region 
Y419 has been associated with colon cancer progression (Cartwright et al., 1990), 
poor survival and increasing tumour size and grade in breast cancer (Elsberger et al., 
2009),  and correlates with cancer aggressiveness in prostate cancer (Asim et al., 
2008, Chang et al., 2008). Phosphorylation at Y419 contributes to Src function and 
allows Src access to several Src substrates to promote Src activation (Xu et al., 
1999). In this study, Src was significantly downregulated at region Y419 in PC-3 
cells overexpressing EPLINα. This was subsequently verified by Western Blot in 
PC-3 and LNCaP cells lines and validated a reduction of Src Y419 expression 
following EPLINα overexpression. This suggests EPLIN expression may lead to a 
reduction of Src phosphorylation within the residue. Y419 of Src is known as the 
classical activation site (Elsberger et al., 2009) so suggests that EPLINα expression 
induces a reduction of c-Src activity in prostate cancer. Src is an integral protein for 
integrin signalling-related cellular functions and is synergistic to paxillin and FAK 
signalling (Irby and Yeatman, 2000). EPLINα could therefore potentially be acting 
on several integrin-related molecules to control cellular functions in prostate cancer. 
The role of Src activation in cancer is widely established (Kim et al., 2009), so if 
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EPLINα functions through Src expression in cancer, this could provide insight into a 
potential mechanism for EPLINα as a tumour suppressive molecule and this may be 
a key regulatory role, particularly in relation to cancer progression. Specifically, 
inhibition of Src activity has been associated with cell cycle arrest, decreased cellular 
migration and invasion in malignant pleural mesothelioma tissues (Tsao et al., 2007). 
Activated Src levels (p-Src Y419) were also associated with advanced staged cancer 
(Tsao et al., 2007). Src is also highly expressed in triple negative breast cancer, and 
targeting c-Src expression using the inhibitor, dasatinib, has demonstrated potential 
for controlling breast cancer cell characteristics including migration and invasion 
(Tryfonopoulos et al., 2011). Thirdly, targeting Src in prostate cancer is able to 
control cell proliferation, migration and invasion, and several clinical trials have 
commenced exploiting Src expression (Chang et al., 2008). If EPLINα expression is 
able to induce a reduction of Src activity in prostate cancer, presumably this may 
have a negative regulatory effect on various cellular characteristics including focal 
adhesion turnover, cellular migration and invasion. This potential mechanism will be 
discussed further in the following chapter. 
Western Blot experiments also revealed a significant increase in PC-3 and LNCaP of 
p-c-Src Y530 when EPLINα is overexpressed (Figure 7.7). Y530 of Src is a known 
region of dephosphorylation to contributes to negative regulation of Src activity, 
with phosphorylation of this residue being associated with a less active form of Src 
(Zhu et al., 2007). When Src is phosphorylated at Y530 it facilitates interaction with 
the SH2 domain of Src, promoting a reduction of kinase activity (Liu et al., 1993). 
Considering EPLINα overexpression promotes an increase in Y530 in PC-3 and 
LNCaP, this could be an additional and/or separate mechanism for controlling 
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cellular functions via a suppression of Src activity. Y530 is phosphorylated by 
Tyrosine Protein-Kinase (CSK), which is a ubiquitously expressed protein kinase 
(Okada and Nakagawa, 1989), so it could be that EPLINα enhances CSK function 
and/or expression in prostate cancer to increase phosphorylation at Y530 and 
ultimately induce a less active form of Src.  
Recognising the notion that Src may be implicated in the role of EPLINα as a tumour 
suppressive molecule, various in vitro tumour functional assays were performed in 
PC-3 and LNCaP in presence of a Src inhibitor, dasatinib (Figure 7.8/Figure 7.9). 
This was done to examine if the suppressive effect of EPLINα overexpression was 
independent to Src activity, and establish if the two molecules are functionally and 
mechanistically associated. Dasatinib is a small molecule tyrosine kinase inhibitor 
used as a commercial treatment under the brand name Sprycel to target various 
tyrosine kinases including the Src family kinases (Montero et al., 2011). Dasatinib 
works specifically by inhibiting Y419 phosphorylation of src, and thus, preventing 
src activity. Dasatinib has been used successfully to treat various cancers including 
Chronic Myeloid Leukaemia and Acute Myeloid Leukaemia by targeting cellular 
traits like cell proliferation and duplication, migration and invasion and the induction 
of apoptosis of tumour cells (Montero et al., 2011, UK). In this study, use of 
dasatinib reduced cellular invasion of PC-3
pEF6
 cells compared to untreated PC-3
pEF6
 
cells. However, use of dasatinib showed no significant differences to cellular 
invasion of PC-3
EPLIN EXP
 cells. This may suggest that EPLINα is acting through 
regulation of Src expression to suppress cellular invasion, as when EPLINα is 
present, and Src activity is blocked, the effect on cellular invasion is comparable and 
not cumulative. For the wound healing assay, dasatinib treatment rendered both PC-
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3
pEF6
 and PC-3
EPLIN EXP
 cells less motile, with significant reductions at the 4 hour 
time point, though the level of significance was lower in the PC-3
EPLIN EXP
 cells. This 
again may suggest that Src could be a mechanism of EPLINα suppression on cell 
migration via EPLINα expression acting through a negative regulation of Src 
activity, though it may not be the only method of regulation governing Src’s role in 
cellular migration.  
Dasatinib was also used in two in vitro tumour functional assays for the LNCaP cell 
model for both LNCaP
pEF6
 and LNCaP
EPLIN EXP
 transfected cells (Figure 7.9). For the 
invasion assay, dasatinib treatment reduced cellular invasion for LNCaP
pEF6
 cells but 
not LNCaP
EPLIN EXP
 cells. This further suggests EPLINα may be acting through Src 
expression to control cellular invasiveness. For a transwell migration assay, dasatinib 
treatment reduced the invasiveness of both LNCaP
pEF6
 and LNCaP
EPLIN EXP
 cells. 
This may suggest that in the LNCaP cell model, the effect of EPLINα expression on 
cellular migration may be less dependent on Src expression, and dasatinib appears to 
markedly reduce cellular invasion regardless of EPLINα expression. 
Finally, EPLIN expression in PC-3 influenced several other key molecules and 
mechanisms, and these included molecules such as p53 and PAK1/2/3 (Table 7.2). 
The associations of p53 in the progression of cancer is widely established (Muller 
and Vousden, 2013) and specifically has implications in the progression of prostate 
cancer (Thomas et al., 1993). p53 has also recently been linked to EPLIN expression 
where the suppressive action of p53 was dependant of EPLIN expression (Ohashi et 
al., 2017). Whereas PAK molecules have roles in RTK signalling to co-ordinate 
cytoskeletal organisations and cell survival (Dummler et al., 2009) in addition to 
being involved in cancer progression (Ye and Field, 2012). Together this suggests 
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EPLINα could also influence several other pathways that haven’t been validated in 
this study and offers interesting future work for this area of prostate cancer biology.  
This study aimed to evaluate key signalling pathways involved in EPLINα’s 
mechanism of action in prostate cancer. This has revealed that EPLINα may act on 
several regulatory mechanisms, and its expression is associated to various crucial 
proteins involving cell proliferation, migration, adhesion and invasion. Several lines 
of evidence indicate Src may be an important factor associated to EPLINα 
expression for its tumour suppressive capacity, and this further substantiates the 
proposed link between EPLINα and paxillin/FAK signalling. Further work is needed 
to elucidate the full role of these two molecules and clarify the regulatory 
mechanisms governing the suppression of prostate cancer progression and 
development induced by EPLINα expression. 
.  
. 
 Chapter VIII 
289 
 
 
 
 
 
 
8 Chapter VIII: General 
discussion 
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Prostate cancer is the most common male cancer in the UK and the incidence has 
been steadily rising over the last twenty years (CancerResearchUK, 2017). 
Compared to other cancers, prostate cancer has a relatively good survival rate, with 
84% of men in the UK surviving over ten years following diagnosis of prostate 
cancer (CancerResearchUK, 2017). However, prostate cancer becomes substantially 
more problematic when the cancer progresses and metastasises to other areas of the 
body, and targeting this metastatic progression is fundamental for overcoming the 
disease. Prostate cancer has a specific tendency to establish bone metastases, and 
once this spread occurs, survival rates are dramatically compromised. For example, 
patients with advanced prostate cancer without bone metastases have a five year 
survival rate of 56% whereas patients with advanced prostate cancer with bone 
metastases have  five year survival rates of approximately only 3% (Higuera, 2016). 
Traditional treatments can only go so far in managing the disease and these have 
various side effects leading to reduced quality of life for the patient. The emphasis 
on specific, molecular targets for treatment of metastatic prostate cancer is now 
larger than ever.  
An additional issue with prostate cancer is the lack of available and reliable 
biomarkers and prognostic markers. The PSA test is a useful indicator for evaluating 
prostate health however this has various drawbacks and can be unreliable in 
producing a true confirmatory result. Recently, the British Broadcasting Channel 
(BBC) reported a study from Science Translational Medicine where a prostate cancer 
blood test was able to determine how certain prostate cancer patients would respond 
to various cancer drugs like abiraterone, avoiding unnecessary side effects and 
potentially extending life span (Romanel et al., 2015). Although developments are 
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being made, a specific molecular target to determine prostate cancer prognosis is yet 
to be established. Without reliable predictive agents, it’s difficult for GP’s and 
clinicians to decipher if a prostate cancer will remain indolent and local, or will 
become an advanced metastatic cancer, and thus difficult to decide on optimal 
treatment procedures.  
The aim of this thesis was to explore the importance of the actin-related, tumour 
suppressive molecule EPLIN in the progression and development of prostate cancer, 
with particular emphasis on generating mechanistic data and investigating potential 
links to the metastatic bone environment. A key focus was to gain a better 
understand of the biology of EPLIN, its role in prostate cancer progression and to 
gain further insight into the usefulness of this molecule and associated mechanism(s) 
as novel potential progression biomarkers or therapeutic strategies. 
8.1 Clinical and cellular significance of EPLIN expression in prostate cancer 
and potential as a biomarker and/or use in prognosis 
Protein and transcript analysis of EPLIN using prostate cancer cell lines revealed 
EPLIN is differentially expressed in prostate cancer, with a reduction of EPLIN 
expression coinciding with aggressiveness of the cell line. Specifically, the EPLIN 
transcript was reduced or abolished in cell lines PC-3, LNCaP and VCaP, compared 
to a high expression in cell lines PZ-HPV-7 and CA-HPV-10, whereas the EPLINβ 
transcript remained relatively constant at low levels for all cell lines. This concurs 
with previous reports using PC-3 and LNCaP where EPLINα is lost in aggressive 
prostate cancer (Maul and Chang, 1999) and is the first study using the VCaP cell 
line to evaluate EPLIN expression. This trend of EPLIN loss was also seen at the 
protein level, where EPLINα and EPLINβ isoforms were markedly reduced 
 Chapter VIII 
292 
 
compared to PZ-HPV-7 and CA-HPV-10. This suggests that EPLIN loss correlates 
with prostate cancer progression and highlights the potential of EPLIN to be used in 
prognostic targeting and a putative marker protein.  
This study also examined the clinical significance of EPLIN in two prostate cancer 
TMA’s, confirming the cellular observations and suggesting that EPLIN expression 
is significantly reduced or lost during the development or progression of prostate 
cancer. Taken together with other studies looking at EPLIN expression in prostate 
cancer cells and tissues (Sanders et al., 2011, Liu et al., 2016, Jiang et al., 2008, 
Zhang et al., 2011), the work presented within this thesis strongly supports the use of 
EPLIN as biomarker/prognostic marker for prostate cancer development and 
progression. 
8.2 The functional effect of EPLINα expression on prostate cancer cell 
proliferation, invasion, adhesion and migration 
To characterise the cellular significance of EPLINα expression on key cancerous 
traits, overexpression models were generated in prostate cancer cell lines. PC-3 and 
LNCaP lines were chosen as they had the lowest EPLIN transcript expression and 
were negative for EPLIN protein expression.   
EPLINα overexpression reduced cellular proliferation of PC-3 and LNCaP  cells and 
this is in keeping with both in vitro and in vivo observations from a previous study 
conducted in the host laboratory (Sanders et al., 2011). The current study is the first 
known study to evaluate EPLINα overexpression on cellular proliferation in the 
LNCaP cell model, and this study confirmed the negative regulatory effects EPLIN 
has on cell proliferation in LNCaP in addition to other prostate cancer cell models. 
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The work here also substantiates EPLINα’s role as a suppressor of cell proliferation 
in other cancers including oesophageal cancer (Liu et al., 2012a) and breast cancer 
(Jiang et al., 2008). This also raises the question as to what effect EPLIN expression 
has on the cell cycle. Previous reports have suggested EPLIN is a key regulator of 
successful mitotic cell division where EPLIN localises to the cleavage furrow of 
cytokinesis (Chircop et al., 2009). EPLIN loss appears to effect the bundling of 
various proteins like actin and myosin to the cleavage furrow, leading to aneuploidy 
signifying cytokinesis failure and thus genomic instability of daughter cells (Chircop 
et al., 2009). Future work would help elucidate this potential role of EPLIN on cell 
cycle progression and establish the anti-proliferative effect EPLIN expression has in 
prostate cancer. 
EPLINα was also shown to be a regulator of cellular invasiveness. Both PC-3 and 
LNCaP EPLINα overexpression models were less able to infiltrate and invade a 
Matrigel membrane, an observation again in keeping with previous data in PC-3 
(Sanders et al., 2011) and LNCaP (Zhang et al., 2011) models, where EPLIN 
expression was able to influence prostate cancer cell invasiveness.   This observation 
has been explored recently in lung and breast cancer where EPLIN influenced the 
invasive nature of metastatic lung cells, H1299 and Lu99, and MDA-MB-231 breast 
cancer cell lines (Ohashi et al., 2017). Overexpression of EPLIN in H1299 was 
shown to significantly reduce cellular invasion compared to control H1299 cells, 
whereas EPLIN lentiviral knock-down in Lu99 and MDA-MB-231 revealed 
significantly enhanced invasive capacities. Collectively, the data presented in this 
thesis, together with additional studies suggesting an anti-invasive role for EPLINα 
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in the invasive nature of breast (Jiang et al., 2008) and oesophageal cancer (Liu et 
al., 2012a), strongly implicate a regulatory role for EPLIN in cancer invasion.  
EPLIN localises to adherens junctions and functions as a linker molecule to bind the 
cadherin-catenin complex to filamentous actin during cell-cell contact and thus likely 
has implications in cell movement and cellular adhesion (Abe and Takeichi, 2008). 
Considering this notion, the role of EPLINα in cancer cell adhesion to the ECM was 
explored. EPLINα overexpression induced a significant increase in cellular adhesion 
to Matrigel for both PC-3 and LNCaP cells. Additionally, cells containing the 
overexpression plasmid also took notably longer to detach in trypsin, during 
subculture, suggesting enhanced substratum adhesion. This contradicts previous 
reports assessing the adhesive nature of cells with forced EPLIN expression in 
cancer, where EPLIN overexpression induced a reduction of adhesion in KYSE150 
oesophageal cancer cells (Liu et al., 2012a) and in endothelial cells (Sanders et al., 
2010). This is the first known study to elucidate the effect of EPLINα overexpression 
on cellular adhesion in prostate cancer and substantiates the notion that EPLINα is 
able to influence cellular characteristics in cancer via altered EPLINα expression. It 
also suggests a role for EPLINα in the regulation of other molecules involved in 
matrix-adhesion, such as integrin’s, and, when taken in context of the wider 
literature, suggests that this level of regulation may differ between differing cancer 
cells or types.  
As discussed, EPLIN is functionally linked to the globular protein actin and 
physically binds actin at sites flanking the LIM domain of EPLIN (Maul et al., 
2003). This binding co-ordinates various cellular processes including cross linking 
and stabilising actin filaments and inhibits membrane ruffling (Maul et al., 2003). 
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Actin is a ubiquitously expressed protein responsible for co-ordinating a myriad of 
cellular functions including cell mobility, movement and migration and has diverse 
implications in cancer progression (Fife et al., 2014). Considering how EPLIN exerts 
function through actin association, it proposes the notion that EPLIN is also 
implicated in cellular functions including cellular migration. EPLINα overexpression 
was therefore evaluated in in vitro tumour migration assays. EPLINα overexpression 
induced a reduction of cellular migration in both PC-3 and LNCaP cells, though this 
effect was not significant in the LNCaP model. This study in prostate cancer 
corroborates previous work elucidating EPLINα in tumour cellular migration in 
endothelial cells (Sanders et al., 2010) and in breast cancer cells, via an Electrical 
Cell Substrate Impedance Sensing (ECIS) assay (Jiang et al., 2008). Taken together 
this work builds on previous work linking EPLINα as an actin related molecule and 
reinforces the notion of EPLINα as a tumour suppressive molecule via its ability to 
impede cellular migration in prostate cancer. 
Work in this thesis has utilised two prostate cancer cell models to establish and 
clarify the functional impact of EPLINα expression in prostate cancer. When taken 
together, the data from PC-3 and LNCaP models substantiates the concept that 
EPLINα is a tumour suppressive molecule in cancer, and through its ability to 
influence key metastatic traits, affirms the potential of EPLINα as a molecular 
regulator of prostate cancer cell metastasis.  
8.3 The role of EPLIN in the establishment of bone metastases 
 Bone metastasis is a key consideration in prostate cancer pathophysiology. Of all the 
prostate cancers that metastasise, approximately 80% will spread to the bones 
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resulting in reduced quality of life and poor patient survival outlooks (Higuera, 
2016). Bone metastasis results in a variety of side effects and symptoms including 
bone pain and osteolysis, in addition to increasing difficulty of treatment and 
management of the disease (AmericanCancerSociety, 2016). It is therefore crucial to 
establish new molecular targets to prevent the spread of prostate cancer to the bone 
and the formation of secondary cancers within this environment.  
Various molecular agents have been suggested to be associated with the 
dissemination of prostate cancer to bone. These include the adhesion molecule 
activated leukocyte cell adhesion molecule (ALCAM) (Hansen et al., 2014), the 
focal adhesion adaptor, Talin1 (Jin et al., 2015) and various mircoRNAs (miRNAs) 
(Weidle et al., 2016). In this thesis, EPLINα overexpression was evaluated as a 
potential factor that could influence prostate cancer metastases establishment in the 
bone environment through the addition of BME or human osteoblasts to the culture 
environment. Generally, the use of BME induced no significant differences to the 
cellular functions of PC-3 and LNCaP cells when compared to respective untreated 
samples. The presence of human osteoblasts generally increased the invasiveness of 
PC-3 cells, but not LNCaP cells. In PC-3 cells, though co-culture with osteoblasts 
enhanced the invasiveness of both control and EPLINα overexpression cells, this 
was only significant in the case of the control, potentially suggesting that EPLINα 
may protect against pro-invasive signals secreted by osteoblasts. In LNCaP cells, 
there was no general change with or without osteoblasts, suggesting LNCaP cells are 
less susceptible to the action of osteoblasts and thus a bone-like environment. Taken 
together, this may suggest that EPLINα plays some role in prostate cancer 
establishment at the bone environment, though its major role appears more related to 
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a general tumour/metastatic suppressive effect, potentially exerting functions earlier 
in the metastatic cascade, rather than a having a substantial involvement at the bone 
environment itself, though further, complex co-culture models and in vivo works are 
needed to explore and validate this relationship further.  
8.4 Mechanistic implications of EPLIN and involvement in signalling 
pathways 
The EPLIN interactome has only been explored briefly in the last decade. Reports 
have associated the mechanism of action of EPLIN to molecules including actin 
(Maul et al., 2003), the cadherin-catenin complex (Abe and Takeichi, 2008), EGF 
and ERK (Zhang et al., 2013) and p53 (Steder et al., 2013, Ohashi et al., 2017). Our 
research group and others have also linked the integrin signalling related molecule, 
paxillin, to EPLIN expression and function (Tsurumi et al., 2014, Sanders et al., 
2011). It is also established in the literature that EPLINα is lost in aggressive cancer, 
and if expression is retained, can act as a tumour suppressive molecule to influence 
metastatic characteristics. The mechanism governing this suppressive role in cancer, 
however, remains elusive and is yet to be determined. A key aim of this thesis was to 
clarify this area and substantiate existing knowledge surrounding EPLIN mechanistic 
biology in cancer progression. 
8.4.1 Mechanistic implications of EPLIN: FAK and paxillin  
Considering the established link between EPLIN and paxillin, the expression and 
phosphorylation status of paxillin was determined in this study in conjunction with 
EPLINα overexpression. Paxillin is functionally and mechanistically linked to FAK 
(Mitra et al., 2005) so FAK was also explored in relation to EPLINα expression. 
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Within the cell models, EPLINα overexpression influenced paxillin and FAK 
expression and also the phosphorylation of certain key residues within these proteins 
such as FAK Y397/Y925 and paxillin Y31/Y118. FAK Y397 is an established 
region of FAK crucial for controlling cellular functions including cell survival and 
cellular migration (Hanks et al., 2003), co-ordinating interaction with regulatory 
proteins like PI3K (Chen et al., 1996) and is a major binding site SH2 domain of Src 
family kinases (Eide et al., 1995). In this study, EPLINα overexpression in LNCaP 
increased the proportion of Y397 phosphorylation in FAK, potentially accounting in 
part for the lack of significance seen in the LNCaP in vitro transwell migration assay 
following EPLINα overexpression. In PC-3 however, EPLINα overexpression 
significantly reduced cellular migration but did not significantly alter the expression 
of Y397. Hence, the differential effect of EPLINα on FAK Y397 in these two cell 
lines may partially account for the differential effects on migration. This may 
suggest the suppressive action of EPLINα may be differentially regulated depending 
on different cell types through the action of FAK phosphorylation. On the other 
hand, EPLINα expression also had differential effects on the status of FAK Y925 in 
PC-3 and LNCaP. Y925 is also an established region of FAK and is important for 
cell migration, focal adhesion turnover and cell protrusion (Deramaudt et al., 2011). 
EPLINα overexpression enhanced FAK Y925 in PC-3 cells and also induced an 
increase in cellular adhesion to Matrigel membrane. It may be increased EPLINα is 
acting through Y925 to reduce focal adhesion disassembly and thus focal adhesion 
turnover. Logically this would result in increased adhesive properties in PC-3 cells 
expressing EPLINα as they are less able to detach from the membrane due to the 
reduced turnover of the focal adhesions and thus not primed to migrate elsewhere, 
potentially also accounting, at least in part, for the reduced migratory potential seen 
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in this cell line. This provides insights in the potential mechanism of EPLINα to 
regulate several cellular functions in prostate cancer through the action of key FAK 
phosphorylation regions. Functional analysis examining the significance of EPLINα 
expression in conjunction with a FAK Y397 inhibitor further suggested mechanistic 
links between these two molecules. FAK inhibition had a reduced impact on the 
proliferation, invasion and migration of PC-3 cells overexpressing EPLINα, 
compared to controls, though this trend was not so clear in LNCaP cells. As 
discussed in Chapter 6, these differential responses may be due to different 
mechanistic actions of EPLINα in different cell types and/or due to different 
expression profiles of FAK in each PC-3 and LNCaP cells. Taken together it suggest 
that FAK may be one means through which EPLINα can exert its regulation. It is 
interesting to consider that EPLINα may also act upstream/downstream of FAK, 
potentially targeting this pathway at a number of points, as suggested in Chapter 7, 
through its action on Src, a molecule which associates with FAK at Y397 to 
phosphorylate several other regions of FAK during integrin clustering to propagate 
integrin signalling (Schaller et al., 1994, McLean et al., 2005).  This could result in 
potentially less available FAK Y397 in cells with retained EPLINα expression and 
thus a less prominent change in cellular function.   
EPLINα expression also influenced the proportion of paxillin phosphorylation at 
Y31 and Y118. These regions are critical to paxillin function and have implication in 
cellular migration and cancer progression (Brown and Turner, 2004). These regions 
of paxillin also serve as docking sites for signalling proteins including Crk, a 
downstream event of FAK phosphorylation (Schaller and Parsons, 1995). Tyrosine 
phosphorylation in paxillin is also important for controlling FA dynamics for 
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integrin dynamics and altering these regions can affect FA turnover (Zaidel-Bar et 
al., 2007). Chapter 6 highlighted that EPLINα overexpression enhanced paxillin 
phosphorylation at both Y31/Y118 in PC-3. Phosphorylation within these residues 
have been associated with both an increase in cellular migration (Petit et al., 2000) 
but also a decrease in cellular migration (Yano et al., 2000). In the case of the latter, 
this could be a potential mechanism through which EPLINα can negatively regulate 
cellular migration. Contrary, in LNCaPs, a significant reduction of paxillin Y118 
was seen following EPLINα overexpression. Paxillin Y31/Y118 has also been 
associated with increased FAK recruitment and FA turnover (Zaidel-Bar et al., 
2007). If Y118 is reduced in LNCaP cells expressing EPLINα, this could lead to a 
reduction of FA turnover and hence induces increased adhesion and reduced cellular 
migration, again proposing a potential mechanism of EPLINα function through the 
action of paxillin phosphorylation. Further, if EPLINα exerts varying effects on 
paxillin Y31/Y118 phosphorylation in cancer, depending on cell type, this could lead 
to differential effects on paxillin:FAK association, thus leading to changes in cellular 
migration, adhesion and invasion (Deramaudt et al., 2014). For example if PC-3 cells 
with retained EPLINα expression also have increased paxillin Y31/Y118, this could 
increase FAK recruitment and association (Zaidel-Bar et al., 2007), leading to 
increased FA turnover and cellular adhesion (Deramaudt et al., 2014). Conversely, 
with weakened Y31/Y118 (seen partly in LNCaP
EPLIN EXP
 with Y118) this could 
negatively affect FAK recruitment and association (Zaidel-Bar et al., 2007), leading 
to a reduction of migration and invasion (Deramaudt et al., 2014). Altogether this 
suggests a complex network of interactions orchestrating cellular function in prostate 
cancer. It seems EPLINα is able to influence several parameters of FAK/paxillin 
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biology, and this provides key indications into the mechanism of action of EPLINα 
to suppress and regulate metastatic traits in prostate cancer.   
8.4.2 Mechanistic implications of EPLIN: ITGB1  
EPLIN has recently been linked to proteins involved in integrin signalling, these 
include paxillin and FAK as above, but also the focal adhesion protein PINCH-1 
(Karakose et al., 2015). EPLIN has been shown to associate to integrin adhesion 
sites, a process that can control cellular adhesion in keratinocytes (Karakose et al., 
2015). Given this, it’s conceivable that EPLIN may be involved in other integrin-
related signalling pathways and processes. PINCH-1 is functionally linked to the 
kinase molecule, ILK, during integrin signalling (Legate et al., 2006). As discussed 
in Chapter 7, EPLINα overexpression enhanced the phosphorylation of ILK at Y351 
in PC-3 cells, identified in the protein microarray. This could suggest that EPLINα 
interacts with not only PINCH-1, but the PINCH1:ILK complex or even possibly 
effect the interactions between the two molecules.  
The protein microarray highlighted increased phosphorylation of ITGB1 S785 
following EPLINα overexpression in PC-3 cells, though, due to antibody availability 
and performance issues, this could not be verified using western blot analysis in cell 
models. However, the S785 region of ITGB1 has been proposed to modulate ITGB1 
function via enhanced attachment of cells and also inhibit cell spreading and 
migration (Mulrooney et al., 2001). This association was also validated using an 
antibody targeting total ITGB1 expression and confirmed an increase in ITGB1 
expression in conjunction with EPLIN expression. Considering this notion, this 
illustrates a potential mechanism for the enhanced adhesive and reduced migratory 
 Chapter VIII 
302 
 
properties seen in PC-3 and LNCaP cells with forced EPLINα expression. Previously 
this has been explored with F9 and GD25 murine cell lines (Mulrooney et al., 2001), 
but it’s reasonable that a similar mechanism could be occurring in prostate cancer 
cells upon EPLINα expression. This line of evidence substantiates current research 
that EPLINα may act not only on cytoplasmic related molecules of integrin 
signalling but also provides evidence of associations to membrane bound signalling 
molecules and represents another novel mechanism through which EPLINα may 
exert regulation of cellular traits in prostate cancer cells. 
8.4.3 Mechanistic implications of EPLIN: ERK1/2 
As discussed in Chapter 7, ERK1/2 was also highlighted as a protein of interest in 
relation to EPLINα’s mechanism of action. ERK has previously been linked to 
EPLIN, initially by phosphorylation of EPLIN and contributing to cellular migration 
(Han et al., 2007), and by controlling EPLIN phosphorylation, ubiquitination and 
protein turnover in tandem with EGF (Zhang et al., 2013). The protein microarray 
analysis revealed EPLINα expression reduces phosphorylation of  an activation site 
within ERK1/2; T202/Y204, in addition to downregulating several other ERK1/2 
proteins. As discussed, ERK is an imperative molecule involved in a plethora of 
signalling pathways responsible for inducing several pleiotropic cellular responses 
(Roskoski, 2012). ERK1/2 is particularly important for regulating cell proliferation 
and proliferation (Mebratu and Tesfaigzi, 2009), so this could provide indications 
into the mechanism of proliferation suppression observed in prostate cancer cells 
with forced EPLINα expression seen in Chapters 4 and 5 of this study. ERK also had 
implications on cell cycle progression (Meloche and Pouyssegur, 2007),  and this 
corroborates previous data associating EPLIN with cytokinesis and cell mitotic 
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division (Chircop et al., 2009). Collectively, considering previous associations 
between ERK and EPLIN, and data from this study, it could be that there is a dual 
feedback system occurring in prostate cancer to orchestrate cellular dynamics and 
control cellular functions like proliferation and migration, by virtue of ERK1/2 and 
EPLIN interplay. Further, Src activity is functionally linked to ERK signalling where 
both molecules have regulatory roles critical for focal adhesion turnover and cell 
migration (Webb et al., 2004). Given the potential loss of ERK activity in PC-3 cells 
evidenced from the Kinexus protein microarray, it could be that ERK is unable to 
promote Src-induced focal adhesion turnover as a result of EPLINα overexpression, 
thus reducing cellular migration of prostate cancer cells.  Finally, given the 
observations linking EPLINα to both ITGB1 and ERK, this could suggest EPLINα is 
a potential candidate protein for monitoring and regulating ‘inside-out’ signalling in 
prostate cancer. Inside out signalling is a signalling process to co-ordinate integrin 
activation which leads to increased affinity of receptor binding to extracellular 
ligands (Shattil et al., 2010). Inside out signalling has implications on cellular 
function (Shen et al., 2012), influences FAK/Src signalling (Thamilselvan and 
Basson, 2004) and has significance in cancer (Li et al., 2009). This could provide 
insights into EPLINα’s mechanistic role to regulate various proteins including 
ITGB1, ERK and Src, all with key roles in integrin signalling to co-ordinate cellular 
function, suggesting a complex variety of molecules acting synergistically in prostate 
cancer development.  
8.4.4 Mechanistic implications of EPLIN: Src  
 As discussed, EPLINα is able to influence various integrin related signalling 
proteins including paxillin, FAK, ERK1/2 and ITGB1. Paxillin and FAK are 
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functionally and mechanistically linked to Src, a protein crucial for various cellular 
processes like focal adhesion, migration and cellular invasion (Mitra and Schlaepfer, 
2006). This study has demonstrated that EPLINα is able to influence paxillin and 
FAK phosphorylation and  function. This study also highlighted a novel association 
to Src protein, where EPLINα overexpression in PC-3 cells induced a reduction of 
active Src via the Y419 domain. The Y419 region of Src is the classical activation 
domain and is associated with the progression of various cancers and is linked to 
function and catalytic activity (Cartwright et al., 1990). This study revealed that 
EPLINα is a potential negative regulator of Src signalling, with a reduction of Y419 
Src, and also an increase of the inactive Y530 form, in response to EPLINα 
overexpression in prostate cancer cells. This provides mechanistic evidence of the 
suppressive action of EPLINα in prostate cancer. If EPLINα is able to negatively 
regulate Src signalling, that will have diverse effects of various signalling 
mechanisms. As discussed, Src is commonly elevated in cancer and is synergistic 
with paxillin and FAK, and propagation of this pathway is generally associated with 
cancer progression (Mitra and Schlaepfer, 2006). A reduction of Src activity would 
likely influence paxillin and FAK activity. Physiologically, these three proteins are 
activated by integrin engagement with the ECM which leads to subsequent 
phosphorylation of paxillin by FAK (Turner, 2000a). Src would usually bind FAK at 
Y397 and create additional binding sites for various proteins in the cascade including 
adaptor proteins Crk and Cas, following phosphorylation by Src (Turner, 2000a). 
Ultimately, these signalling interactions, driven by elevated Src activity, signal to 
activate proteins involved in the MAPK pathway to co-ordinate a myriad of cellular 
functions and control gene expression (Turner, 2000a). Elevated Src activity in 
cancer is also linked to increased cellular invasion and progression-related events 
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like EMT (Guarino, 2010), influences actin dynamics and invasion (Angers-Loustau 
et al., 2004) and is also implicated in cancer cell migration and invasion to a bone 
derived microenvironment (Pohorelic et al., 2012). As discussed in Chapter 7, Src 
activity is also associated with cell cycle arrest and decreased cellular migration and 
invasion (Tsao et al., 2007), has implications on cellular functions in triple negative 
breast cancer  (Tryfonopoulos et al., 2011) and has significance in prostate cancer 
progression (Chang et al., 2008). Finally, expression of Src is heavily tied to FAK 
activity and specifically monitors focal adhesion dynamics to control cellular 
functions like cellular migration and focal adhesion turnover (Fincham and Frame, 
1998, Webb et al., 2004). When Src is lost, cells are less migratory and have 
reorganised focal adhesion distribution of matrix adhesions (Volberg et al., 2001). 
This proposes that Src activity is fundamental for focal adhesion turnover and cell 
motility through interaction and association with FAK (Westhoff et al., 2004). This 
could explain the enhanced adhesive capacity and reduced migratory capacity in PC-
3 and LNCaP cells when EPLINα is overexpressed, as cells with altered focal 
adhesion turnover leads to less effective cellular migration, locomotion and 
spreading of cells (Wozniak et al., 2004).  Taken together, functional Src expression 
is fundamental for cancer progression. If EPLINα is able to negate Src expression 
this could further clarify the mechanism of action of EPLINα as a tumour suppressor 
seen in prostate cancer cells. Considering the abundance of evidence for Src as a pro-
metastasis molecule, and the demonstrated loss of Src Y419 when EPLINα is 
overexpressed in the protein microarray described in this study, it could be that 
EPLINα is acting through Src in prostate cancer as a negative regulator to suppress 
metastatic traits. This could help explain the suppressive effect of EPLINα in PC-3 
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cells and LNCaP cells when EPLINα expression is enhanced, unveiling a more 
comprehensive look at the mechanism of action of EPLIN in prostate cancer. 
The use of a Src inhibitor corroborated these findings, particularly when evaluating 
EPLINα and Src activity in an invasion assay. Dasatinib offered no further effect on 
cellular invasion in cells with forced EPLINα expression following treatment. This 
further suggests that EPLIN may be acting as a suppressor of Src signalling to 
influence traits like cellular invasion in prostate cancer, especially since Src is 
known to regulate cellular invasiveness (Guarino, 2010). Inhibition of Src is already 
an established area of therapeutics for cancer biology (Creedon and Brunton, 2012), 
so this demonstrates interesting avenues of future work in this area of research for 
EPLIN biology in prostate cancer metastasis. 
8.4.5 Mechanistic implications of EPLIN: proposed signalling pathway 
Taken together, EPLINα appears to regulate several signalling pathways in prostate 
cancer, which in turn may account for the various functional effects of EPLINα 
expression. Furthermore, many of the potential mechanistic pathways discussed in 
this section and throughout this thesis are linked and also highly relevant in cancer 
biology. Thus, it appears that EPLINα exerts many levels of regulations within the 
cells and highlights the impact of EPLIN loss frequently seen in cancer progression. 
An integrated mechanism illustrating the mechanisms of action and cross-talk 
undertaken by EPLINα in prostate cancer cells is proposed in Figure 8.1 based on the 
key findings of this thesis as well as the current knowledge of EPLINs actions within 
the literature. Further exploration, clarification and validation of this pathway will be 
crucial in establishing EPLIN’s functional role in prostate cancer metastasis. 
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Figure 8.1Proposed signalling pathways of EPLINα in cancer.  
EPLINα affects several mechanisms and signalling pathways in cancer. EPLINα is 
implicated in paxillin and FAK signalling and expression of EPLINα protein can 
provoke alterations to the phosphorylation status of paxillin and FAK, as determined 
by Western Blot experiments, potentially affecting cellular function in cancer. 
EPLINα enhances phosphorylation of integrin receptor-related proteins ITGB1 and 
ILK, with increased phosphorylation of S785 in ITGB1 and Y351, as determined 
from the Kinexus protein microarray. EPLINα forms a physical complex with 
paxillin and also the ILK-associated protein PINCH1. EPLINα expression appears to 
cause a reduction of the dual activation site of ERK at T202/Y204 from the protein 
microarray, suggesting EPLINα influences ERK signalling. ERK also acts on EPLIN 
through phosphorylation at three separate residues: S360, S602 and S692. EPLINα 
expression in prostate cancer induces a negative regulatory effect of Src signalling, 
with a reduction of pSrc Y419 and an increase in Y530. Blocking src signalling has 
many implications in cancer, including reducing further FAK and paxillin activity 
and downstream effects on ERK signalling. Taken together, these changes brought 
about by EPLINα may explain EPLIN’s mechanism of action in cancer as a tumour 
suppressive molecule to impede metastatic traits. Image generated from data 
obtained in this study and combined with data extracted from (Karakose et al., 2015, 
Tsurumi et al., 2014, Han et al., 2007). 
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8.5 Main findings and significance 
EPLIN expression was evaluated in two TMA’s in clinical prostate cancer tissue and 
revealed significant downregulation when compared to normal prostate tissue. 
EPLIN loss correlated with higher Stage cancer tissue and also higher Gleason 
scores. In the second TMA, EPLIN expression was significantly reduced in samples 
with cancer hyperplasia and adenocarcinoma compared to normal prostate tissue. A 
significant reduction in EPLIN expression was also seen comparing cancers in 
adjacent tissue to cancer hyperplasia. Hence, this data suggests an association 
between prostate cancer progression and amount of EPLIN protein available and 
supports the evidence for use of EPLIN as a predictive marker in clinical prostate 
cancer progression. EPLIN expression was at its weakest in the most aggressive 
cancer tissues, suggesting EPLIN could identify cancer aggressiveness and 
metastatic potential in clinical cancer. Work utilising the prostate cancer cell lines 
corroborate this notion, as EPLIN transcript and protein was downregulated or lost in 
aggressive cancer cell lines like PC-3, LNCaP and VCaP, whereas expression was 
higher in less aggressive cancer cell lines, like CA-HPV-10, and  the normal prostate 
cell line PZ-HPV-7. 
Characterisation of the EPLINα overexpressed PC-3 and LNCaP lines has led to the 
implication and clarification that EPLINα functions as a tumour suppressor molecule 
in the progression of prostate cancer. EPLINα is able to influence several key traits 
on prostate cancer cells including cellular proliferation, proliferation, adhesion, 
migration and invasion, all characteristics that are fundamental to metastatic 
progression and development. This protective effect may also be active in the 
establishment of secondary bone metastases; however it seems that EPLINα 
 Chapter VIII 
310 
 
primarily functions as a general cancer metastasis regulator, rather than a specific 
molecular target for bone dissemination.  
The work utilising the prostate cell model functional assays lead to developments 
with mechanistic data, implicating signalling molecules paxillin and FAK in EPLINα 
tumour biology. Forcing EPLINα expression in prostate cell lines had diverse effects 
on paxillin and FAK gene expression, protein expression and phospho-protein 
expression. Specifically, enhanced EPLINα engendered changes to FAK Y397/Y925 
status and paxillin Y31/Y118 in prostate cancer cell lines, which are crucial to FAK 
and paxillin function and have implications in cancer. It also appeared that EPLINα 
expression on FAK/paxillin might be differential depending on different cell types, 
and could provoke distinct downstream effects in different cell lines. 
Lastly, EPLIN exhibited various effects to other signalling molecules, not previously 
identified in the literature. Namely, EPLINα enhanced expression of ITGB1 and ILK 
expression in PC-3 cells, whilst also downregulating ERK1/2 and Src signalling. 
Importantly, Src is a crucial signalling protein associated to various cellular 
mechanisms and has implications in cancer progression (Mitra and Schlaepfer, 
2006). The protein microarray revealed that EPLINα is a potential negative regulator 
of Src signalling, able to specifically downregulate the Y419 form of Src and 
increase the inactive Y530 phospho-protein. This revealed a possible mechanism for 
EPLINα function in the observed suppression of prostate cancer cell characteristics 
in this study. It holds particularly plausible due to the prominence of Src in co-
ordinating cellular functions like migration and invasion (Guarino, 2010). The 
functional assays utilising dasatinib strengthen this notion of Src association, 
particularly for regulating cellular invasiveness.  
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A key clinical question from this study would be the problem of retaining EPLINα 
expression and preventing loss in aggressive cancer, to encompass the advantageous 
effects of EPLINα expression in prostate cancer. Understanding the mechanism of 
action of EPLINα in prostate cancer is crucial to this enigma. Only recently is this 
area of science beginning to emerge, for example, only this year it was published that 
a small molecule inhibitor, Nutlin3a, was able to enhance EPLINα protein 
expression, an effect linked to the suppressive action of p53 in cancer (Ohashi et al., 
2017). Further work is needed in this area and will be key for producing improved 
cancer therapeutics. As seen with the differential effects observed upon EPLINα 
expression to FAK and paxillin, further work utilising additional cancer cell models 
would be of benefit to these interpretations and is warranted for full elucidation of 
EPLINα’s mechanism of action in prostate cancer. It is hoped that the greater 
understanding of EPLINα biology, combined with mechanisms to re-establish 
expression in cancer cells or prevent loss in the first instance will aid in the 
development of multi-target therapeutics to combat the significant issue of cancer 
metastasis. 
8.6 Future work 
There are various avenues of future work following this thesis. The current study 
focussed on EPLINα in the progress of prostate cancer, but also has demonstrated 
significance in various other cancers (Jiang et al., 2008, Liu et al., 2012a, Liu et al., 
2016). It would therefore be interesting to explore EPLINα further in other cancer 
systems that are less established in the literature, possibly in pancreatic, gastric or 
colorectal cancer. Larger tissue samples would also be beneficial to gain a broader 
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understanding of EPLINα loss in clinical prostate cancer; including sections from 
metastatic bone derived areas and paired primary tumours. 
For the molecular and cellular study, use of the VCaP cancer cell model would be 
favourable due to the osteoblastic nature of VCaP cells, to understand the functional 
impact of EPLINα when expression is manipulated in VCaP cells. Knock-down 
analysis could also be performed to corroborate the functional observations in this 
study, possibly in lines where EPLINα expression is relatively high, like CA-HPV-
10 and PZ-HPV-7 cell lines, and such analysis would aid to demonstrate the 
significance of EPLINα loss in less aggressive or normal prostate lines. EPLINα’s 
role on cell cycle progression could be explored, due to the established anti-
proliferative effects observed in this study. In addition to in vitro models, a logical 
progression would be to use in vivo models to explore the observed functional effects 
in prostate cancer in animal models. This would complement the highlighted effects 
observed in Chapter 4 and Chapter 5 of this study. 
For EPLINα’s mechanism of action, various proteins could be elucidated in relation 
to EPLINα expression and cancer progression, in addition to the molecules evaluated 
here. The protein microarray revealed several proteins related to EPLINα that 
weren’t resolved in this study. Molecules like p53, ILK, Cyclins, PAK1 and 
ERBB2/HER, all displayed some form of differential expression in response to 
EPLINα overexpression in PC-3 cells, and introduce compelling options for 
mechanistic analysis in relation to EPLINα function in cancer. Links to other 
signalling cascades like RTK activation through PAK1/2/3 could be explored, 
especially as PAK was validated to be increased in tandem with EPLINα 
overexpression in prostate cell lines following the protein microarray. The S785 
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region of ITGB1, and Y351 region of ILK, also requires further validation due to 
antibody availability/performance issues described in Chapter 7. ERK antibodies 
also displayed some performance issues in Chapter 7, so sourcing additional 
antibodies for regions of ERK1/2 influenced by EPLIN expression would be 
valuable for verifying this association. Various other inhibitors could be used in 
combination with functional assays, like ERK, JNK or other MAPK inhibitors, also 
highlighted from the protein microarray. Given EPLINα’s regulatory role and 
significance of loss of EPLINα in cancer progression, identification of these 
mechanisms and thus therapies to enhance EPLINα should be key focus, and only 
recently has research on EPLINα began to focus on this area. Once the mechanism of 
EPLIN is better understood, this would assist the development of potential therapies 
which aim to target metastatic progression and development. These could be used in 
conjunction with other inhibitory therapies implicated in the mechanism of EPLINα 
(for example dasatinib use or the nutlin3a inhibitor) to suppress cancer cell 
characteristics.  Lastly, it would be interesting to explore if these suppressive effects 
EPLINα exerts can influence certain chemotherapies, or influence cell response to 
chemotherapy, in addition to other traditional prostate cancer treatments. 
Understanding the molecular architecture and signalling interactions in cancer 
biology is paramount. Full elucidation of these downstream signalling cascades may 
aid clinical significance utilising molecules like EPLINα. Once fully understood, this 
could hopefully lead to more personalised, multi target therapeutic design.  
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